NEW EMBO MEMBERS' REVIEW: The ErbB signaling ne development and cancer

EMBO Journal 19, 3159-3167 DOI: 10.1093/emboj/19.13.3159

Citation Report

#	Article	IF	CITATIONS
1	Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene, 2000, 19, 5568-5573.	5.9	82
2	Transgenic mouse models of human breast cancer. Oncogene, 2000, 19, 6130-6137.	5.9	130
3	The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19, 6550-6565.	5.9	1,251
4	ErbB4 and Its Isoforms Selective Regulation of Growth Factor Responses by Naturally Occurring Receptor Variants. Trends in Cardiovascular Medicine, 2000, 10, 304-310.	4.9	115
5	Effects of HER-2/neu on chemosensitivity of tumor cells. Drug Resistance Updates, 2000, 3, 319-324.	14.4	14
6	Cell Signaling by Receptor Tyrosine Kinases. Cell, 2000, 103, 211-225.	28.9	3,724
7	ZD1839 (???lressa???)*,??? as an Anticancer Agent. Drugs, 2000, 60, 33-40.	10.9	267
8	Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 2001, 120, 1713-1719.	1.3	179
9	2000 Highlights From: 23rd Annual San Antonio Breast Cancer Symposium; San Antonio, Texas December 6-9, 2000. Clinical Breast Cancer, 2001, 1, 264-269.	2.4	0
10	Differential Utilization and Localization of ErbB Receptor Tyrosine Kinases in Skin Compared to Normal and Malignant Keratinocytes. Neoplasia, 2001, 3, 339-350.	5.3	68
11	Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing Function. Biochemical and Biophysical Research Communications, 2001, 280, 274-279.	2.1	51
12	BIBX1382BS, but Not AG1478 or PD153035, Inhibits the ErbB Kinases at Different Concentrations in Intact Cells. Biochemical and Biophysical Research Communications, 2001, 281, 25-31.	2.1	39
13	Mapping a Heparin Binding Site on ErbB-3 Epidermal Growth Factor Receptor. Biochemical and Biophysical Research Communications, 2001, 283, 1-5.	2.1	1
14	An Essential Role for Src Kinase in ErbB Receptor Signaling through the MAPK Pathway. Experimental Cell Research, 2001, 267, 81-87.	2.6	49
15	Estradiol, in the CNS, targets several physiologically relevant membrane-associated proteins. Brain Research Reviews, 2001, 37, 141-152.	9.0	43
16	The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5526-5531.	7.1	27
17	The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocrine-Related Cancer, 2001, 8, 11-31.	3.1	558
18	The role of EGF-related peptides in tumor growth. Frontiers in Bioscience - Landmark, 2001, 6, d685.	3.0	141

#	Article	IF	CITATIONS
19	Expression PAtterns of the erbB Subfamily mRNA in Canine Benign and Malignant Mammary Tumors Journal of Veterinary Medical Science, 2001, 63, 949-954.	0.9	18
20	Neuregulin Signaling Regulates Neural Precursor Growth and the Generation of Oligodendrocytes <i>In Vitro</i> . Journal of Neuroscience, 2001, 21, 4740-4751.	3.6	118
21	Regulation of functional nitric oxide synthase-1 expression in cerebellar granule neurons by heregulin is post-transcriptional, and involves mitogen-activated protein kinase. Journal of Neurochemistry, 2001, 78, 552-559.	3.9	14
22	Heparin-Binding Epidermal-Growth-Factor-Like Growth Factor Activation of Keratinocyte ErbB Receptors Mediates Epidermal Hyperplasia, a Prominent Side-Effect of Retinoid Therapy. Journal of Investigative Dermatology, 2001, 117, 1335-1341.	0.7	61
23	ErbB-4 and neuregulin expression in the adult mouse olfactory bulb after peripheral denervation. European Journal of Neuroscience, 2001, 14, 513-521.	2.6	18
24	Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. Journal of Pathology, 2001, 195, 343-348.	4.5	69
25	Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Molecular Carcinogenesis, 2001, 30, 224-236.	2.7	53
26	Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry, 2001, 44, 338-348.	1.8	46
27	Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. International Journal of Cancer, 2001, 94, 185-191.	5.1	35
28	ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. International Journal of Cancer, 2001, 94, 774-782.	5.1	185
29	Signal Transduction: Multiple Pathways, Multiple Options for Therapy. Stem Cells, 2001, 19, 295-303.	3.2	35
30	The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model. Seminars in Cancer Biology, 2001, 11, 201-218.	9.6	34
31	Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 141-150.	2.7	34
32	N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. EMBO Journal, 2001, 20, 3342-3350.	7.8	115
33	ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nature Cell Biology, 2001, 3, 785-792.	10.3	523
34	Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene, 2001, 20, 1594-1600.	5.9	441
35	Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene, 2001, 20, 5199-5209.	5.9	55
36	Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene, 2001, 20, 5459-5465.	5.9	37

		LPORT	
# 37	ARTICLE Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2001, 2, 127-137.	lF 37.0	Citations 5,977
38	Akt takes centre stage in cell-cycle deregulation. Nature Cell Biology, 2001, 3, E71-E73.	10.3	45
39	Tumor targeting using anti-her2 immunoliposomes. Journal of Controlled Release, 2001, 74, 95-113.	9.9	309
40	Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Seminars in Oncology, 2001, 28, 67-79.	2.2	115
41	CI-1033, a pan-erbB tyrosine kinase inhibitor. Seminars in Oncology, 2001, 28, 80-85.	2.2	138
42	Epidermal growth factor receptor signaling. Current Biology, 2001, 11, R292-R295.	3.9	182
43	Regulation of the Epithelial–Mesenchymal Transformation through Gap Junction Channels in Heart Development. Trends in Cardiovascular Medicine, 2001, 11, 213-218.	4.9	33
44	HER-Kinase-Directed Therapy of Prostate Cancer. Prostate Journal, 2001, 3, 53-58.	0.2	2
45	Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. Journal of Biological Chemistry, 2001, 276, 38921-38928.	3.4	74
46	Growth Factor-specific Signaling Pathway Stimulation and Gene Expression Mediated by ErbB Receptors. Journal of Biological Chemistry, 2001, 276, 22685-22698.	3.4	113
47	Transgenic MUC1 Interacts with Epidermal Growth Factor Receptor and Correlates with Mitogen-activated Protein Kinase Activation in the Mouse Mammary Gland. Journal of Biological Chemistry, 2001, 276, 13057-13064.	3.4	304
48	The Type 1 growth factor receptors and their ligands considered as a complex system Endocrine-Related Cancer, 2001, 8, 75-82.	3.1	67
49	Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor. Journal of Biological Chemistry, 2001, 276, 42153-42161.	3.4	135
50	Clinical and molecular stratification of disease risk in medulloblastoma. British Journal of Cancer, 2001, 85, 705-712.	6.4	154
51	Recruitment of the Class II Phosphoinositide 3-Kinase C2β to the Epidermal Growth Factor Receptor: Role of Grb2. Molecular and Cellular Biology, 2001, 21, 6660-6667.	2.3	64
52	Preserved Pancreatic β-Cell Development and Function in Mice Lacking the Insulin Receptor-Related Receptor. Molecular and Cellular Biology, 2001, 21, 5624-5630.	2.3	97
53	Transforming Growth Factor-α Prevents Detachment-induced Inhibition of c-Src Kinase Activity, Bcl-XLDown-regulation, and Apoptosis of Intestinal Epithelial Cells. Journal of Biological Chemistry, 2001, 276, 37273-37279.	3.4	154
54	Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by <i>Neisseria meningitidis </i> . Journal of Cell Biology, 2001, 155, 133-144.	5.2	123

#	Article	IF	Citations
55	Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer. Molecular and Cellular Biology, 2001, 21, 1540-1551.	2.3	147
56	The Protein Tyrosine Phosphatase-PEST Is Implicated in the Negative Regulation of Epidermal Growth Factor on PRL Signaling in Mammary Epithelial Cells. Molecular Endocrinology, 2001, 15, 2182-2196.	3.7	13
57	Chimeric Antigen Receptors for the Retargeting of Cytotoxic Effector Cells. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 523-534.	1.8	13
58	Comparison of the Biochemical and Kinetic Properties of the Type 1 Receptor Tyrosine Kinase Intracellular Domains. Journal of Biological Chemistry, 2002, 277, 1576-1585.	3.4	67
59	The Expression of EGFR Family Ligands in Breast Carcinomas. International Journal of Surgical Pathology, 2002, 10, 91-99.	0.8	52
60	ErbB-2 Activates Stat3α in a Src- and JAK2-dependent Manner. Journal of Biological Chemistry, 2002, 277, 38486-38493.	3.4	99
61	Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity. Journal of Immunology, 2002, 168, 3275-3282.	0.8	24
62	EGF controls the in vivo developmental potential of a mammary epithelial cell line possessing progenitor properties. Journal of Cell Biology, 2002, 159, 453-463.	5.2	45
63	An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proceedings of the United States of America, 2002, 99, 2866-2871.	7.1	112
64	Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor. Journal of Biological Chemistry, 2002, 277, 27643-27650.	3.4	186
65	Herstatin, an Autoinhibitor of the Human Epidermal Growth Factor Receptor 2 Tyrosine Kinase, Modulates Epidermal Growth Factor Signaling Pathways Resulting in Growth Arrest. Journal of Biological Chemistry, 2002, 277, 20618-20624.	3.4	35
66	Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association. Journal of Biological Chemistry, 2002, 277, 28468-28473.	3.4	60
67	Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines. Journal of Biological Chemistry, 2002, 277, 49127-49133.	3.4	82
68	Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of câ€erbBâ€2 receptor via epidermal growth factor receptor. FASEB Journal, 2002, 16, 1-21.	0.5	121
69	ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27 -Haploinsufficient Mammary Epithelial Cells but Impaired in p27 -Null Cells. Molecular and Cellular Biology, 2002, 22, 2204-2219.	2.3	113
70	The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes. Journal of Biological Chemistry, 2002, 277, 4704-4712.	3.4	269
71	MECHANISTIC APPROACHES TO PHASE I CLINICAL TRIALS. , 2002, , 371-384.		1
72	Differential Regulation of Tumor Angiogenesis by Distinct ErbB Homo- and Heterodimers. Molecular Biology of the Cell, 2002, 13, 4029-4044.	2.1	124

#	Article	IF	CITATIONS
73	Obligate Roles for p16 Ink4a and p19 Arf -p53 in the Suppression of Murine Pancreatic Neoplasia. Molecular and Cellular Biology, 2002, 22, 635-643.	2.3	68
74	CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes and Development, 2002, 16, 307-323.	5.9	399
75	Vaccination against the HER-2/neu oncogenic protein Endocrine-Related Cancer, 2002, 9, 33-44.	3.1	48
76	Immunologic targets for breast cancer1. Breast Disease, 2002, 15, 83-90.	0.8	6
77	Cross signaling, cell specificity, and physiology. American Journal of Physiology - Cell Physiology, 2002, 283, C2-C28.	4.6	66
78	Effect of ErbB2 Coexpression on the Kinetic Interactions of Epidermal Growth Factor with Its Receptor in Intact Cellsâ€. Biochemistry, 2002, 41, 8-14.	2.5	21
79	Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether. Science, 2002, 297, 1330-1333.	12.6	388
80	Molecules in blastocyst implantation: Uterine and embryonic perspectives. Vitamins and Hormones, 2002, 64, 43-76.	1.7	94
81	Frequent Co-Localization of Cox-2 and Laminin-5 γ2 Chain at the Invasive Front of Early-Stage Lung Adenocarcinomas. American Journal of Pathology, 2002, 160, 1129-1141.	3.8	91
82	Signal Transduction by Cell Adhesion Receptors and the Cytoskeleton: Functions of Integrins, Cadherins, Selectins, and Immunoglobulin-Superfamily Members. Annual Review of Pharmacology and Toxicology, 2002, 42, 283-323.	9.4	540
83	Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. Gastroenterology, 2002, 122, 1898-1912.	1.3	51
84	Expression of c-erbB receptors and ligands in the bronchial epithelium of asthmatic subjects. Journal of Allergy and Clinical Immunology, 2002, 109, 75-81.	2.9	115
85	Gefitinib. Drugs, 2002, 62, 2237-2248.	10.9	58
86	The EGF/ErbB Receptor Family and Apoptosis. Growth Factors, 2002, 20, 1-15.	1.7	95
87	BAD: a good therapeutic target?. Breast Cancer Research, 2002, 5, 27-30.	5.0	5
88	The importance of being a myoepithelial cell. Breast Cancer Research, 2002, 4, 224-30.	5.0	131
89	Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains. Cell, 2002, 110, 775-787.	28.9	1,013
90	Structural aspects of oligomerization taking place between the transmembrane α-helices of bitopic membrane proteins. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1565, 347-363.	2.6	52

#	Article	IF	CITATIONS
91	Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer, 2002, 37, 17-27.	2.0	27
92	Epidermal growth factor receptor tyrosine kinase inhibitors. Current Opinion in Pharmacology, 2002, 2, 382-387.	3.5	81
93	Paediatric embryonic brain tumours. European Journal of Cancer, 2002, 38, 675-685.	2.8	48
94	The role of new agents in the treatment of non-small cell lung cancer. European Journal of Cancer, 2002, 38, 2347-2361.	2.8	33
95	Epithelial growth factor receptor interacting agents. Hematology/Oncology Clinics of North America, 2002, 16, 1041-1063.	2.2	38
96	Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood, 2002, 100, 1265-1273.	1.4	229
97	EGFR Inhibitors: Clinical Results. Tumori, 2002, 1, S5-S6.	1.1	4
98	Targeting the Epidermal Growth Factor Receptor With Tyrosine Kinase Inhibitors: Small Molecules, Big Hopes. Journal of Clinical Oncology, 2002, 20, 2217-2219.	1.6	68
99	Total Internal Reflection Fluorescence Microscopy for Single-molecule Imaging in Living Cells Cell Structure and Function, 2002, 27, 357-365.	1.1	88
100	The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry, 2002, 2, 8.	2.6	115
101	Chemotherapy in Advanced non—small-Cell Lung Cancer: A Look Behind and Ahead. Clinical Lung Cancer, 2002, 4, 26-34.	2.6	1
102	HER2/neu expression in malignant lung tumors. Seminars in Oncology, 2002, 29, 51-58.	2.2	92
103	Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. Seminars in Oncology, 2002, 29, 2-8.	2.2	9
104	Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Seminars in Oncology, 2002, 29, 3-9.	2.2	209
105	HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Seminars in Oncology, 2002, 29, 4-10.	2.2	25
106	Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Seminars in Oncology, 2002, 29, 11-21.	2.2	40
107	Irreversible inhibitors of the erbB family of protein tyrosine kinases. , 2002, 93, 253-261.		33
108	The α5β1 integrin selectively enhances epidermal growth factor signaling to the phosphatidylinositol-3-kinase/Akt pathway in intestinal epithelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1542, 23-31.	4.1	53

\sim		· ·	Deec	
		ON	K F D (ו גוו
\sim	/			

#	Article	IF	CITATIONS
109	A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell, 2002, 2, 29-42.	16.8	225
110	Phosphorylation of LRP1 Regulation of Transport and Signal Transduction. Trends in Cardiovascular Medicine, 2002, 12, 160-165.	4.9	56
111	The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling, 2002, 14, 381-395.	3.6	1,475
112	Interactions between the juxtamembrane domain of the EGFR and calmodulin measured by surface plasmon resonance. Cellular Signalling, 2002, 14, 1005-1013.	3.6	31
113	Clinical relevance of molecular markers in lung cancer. Surgical Oncology, 2002, 11, 167-179.	1.6	30
114	Protein kinases in mammary gland development and cancer. Microscopy Research and Technique, 2002, 59, 49-57.	2.2	18
115	Heparin-derived disaccharides modulate proliferation andErb-B2-mediated signal transduction in colon cancer cell lines. International Journal of Cancer, 2002, 99, 179-184.	5.1	10
116	Replacement of N-terminal portions of TGF-? with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins. International Journal of Cancer, 2002, 97, 349-356.	5.1	4
117	Expression of ErbB3, ErbB4, and neuregulin-1 mRNA during tooth development. Developmental Dynamics, 2002, 224, 356-360.	1.8	14
118	Regulation ofHer2/neu promoter activity by the ETS transcription factor, ER81. Journal of Cellular Biochemistry, 2002, 86, 174-183.	2.6	41
119	Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin ? 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression. Journal of Cellular Physiology, 2002, 192, 225-233.	4.1	18
120	ErbB2 oncogene expression supports the acute pancreatitis-chronic pancreatitis sequence. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 441, 385-391.	2.8	10
121	Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathology and Applied Neurobiology, 2002, 28, 257-282.	3.2	195
122	Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene, 2002, 21, 78-86.	5.9	72
123	Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene, 2002, 21, 198-206.	5.9	99
124	Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells. Oncogene, 2002, 21, 2066-2078.	5.9	114
125	ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 2002, 8, 459-465.	30.7	796
126	Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2–ErbB3 receptors. Nature Medicine, 2002, 8, 850-855.	30.7	298

#	Article	IF	CITATIONS
127	Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (â€~Iressa'). British Journal of Cancer, 2002, 86, 456-462.	6.4	73
128	Chimeric Ecotropic MLV Envelope Proteins that Carry EGF Receptor-Specific Ligands and the Pseudomonas Exotoxin A Translocation Domain to Target Gene Transfer to Human Cancer Cells. Virology, 2002, 302, 333-341.	2.4	15
129	The epidermal growth factor receptor: A new target for anticancer therapy. Current Problems in Cancer, 2002, 26, 114-164.	2.0	54
130	Neuregulin Signaling via ErbB Receptor Assemblies in the Nervous System. Molecular Neurobiology, 2002, 25, 067-078.	4.0	31
131	Her-2/neu and Topoisomerase iil ${ m \dot{l}\pm}$ in Breast Cancer. Breast Cancer Research and Treatment, 2003, 78, 299-311.	2.5	84
132	HER2 Codon 655 Polymorphism and Risk of Breast Cancer in African Americans and Whites. Breast Cancer Research and Treatment, 2003, 79, 355-364.	2.5	70
133	Co-Expression of ErbB-Family Members in Human Breast Cancer: Her-2/neu is the Preferred Dimerization Candidate in Nodal-positive Tumors. Breast Cancer Research and Treatment, 2003, 80, 353-361.	2.5	55
134	Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells. Breast Cancer Research and Treatment, 2003, 81, 81-93.	2.5	165
135	Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2. Breast Cancer Research and Treatment, 2003, 82, 155-164.	2.5	86
136	Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-tumor Immunity to the †Self' tumor-associated antigen, neu in a Rat Mammary Tumor Model. Breast Cancer Research and Treatment, 2003, 82, 169-183.	2.5	34
137	Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. Journal of Molecular Medicine, 2003, 81, 392-403.	3.9	182
138	ErbB2 Pathways in Heart and Neural Diseases. Trends in Cardiovascular Medicine, 2003, 13, 80-86.	4.9	90
139	CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Seminars in Oncology, 2003, 30, 65-78.	2.2	99
140	The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors. Seminars in Oncology, 2003, 30, 3-11.	2.2	162
141	Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides. Biochemical Pharmacology, 2003, 66, 819-830.	4.4	29
142	The neuregulin GGF2 attenuates free radical release from activated microglial cells. Journal of Neuroimmunology, 2003, 136, 67-74.	2.3	55
143	A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/ <i>NRG1</i> gene. Genes Chromosomes and Cancer, 2003, 37, 333-345.	2.8	56
144	Pattern of secondary genomic changes in pancreatic tumors ofTgfα/Trp53+/â^'transgenic mice. Genes Chromosomes and Cancer, 2003, 38, 240-248.	2.8	17

# 145	ARTICLE The biology of breast carcinoma. Cancer, 2003, 97, 825-833.	lF 4.1	Citations 181
146	Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. International Journal of Cancer, 2003, 104, 19-27.	5.1	50
147	Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling. International Journal of Cancer, 2003, 104, 303-309.	5.1	15
148	Prognostic value ofERBBfamily mRNA expression in breast carcinomas. International Journal of Cancer, 2003, 106, 758-765.	5.1	184
149	Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. Journal of Cellular Biochemistry, 2003, 89, 1177-1192.	2.6	65
150	ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes. Journal of Cellular Biochemistry, 2003, 90, 561-572.	2.6	18
151	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFRâ€TKIs): Simple drugs with a complex mechanism of action?. Journal of Cellular Physiology, 2003, 194, 13-19.	4.1	124
152	EGF receptor-mediated, c-Src-dependent, activation of Stat5b is downregulated in mitogenically responsive hepatocytes. Journal of Cellular Physiology, 2003, 196, 113-123.	4.1	17
153	EGF-stimulated signaling by means of PI3K, PLC?1, and PKC isozymes regulates branching morphogenesis of the fetal mouse submandibular gland. Developmental Dynamics, 2003, 227, 216-226.	1.8	49
154	Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor. Journal of the American Society for Mass Spectrometry, 2003, 14, 1022-1031.	2.8	60
155	Erb-B2 homodimerization inhibits MUC1 transcription in cultured human mammary epithelial cells. Cell Biology International, 2003, 27, 477-481.	3.0	7
156	Restoring Apoptosis in Pancreatic Cancer Cells by Targeting the Nuclear Factor-ήB Signaling Pathway With the Anti-Epidermal Growth Factor Antibody IMC-C225. Journal of Gastrointestinal Surgery, 2003, 7, 37-43.	1.7	52
157	Inhibition of erbB Receptor Family Members Protects HaCaT Keratinocytes from Ultraviolet-B-Induced Apoptosis. Journal of Investigative Dermatology, 2003, 120, 483-488.	0.7	19
158	The Heregulin/Human Epidermal Growth Factor Receptor as a New Growth Factor System in Melanoma with Multiple Ways of Deregulation. Journal of Investigative Dermatology, 2003, 121, 802-812.	0.7	41
159	The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clinical and Experimental Allergy, 2003, 33, 233-240.	2.9	126
160	ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate, 2003, 56, 142-149.	2.3	39
161	Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. Journal of Pathology, 2003, 200, 290-297.	4.5	550
162	Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. British Journal of Cancer, 2003, 89, 983-991.	6.4	62

#	Article	IF	CITATIONS
163	Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area. British Journal of Cancer, 2003, 89, 681-686.	6.4	90
164	Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 2003, 421, 756-760.	27.8	1,363
165	Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature, 2003, 424, 456-461.	27.8	382
166	Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Reports, 2003, 4, 166-171.	4.5	125
167	Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2. Oncogene, 2003, 22, 1546-1556.	5.9	71
168	Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene, 2003, 22, 1557-1567.	5.9	32
169	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene, 2003, 22, 2812-2822.	5.9	449
170	Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-α signaling complex. Oncogene, 2003, 22, 3598-3607.	5.9	18
171	Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene, 2003, 22, 4221-4234.	5.9	112
172	Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene, 2003, 22, 5006-5010.	5.9	74
173	Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. Oncogene, 2003, 22, 4488-4497.	5.9	53
174	TACE/ADAM17 Processing of EGFR Ligands Indicates a Role as a Physiological Convertase. Annals of the New York Academy of Sciences, 2003, 995, 22-38.	3.8	169
175	Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/Oncology Clinics of North America, 2003, 17, 1051-1073.	2.2	18
176	Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer. Journal of Clinical Oncology, 2003, 21, 2787-2799.	1.6	1,195
177	Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer, 2003, 41, 15-22.	2.0	8
178	Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects. Mechanisms of Development, 2003, 120, 811-822.	1.7	66
179	Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion. Journal of Surgical Research, 2003, 109, 123-129.	1.6	12
180	Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. Journal of Surgical Research, 2003, 111, 274-283.	1.6	43

#		IF	CITATIONS
181	Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Experimental Cell Research, 2003, 282, 121-131.	2.6	40
182	Roles of mitogen-activated protein kinase and phosphoinositide 3′-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signalingâ~†. Experimental Cell Research, 2003, 284, 289-300.	2.6	47
183	UVB-induced apoptosis in normal human keratinocytes: role of the erbB receptor family. Experimental Cell Research, 2003, 284, 314-325.	2.6	23
184	Mechanism of action of erbB tyrosine kinase inhibitors. Experimental Cell Research, 2003, 284, 131-139.	2.6	71
185	Epidermal growth factor receptor: mechanisms of activation and signalling. Experimental Cell Research, 2003, 284, 31-53.	2.6	1,353
186	The ErbB receptors and their role in cancer progression. Experimental Cell Research, 2003, 284, 99-110.	2.6	567
187	ErbB-4: mechanism of action and biology. Experimental Cell Research, 2003, 284, 66-77.	2.6	213
188	Neuregulins: functions, forms, and signaling strategies. Experimental Cell Research, 2003, 284, 14-30.	2.6	942
189	ErbBs in mammary development. Experimental Cell Research, 2003, 284, 89-98.	2.6	113
191	Molecular diagnostics for determination of HER2 status in breast cancer. Current Diagnostic Pathology, 2003, 9, 48-55.	0.4	6
192	The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors. Molecular Cell, 2003, 11, 495-505.	9.7	510
193	The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resistance Updates, 2003, 6, 95-107.	14.4	18
194	Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncology, The, 2003, 4, 639-642.	10.7	57
195	The ErbB receptors and their role in cancer progression. , 2003, , 103-114.		2
197	Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Research, 2003, 5, 96-100.	5.0	48
198	Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells. Journal of Biological Chemistry, 2003, 278, 37610-37621.	3.4	75
199	The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8933-8938.	7.1	855
200	Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4. Advances in Experimental Medicine and Biology, 2003, 532, 253-268.	1.6	173

#	Article	IF	CITATIONS
201	Identification of a Second egfr Gene in Xiphophorus Uncovers an Expansion of the Epidermal Growth Factor Receptor Family in Fish. Molecular Biology and Evolution, 2003, 21, 266-275.	8.9	40
202	Angiopoietinâ€regulated recruitment of vascular smooth muscle cells by endothelialâ€derived heparin binding EGFâ€like growth factor. FASEB Journal, 2003, 17, 1609-1621.	0.5	106
203	Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis, 2003, 24, 1581-1592.	2.8	38
204	Betacellulin and Amphiregulin Induce Upregulation of Cyclin D1 and DNA Synthesis Activity Through Differential Signaling Pathways in Vascular Smooth Muscle Cells. Circulation Research, 2003, 93, 302-310.	4.5	67
205	Adaptation of the Ras-recruitment system to the analysis of interactions between membrane-associated proteins. Nucleic Acids Research, 2003, 31, 28e-28.	14.5	20
206	Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment. Journal of the National Cancer Institute, 2003, 95, 851-867.	6.3	349
207	Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2003, 21, 1980-1987.	1.6	568
208	Signal Events: Cell Signal Transduction and Its Inhibition in Cancer. Oncologist, 2003, 8, 5-17.	3.7	69
209	Prognostic Values of p53 and HER-2/neu Coexpression in Invasive Bladder Cancer in Taiwan. Urologia Internationalis, 2003, 71, 262-270.	1.3	23
210	Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1. Molecular and Cellular Biology, 2003, 23, 8691-8703.	2.3	190
211	Activation of Tyrosine Kinases in Cancer. Oncologist, 2003, 8, 531-538.	3.7	166
212	Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. Journal of Cell Science, 2003, 116, 4557-4566.	2.0	180
213	Induction of DNA synthesis in primary mouse hepatocytes is associated with nuclear pro-transforming growth factor alpha and erbb-1 and is independent of c-jun. Carcinogenesis, 2003, 24, 835-841.	2.8	25
214	Molecular Dynamics Simulations of the Transmembrane Domain of the Oncogenic ErbB2 Receptor Dimer in a DMPC Bilayer. Journal of Biomolecular Structure and Dynamics, 2003, 21, 179-199.	3.5	12
215	HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. British Journal of Cancer, 2003, 89, 1305-1309.	6.4	74
216	Neuregulin-1 Enhances Motility and Migration of Human Astrocytic Glioma Cells. Journal of Biological Chemistry, 2003, 278, 20971-20978.	3.4	47
217	Bcl-2 expression decreases cadherin-mediated cell-cell adhesion. Journal of Cell Science, 2003, 116, 3687-3700.	2.0	49
218	Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3221-3226.	7.1	312

#	Article	IF	CITATIONS
219	Identification of Novel ErbB3-Interacting Factors Using the Split-Ubiquitin Membrane Yeast Two-Hybrid System. Genome Research, 2003, 13, 1744-1753.	5.5	99
220	Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK. Journal of Biological Chemistry, 2003, 278, 24951-24959.	3.4	28
221	ADP-ribosylation Factor 4 Small GTPase Mediates Epidermal Growth Factor Receptor-dependent Phospholipase D2 Activation. Journal of Biological Chemistry, 2003, 278, 2661-2668.	3.4	52
222	Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9220-9225.	7.1	23
223	Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development (Cambridge), 2003, 130, 4515-4525.	2.5	113
224	Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Annals of Oncology, 2003, 14, 873-880.	1.2	57
225	Suppression of TNF-α Mediated Apoptosis by EGF in TNF-α Sensitive Human Cervical Carcinoma Cell Line. Growth Factors, 2003, 21, 31-39.	1.7	9
226	Genetic Alterations in Esophageal Cancer. , 2003, 222, 131-145.		25
227	Isoform-Selective Interactions between Estrogen Receptors and Steroid Receptor Coactivators Promoted by Estradiol and ErbB-2 Signaling in Living Cells. Molecular Endocrinology, 2003, 17, 589-599.	3.7	71
228	Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells. Endocrinology, 2003, 144, 1032-1044.	2.8	513
229	A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. Biochemical Journal, 2003, 373, 451-463.	3.7	220
230	Optical Bioimaging: From Living Tissue to a Single Molecule: Single-Molecule Visualization of Cell Signaling Processes of Epidermal Growth Factor Receptor. Journal of Pharmacological Sciences, 2003, 93, 253-258.	2.5	17
231	Mechanism of action of erbB tyrosine kinase inhibitors. , 2003, , 137-145.		1
232	Neuregulins. , 2003, , 15-31.		4
233	Role of Lipid Domains in EGF Receptor Signaling. , 2003, , 323-326.		0
234	Epidermal growth factor receptor. , 2003, , 33-55.		51
235	ErbBs in mammary development. , 2003, , 93-102.		3
236	Role of ErbB2 in Corneal Epithelial Wound Healing. , 2004, 45, 4277.		45

#	Article	IF	CITATIONS
237	Emerging Treatments in Oncology: Focus on Tyrosine Kinase (erbB) Receptor Inhibitors. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 52-58.	1.5	23
238	Chemopreventive role of folic acid in colorectal cancer. Frontiers in Bioscience - Landmark, 2004, 9, 2725.	3.0	20
239	Signal Transduction Associated with Hyaluronan. , 2004, , 153-188.		3
240	Therapeutic Strategies to Improve the Efficacy of Oxaliplatin in Gastrointestinal Tumors. International Journal of Biological Markers, 2004, 19, 183-189.	1.8	1
241	Stimulation of Insulin-Like Growth Factor (IGF) Binding Protein-3 Synthesis by IGF-I and Transforming Growth Factor-α Is Mediated by Both Phosphatidylinositol-3 Kinase and Mitogen-Activated Protein Kinase Pathways in Mammary Epithelial Cells. Endocrinology, 2004, 145, 4213-4221.	2.8	23
242	Early Phase I Data on an Irreversible Pan-Er Inhibitor: CI-1033. What Did We Learn?. Journal of Chemotherapy, 2004, 16, 44-48.	1.5	14
243	Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neu in HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway. Journal of Biological Chemistry, 2004, 279, 4479-4489.	3.4	206
244	Heterodimeric interactions among the 1-amino-cyclopropane-1-carboxylate synthase polypeptides encoded by the Arabidopsis gene family. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2275-2280.	7.1	126
245	Wound-Induced HB-EGF Ectodomain Shedding and EGFR Activation in Corneal Epithelial Cells. , 2004, 45, 813.		126
246	Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbBâ ${\in}2$ Inhibitor Lapatinib. Oncologist, 2004, 9, 10-15.	3.7	737
247	Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-γ in liposarcomas. , 2004, 120, 151-167.		14
248	Embryo-Uterine Interactions via the Neuregulin Family of Growth Factors During Implantation in the Mouse1. Biology of Reproduction, 2004, 71, 2003-2011.	2.7	28
249	Differential Expression of Ezrin/Radixin/Moesin (ERM) and ERM-Associated Adhesion Molecules in the Blastocyst and Uterus Suggests Their Functions During Implantation1. Biology of Reproduction, 2004, 70, 729-736.	2.7	43
250	Molecular Cues to Implantation. Endocrine Reviews, 2004, 25, 341-373.	20.1	956
251	Structure and Function of the Epidermal Growth Factor (EGFâ§,ErbB) Family of Receptors. Advances in Protein Chemistry, 2004, 68, 1-27.	4.4	70
253	Epidermal Growth Factor-stimulated Intestinal Epithelial Cell Migration Requires Src Family Kinase-dependent p38 MAPK Signaling. Journal of Biological Chemistry, 2004, 279, 44513-44521.	3.4	110
254	Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma. Cancer Research, 2004, 64, 2047-2053.	0.9	135
255	Role of EGFR Transactivation in Preventing Apoptosis inPseudomonas aeruginosa–Infected Human Corneal Epithelial Cells. , 2004, 45, 2569.		52

		CITATION REPORT		
#	Article		IF	CITATIONS
256	Molecular Profiling of Inflammatory Breast Cancer. Clinical Cancer Research, 2004, 10,	6789-6795.	7.0	213
257	Regulation of the Drosophila Epidermal Growth Factor-Ligand Vein Is Mediated by Mul Genetics, 2004, 167, 687-698.	tiple Domains.	2.9	11
258	Administration of Cl-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible 7-Day Off Schedule. Clinical Cancer Research, 2004, 10, 7112-7120.	2 on a 7-Day On,	7.0	76
259	High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterr Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan. Clinical Cancer Resea 8195-8203.	ıs in Non–Small ırch, 2004, 10,	7.0	500
260	What Are the Real Roles of Different ErbB Proteins in Barrett's Esophagus. Digestic	on, 2004, 70, 93-94.	2.3	3
261	The Phosphoprotein StarD10 Is Overexpressed in Breast Cancer and Cooperates with I Cellular Transformation. Cancer Research, 2004, 64, 3538-3544.	ErbB Receptors in	0.9	37
262	Tid1, the Human Homologue of a Drosophila Tumor Suppressor, Reduces the Malignar ErbB-2 in Carcinoma Cells. Cancer Research, 2004, 64, 7732-7739.	nt Activity of	0.9	56
263	Plexin-B1/RhoGEF–mediated RhoA activation involves the receptor tyrosine kinase E Cell Biology, 2004, 165, 869-880.	bB-2. Journal of	5.2	146
264	The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors onset of tumor angiogenesis. Proceedings of the National Academy of Sciences of the America, 2004, 101, 2345-2350.	and for early United States of	7.1	69
265	Role of the Epidermal Growth Factor Receptor in Signaling Strain-dependent Activation Natriuretic Peptide Gene. Journal of Biological Chemistry, 2004, 279, 9287-9297.	n of the Brain	3.4	26
266	MUC1 Membrane Trafficking Is Modulated by Multiple Interactions. Journal of Biologic 2004, 279, 53071-53077.	al Chemistry,	3.4	49
267	Autocrine Extracellular Signal-regulated Kinase (ERK) Activation in Normal Human Kera Metalloproteinase-mediated Release of Amphiregulin Triggers Signaling from ErbB1 to Biology of the Cell, 2004, 15, 4299-4309.	tinocytes: ERK. Molecular	2.1	49
268	Cooperation of the ErbB2 receptor and transforming growth factor in induction of m invasion in mammary epithelial cells. Proceedings of the National Academy of Sciences States of America, 2004, 101, 1257-1262.	igration and of the United	7.1	222
269	Mechanisms of Disease: radiosensitization by epidermal growth factor receptor inhibit Clinical Practice Oncology, 2004, 1, 80-87.	ors. Nature	4.3	63
270	Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuz (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction. Clinica Research, 2004, 10, 2512-2524.	umab -2/neu and al Cancer	7.0	77
271	Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10,	6371S-6376S.	7.0	24
272	Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyros Cancer Research, 2004, 64, 3958-3965.	ine Kinase.	0.9	570
273	Heregulin Regulates the Ability of the ErbB3-binding Protein Ebp1 to Bind E2F Promote Repress E2F-mediated Transcription. Journal of Biological Chemistry, 2004, 279, 26126	er Elements and 5-26133.	3.4	42

#	Article	IF	CITATIONS
274	Activation of the ERK1/2 and p38 Mitogen-activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-induced Growth Arrest of Chondrocytes. Journal of Biological Chemistry, 2004, 279, 1747-1756.	3.4	105
275	Bipartite Inhibition of Drosophila Epidermal Growth Factor Receptor by the Extracellular and Transmembrane Domains of Kekkon1. Genetics, 2004, 167, 187-202.	2.9	16
276	ErbB4 Expression in Neural Progenitor Cells (ST14A) Is Necessary to Mediate Neuregulin-1β1-induced Migration. Journal of Biological Chemistry, 2004, 279, 48808-48816.	3.4	57
277	Role of proneuregulin 1 cleavage and human epidermal growth factor receptor activation in hypertonic aquaporin induction. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15799-15804.	7.1	21
278	Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects. Cancer Research, 2004, 64, 2601-2609.	0.9	99
279	Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development (Cambridge), 2004, 131, 5551-5560.	2.5	15
280	Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility. Journal of Biological Chemistry, 2004, 279, 24505-24513.	3.4	144
281	Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. British Journal of Cancer, 2004, 90, 449-454.	6.4	143
282	Targeting the epidermal growth factor receptor. British Journal of Cancer, 2004, 91, 418-424.	6.4	151
283	Prolonged Extracellular Signal-Regulated Kinase 1/2 Activation during Fibroblast Growth Factor 1- or Heregulin β1-Induced Antiestrogen-Resistant Growth of Breast Cancer Cells Is Resistant to Mitogen-Activated Protein/Extracellular Regulated Kinase Kinase Inhibitors. Cancer Research, 2004, 64, 4637-4647.	0.9	35
284	Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. American Journal of Physiology - Cell Physiology, 2004, 287, C807-C813.	4.6	23
285	Direct inhibition of ECF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Science, 2004, 95, 614-618.	3.9	41
286	The involvement of platelet-derived growth factor receptors and insulin-like growth factor-I receptors signaling during mineralized nodule formation by human periodontal ligament cells. Journal of Periodontal Research, 2004, 39, 388-397.	2.7	21
287	Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene, 2004, 23, 1428-1438.	5.9	18
288	Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene, 2004, 23, 5227-5241.	5.9	40
289	Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase. Oncogene, 2004, 23, 5023-5031.	5.9	13
290	Gefitinib (†Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. British Journal of Cancer, 2004, 90, 1679-1685.	6.4	50
291	Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. British Journal of Cancer, 2004, 91, 795-802.	6.4	55

#	Article	IF	CITATIONS
292	Post-ischemic Administration of Heparin-Binding Epidermal Growth Factor-like Growth Factor (HB-EGF) Reduces Infarct Size and Modifies Neurogenesis after Focal Cerebral Ischemia in the Rat. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 399-408.	4.3	93
293	Overexpression of ErbB-2 Protein in Human Middle Ear Cholesteatomas. Laryngoscope, 2004, 114, 1988-1991.	2.0	14
294	Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine. Journal of Controlled Release, 2004, 97, 357-369.	9.9	138
295	Oncogenic growth factor receptors: implications for signal transduction therapy. Seminars in Cancer Biology, 2004, 14, 262-270.	9.6	132
296	Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Progress in Retinal and Eye Research, 2004, 23, 195-228.	15.5	287
297	Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 2004, 5, 317-328.	16.8	977
298	A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Seminars in Oncology, 2004, 31, 83-92.	2.2	16
299	Targeting the HER-kinase axis in cancer. Seminars in Oncology, 2004, 31, 9-20.	2.2	59
300	Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-α. Biochemical Pharmacology, 2004, 68, 2221-2227.	4.4	5
301	HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 2004, 6, 517-527.	16.8	316
302	Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology, 2004, 50, 23-38.	4.4	164
303	PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 667-676.	4.9	1,036
304	Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells. Breast Cancer Research and Treatment, 2004, 87, 167-180.	2.5	120
305	Targeted therapies for non–small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. International Journal of Radiation Oncology Biology Physics, 2004, 59, S27-S38.	0.8	52
306	Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunology, Immunotherapy, 2004, 53, 217-226.	4.2	33
307	Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Critical Reviews in Oncology/Hematology, 2004, 49, 91-107.	4.4	36
308	Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. Journal of Pathology, 2004, 204, 317-325.	4.5	93
309	Differential protein expression in MCF7 breast cancer cells transfected with ErbB2, neomycin resistance and luciferase plus yellow fluorescent protein. Proteomics, 2004, 4, 2175-2183.	2.2	13

#	Article	IF	CITATIONS
310	Tissue interaction mediated by neuregulin-1 and ErbB receptors regulates epithelial morphogenesis of mouse embryonic submandibular gland. Developmental Dynamics, 2004, 230, 591-596.	1.8	38
311	HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. International Journal of Cancer, 2004, 108, 540-548.	5.1	73
312	Role of HER receptors family in development and differentiation. Journal of Cellular Physiology, 2004, 200, 343-350.	4.1	201
313	Negative growth control of renal cell carcinoma cell by connexin 32: Possible involvement of Her-2. Molecular Carcinogenesis, 2004, 40, 135-142.	2.7	35
314	Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Molecular Carcinogenesis, 2004, 41, 164-178.	2.7	71
315	Signal transduction and oncogenesis by ErbB/HER receptors. International Journal of Radiation Oncology Biology Physics, 2004, 58, 903-913.	0.8	333
316	Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. International Journal of Radiation Oncology Biology Physics, 2004, 58, 344-352.	0.8	120
317	Mechanisms of resistance to Erbitux (anti–epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. Journal of Gastrointestinal Surgery, 2004, 8, 960-970.	1.7	39
318	ErbB4 is downregulated in renal cell carcinoma A quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta OncolÃ ³ gica, 2004, 43, 453-459.	1.8	23
319	The erbB Family: Targets for Therapeutic Development Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase Inhibitors. Annual Review of Medicine, 2004, 55, 433-457.	12.2	188
320	Membrane Receptors. , 2004, , 147-213.		1
321	Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor. Journal of Biological Chemistry, 2004, 279, 30375-30384.	3.4	122
322	Inhibition of Proliferation, Migration, and Matrix Metalloprotease Production in Malignant Mesothelioma Cells by Tyrosine Kinase Inhibitors. Neoplasia, 2004, 6, 705-712.	5.3	21
323	Epidermal Growth Factor Receptor as a Therapeutic Target for the Treatment of Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, 51-62.	2.3	15
324	Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, 107-123.	2.3	4
325	Epidermal Growth Factor Receptor Family. , 2004, , 51-55.		2
326	ErbB Receptors: Directing Key Signaling Networks Throughout Life. Annual Review of Pharmacology and Toxicology, 2004, 44, 195-217.	9.4	533
327	A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib). Cancer	0.9	1,025

# 328	ARTICLE Androgen Receptor in Prostate Cancer. Endocrine Reviews, 2004, 25, 276-308.	lF 20.1	CITATIONS 1,475
329	Essential function for ErbB3 in breast cancer proliferation. Breast Cancer Research, 2004, 6, 137-9.	5.0	9
330	PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews, 2004, 30, 193-204.	7.7	1,918
331	Targeting of epidermal growth factor receptor by cyclopentenone prostaglandin 15-Deoxy-l"12,14-prostaglandin J2 in human oral squamous carcinoma cells. Cancer Letters, 2004, 211, 97-103.	7.2	7
332	Epidermal growth factor stimulation of RPE cell survival: contribution of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Experimental Eye Research, 2004, 79, 51-59.	2.6	44
333	ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Letters, 2004, 569, 332-336.	2.8	126
334	HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?. European Journal of Cancer, 2004, 40, 56-63.	2.8	112
335	Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochimica Et Biophysica Acta - General Subjects, 2004, 1673, 186-193.	2.4	19
336	Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochemical and Biophysical Research Communications, 2004, 324, 909-915.	2.1	55
337	EGF-dependent cell cycle progression is controlled by density-dependent regulation of Akt activation. Experimental Cell Research, 2004, 297, 272-284.	2.6	17
338	Bioactive recombinant neuregulin-1, -2, and -3 expressed in Escherichia coli. Protein Expression and Purification, 2004, 35, 25-31.	1.3	13
339	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Current Opinion in Urology, 2004, 14, 295-300.	1.8	16
340	Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. American Journal of Physiology - Renal Physiology, 2004, 287, G541-G546.	3.4	19
341	An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti–IL-6 antibody-induced apoptosis. Blood, 2004, 103, 1829-1837.	1.4	65
342	The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein. Biochemical Journal, 2004, 381, 257-266.	3.7	37
343	Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262.		0
344	Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity. Journal of Immunology, 2005, 174, 5481-5489.	0.8	25
345	Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. , 2005, , 433-450.		2

#	Article	IF	CITATIONS
346	EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity. Biochemical Journal, 2005, 392, 417-423.	3.7	29
347	HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. Pathology Research and Practice, 2005, 201, 141-144.	2.3	6
348	New dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4774-4779.	2.2	41
349	In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. European Radiology, 2005, 15, 4-13.	4.5	169
350	Genetic Alterations in Esophageal Cancer. Surgery Today, 2005, 35, 7-18.	1.5	111
351	Hyposmolarity-induced ErbB4 phosphorylation and its influence on the non-receptor tyrosine kinase network response in cultured cerebellar granule neurons. Journal of Neurochemistry, 2005, 93, 1189-1198.	3.9	20
352	Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas British Journal of Dermatology, 2005, 152, 1248-1255.	1.5	22
353	Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens. Cytopathology, 2005, 16, 303-308.	0.7	7
354	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). British Journal of Cancer, 2005, 92, 1711-1719.	6.4	128
355	Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. British Journal of Cancer, 2005, 93, 107-115.	6.4	133
356	ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer, 2005, 5, 341-354.	28.4	2,930
357	Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia, 2005, 19, 18-26.	7.2	38
358	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene, 2005, 24, 4540-4548.	5.9	111
359	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell, 2005, 8, 287-297.	16.8	372
360	Mechanism of action of a novel "combi-triazene―engineered to possess a polar functional group on the alkylating moiety: Evidence for enhancement of potency. Biochemical Pharmacology, 2005, 70, 511-519.	4.4	24
361	Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Biochemical Pharmacology, 2005, 70, 1035-1047.	4.4	125
362	2004 Highlights from: 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2004. Clinical Breast Cancer, 2005, 5, 413-420.	2.4	0
363	Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. Seminars in Oncology, 2005, 32, 315-328.	2.2	43

#	Article	IF	CITATIONS
364	N-methyl-N′-nitro-N-nitrosoguanidine interferes with the epidermal growth factor receptor-mediated signaling pathway. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 570, 175-184.	1.0	17
365	Modulation of signal transduction by tea catechins and related phytochemicals. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 591, 147-160.	1.0	109
366	Multiple Anti-apoptotic Pathways Stimulated by EGF in Cytotrophoblasts. Placenta, 2005, 26, 548-555.	1.5	37
367	In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor. Journal of Cellular Physiology, 2005, 205, 335-343.	4.1	15
368	Neuregulin-1 enhances survival of human astrocytic glioma cells. Glia, 2005, 51, 217-228.	4.9	45
369	Herceptinâ€induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic downâ€regulation of ErbB2. International Journal of Cancer, 2005, 116, 359-367.	5.1	130
370	Amplification of c-erbB2 oncogene. Cancer, 2005, 104, 1391-1397.	4.1	150
371	Developmental profile of ErbB receptors in murine central nervous system: Implications for functional interactions. Journal of Neuroscience Research, 2005, 79, 584-597.	2.9	95
372	Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 771-777.	6.4	11
373	Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD1839 (Iressa®). Strahlentherapie Und Onkologie, 2005, 181, 197-204.	2.0	32
374	Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers. Journal of Cancer Research and Clinical Oncology, 2005, 131, 49-59.	2.5	6
375	Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. Journal of Cancer Research and Clinical Oncology, 2005, 131, 649-652.	2.5	100
377	Transactivation of the Epidermal Growth Factor Receptor by Oxidized Glutathione and Its Pharmacological Analogue Glutoxim® in A431 Cells. Doklady Biological Sciences, 2005, 404, 392-394.	0.6	9
378	Roles for neuregulins in human cancer. Clinical and Experimental Metastasis, 2005, 21, 665-684.	3.3	45
379	Molecular mechanisms of drug resistance. Journal of Pathology, 2005, 205, 275-292.	4.5	1,270
380	Electrostatic interactions of peptides flanking the tyrosine kinase domain in the epidermal growth factor receptor provides a model for intracellular dimerization and autophosphorylation. Proteins: Structure, Function and Bioinformatics, 2005, 62, 1036-1043.	2.6	24
381	Targeting of the EGFR As a Modulator of Cancer Chemotherapy. , 2005, , 1-26.		2
382	Lapatinib: the evidence for its therapeutic value in metastatic breast cancer. Core Evidence, 2005, Volume 1-Issues 1 & 2, 0-0.	4.7	1

#	Article	IF	CITATIONS
383	Growth Factors, Receptors, and Kinases: Their Exploration to Target Cancer. , 2005, , 173-195.		3
384	Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Molecular Human Reproduction, 2005, 11, 543-551.	2.8	55
385	Reorganization of ErbB Family and Cell Survival Signaling after Knock-down of ErbB2 in Colon Cancer Cells. Journal of Biological Chemistry, 2005, 280, 27383-27392.	3.4	22
386	Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H660-H666.	3.2	104
387	Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. PLoS Medicine, 2005, 2, e313.	8.4	603
388	Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis. Journal of Biological Chemistry, 2005, 280, 30392-30399.	3.4	232
389	Induction of Human NF-IL6β by Epidermal Growth Factor Is Mediated through the p38 Signaling Pathway and cAMP Response Element-binding Protein Activation in A431 Cells. Molecular Biology of the Cell, 2005, 16, 3365-3376.	2.1	32
390	HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells. Cancer Research, 2005, 65, 4253-4260.	0.9	102
391	The secretory leukocyte protease inhibitor gene is a target of epidermal growth factor receptor action in endometrial epithelial cells. Journal of Endocrinology, 2005, 184, 141-151.	2.6	22
392	FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. Journal of Cell Biology, 2005, 171, 505-516.	5.2	126
393	The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15024-15029.	7.1	156
394	Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel. Clinical Cancer Research, 2005, 11, 1983-1989.	7.0	128
395	Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. Cancer Research, 2005, 65, 6801-6810.	0.9	63
396	Survivin Expression Is Regulated by Coexpression of Human Epidermal Growth Factor Receptor 2 and Epidermal Growth Factor Receptor via Phosphatidylinositol 3-Kinase/AKT Signaling Pathway in Breast Cancer Cells. Cancer Research, 2005, 65, 11018-11025.	0.9	163
397	Overexpression of RasN17 Fails to Neutralize Endogenous Ras in MCF7 Breast Cancer Cells. Journal of Biochemistry, 2005, 137, 731-739.	1.7	4
398	Role of Epidermal Growth Factor Receptor Signaling in RAS-Driven Melanoma. Molecular and Cellular Biology, 2005, 25, 4176-4188.	2.3	58
399	Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer. Clinical Cancer Research, 2005, 11, 3846-3853.	7.0	81
400	Lung Cancer in Women. Journal of Clinical Oncology, 2005, 23, 3212-3218.	1.6	137

#	Article	IF	CITATIONS
401	Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Tumor Biology, 2005, 26, 281-293.	1.8	287
402	Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer. Cancer Research, 2005, 65, 6789-6800.	0.9	135
403	Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Journal of Clinical Pathology, 2005, 58, 1076-1080.	2.0	38
404	Matrix Metalloproteinase/Epidermal Growth Factor Receptor/Mitogen-Activated Protein Kinase Signaling Regulatefra-1Induction by Cigarette Smoke in Lung Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 72-81.	2.9	62
405	Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. Future Oncology, 2005, 1, 235-245.	2.4	14
406	Stathmin Expression Modulates Migratory Properties of GN-11 Neurons in Vitro. Endocrinology, 2005, 146, 1825-1834.	2.8	35
407	Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncology, 2005, 1, 221-234.	2.4	58
408	Cetuximab in the treatment of colorectal cancer. Future Oncology, 2005, 1, 173-181.	2.4	17
409	Gene expression and immunolocalization of heparin-binding epidermal growth factor-like growth factor and human epidermal growth factor receptors in human corpus luteum. Human Reproduction, 2005, 20, 2708-2714.	0.9	14
410	Correlation between Laminin-5 γ ₂ Chain and Epidermal Growth Factor Receptor Expression in Esophageal Squamous Cell Carcinomas. Oncology, 2005, 69, 71-80.	1.9	33
411	Alternate Paths from Epidermal Growth Factor Receptor to Akt in Malignant Versus Nontransformed Lung Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 490-499.	2.9	31
412	Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Therapy, 2005, 12, 1394-1404.	4.5	42
413	Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2005, 23, 5578-5587.	1.6	382
414	Differential Localization of ErbB Receptor Ensembles Influences Their Signaling in Hippocampal Neurons. DNA and Cell Biology, 2005, 24, 553-562.	1.9	1
415	ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty. Oncologist, 2005, 10, 508-517.	3.7	27
416	Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. British Journal of Cancer, 2005, 92, 1421-1429.	6.4	37
417	The epidermal growth factor receptor family. Endocrine-Related Cancer, 2005, 12, S17-S27.	3.1	206
418	Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients, Journal of Clinical Oncology, 2005, 23, 1152-1160.	1.6	265

#	Article	IF	CITATIONS
419	Epidermal Growth Factor Receptor Acts as a Negative Regulator for Bacterium Nontypeable Haemophilus influenzae-induced Toll-like Receptor 2 Expression via an Src-dependent p38 Mitogen-activated Protein Kinase Signaling Pathway. Journal of Biological Chemistry, 2005, 280, 36185-36194.	3.4	53
420	A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2. Journal of Biological Chemistry, 2005, 280, 4656-4662.	3.4	46
421	Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy. Clinical Cancer Research, 2005, 11, 7480-7489.	7.0	95
422	<i>Darpp-32</i> : a Novel Antiapoptotic Gene in Upper Gastrointestinal Carcinomas. Cancer Research, 2005, 65, 6583-6592.	0.9	64
423	ErbB3 Expression Predicts Tumor Cell Radiosensitization Induced by Hsp90 Inhibition. Cancer Research, 2005, 65, 6967-6975.	0.9	46
424	Transmembrane Peptides from Tyrosine Kinase Receptor. Mutation-related Behavior in a Lipid Bilayer Investigated by Molecular Dynamics Simulations. Journal of Biomolecular Structure and Dynamics, 2005, 23, 91-100.	3.5	10
425	Novel Mechanism of Interaction of p85 Subunit of Phosphatidylinositol 3-Kinase and ErbB3 Receptor-derived Phosphotyrosyl Peptides. Journal of Biological Chemistry, 2005, 280, 1321-1326.	3.4	40
426	Proliferation of Human Neuroblastomas Mediated by the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 9868-9875.	0.9	122
427	Zinc Finger Transcription Factors Designed for Bispecific Coregulation of ErbB2 and ErbB3 Receptors: Insights into ErbB Receptor Biology. Molecular and Cellular Biology, 2005, 25, 9082-9091.	2.3	18
428	Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression. Cancer Research, 2005, 65, 8968-8974.	0.9	165
429	Phosphotyrosine interactome of the ErbBâ€receptor kinase family. Molecular Systems Biology, 2005, 1, 2005.0008.	7.2	468
430	Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis. Cancer Research, 2005, 65, 5848-5856.	0.9	44
431	A Single Nucleotide Polymorphism in the 5′ Untranslated Region of the <i>EGF</i> Gene Is Associated with Occurrence and Malignant Progression of Gastric Cancer. Pathobiology, 2005, 72, 133-138.	3.8	58
432	Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. Lancet Oncology, The, 2005, 6, 589-598.	10.7	40
433	Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Experimental Cell Research, 2005, 304, 604-619.	2.6	155
434	Differentiation of a mouse submandibular gland-derived cell line (SCA) grown on matrigel. Experimental Cell Research, 2005, 308, 394-406.	2.6	5
435	Differential effects of amphiregulin and TGF-α on the morphology of MDCK cells. Experimental Cell Research, 2005, 309, 149-160.	2.6	36
436	Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene, 2005, 24, 4220-4231.	5.9	44

#	Article	IF	CITATIONS
437	(â^')-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer Cells. Clinical Cancer Research, 2005, 11, 2735-2746.	7.0	312
438	ErbB2 growth factor receptor, a marker for neuroendocrine cells?. Pancreatology, 2005, 5, 44-58.	1.1	3
439	Predictive Markers in Breast and Other Cancers: A Review. Clinical Chemistry, 2005, 51, 494-503.	3.2	143
440	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. Expert Opinion on Therapeutic Targets, 2005, 9, 1009-1030.	3.4	47
441	Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR. Journal of Biological Chemistry, 2005, 280, 10025-10033.	3.4	88
442	Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor. Endocrinology, 2005, 146, 4609-4618.	2.8	177
443	A Novel Bispecific Tetravalent Antibody Fusion Protein to Target Costimulatory Activity for T-cell Activation to Tumor Cells Overexpressing ErbB2/HER2. Journal of Molecular Biology, 2005, 346, 1299-1311.	4.2	21
444	Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition. Molecular Immunology, 2005, 42, 1121-1124.	2.2	32
445	Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 23-37.	2.5	30
446	Growth factors and their relationship to neoplastic and paraneoplastic disease. European Journal of Internal Medicine, 2005, 16, 83-94.	2.2	3
447	Antitumor activity of HER-2 inhibitors. Cancer Letters, 2005, 227, 9-23.	7.2	82
448	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Letters, 2005, 230, 33-46.	7.2	34
449	Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Letters, 2005, 226, 169-184.	7.2	30
450	Differential effects of the EGF family of growth factors on protein secretion, MAPK activation, and intracellular calcium concentration in rat lacrimal gland. Experimental Eye Research, 2005, 80, 379-389.	2.6	15
451	Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation. FEBS Letters, 2005, 579, 1665-1669.	2.8	37
452	ZD1839 (Gefitinib, †Iressa'), an epidermal growth factor receptorâ€tyrosine kinase inhibitor, enhances the antiâ€cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Letters, 2005, 579, 4069-4075.	2.8	59
453	HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: Systematic analysis applying tissue microarray technique. Urology, 2005, 65, 176-180.	1.0	25
454	Role of HER2/HER3 co-receptor in breast carcinogenesis. Future Oncology, 2005, 1, 841-849.	2.4	37

#	Article	IF	CITATIONS
455	A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular Systems Biology, 2005, 1, 2005.0010.	7.2	902
456	Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6816-6822.	7.0	135
457	Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Research, 2005, 7, R589-97.	5.0	75
458	Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Research, 2005, 7, R708-18.	5.0	40
459	Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Research, 2005, 7, R617-26.	5.0	84
460	Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biology, 2005, 6, R84.	9.6	40
461	Transmembrane Helix Packing of ErbB/Neu Receptor in Membrane Environment: A Molecular Dynamics Study. Journal of Biomolecular Structure and Dynamics, 2006, 24, 209-228.	3.5	8
462	Effect of Dominant-Negative Epidermal Growth Factor Receptors on Cardiomyocyte Hypertrophy. Journal of Receptor and Signal Transduction Research, 2006, 26, 659-677.	2.5	14
463	Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opinion on Biological Therapy, 2006, 6, 1175-1192.	3.1	18
464	Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents, 2006, 16, 147-164.	5.0	3
465	Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients. Cancer Investigation, 2006, 24, 310-317.	1.3	39
466	Laminin α2 Chain-Positive Vessels and Epidermal Growth Factor in Lung Neuroendocrine Carcinoma. American Journal of Pathology, 2006, 168, 991-1003.	3.8	11
467	Prolactin Potentiates Transforming Growth Factor α Induction of Mammary Neoplasia in Transgenic Mice. American Journal of Pathology, 2006, 168, 1365-1374.	3.8	37
468	The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. Atherosclerosis, 2006, 186, 38-53.	0.8	163
469	Modeling the Effects of HER/ErbB1-3 Coexpression on Receptor Dimerization and Biological Response. Biophysical Journal, 2006, 90, 3993-4009.	0.5	62
470	Steroid Receptor Imaging in Breast Cancer. PET Clinics, 2006, 1, 51-70.	3.0	9
471	Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer. Drugs, 2006, 66, 1441-1463.	10.9	12
472	Lung Cancer in Women: Exploring Sex Differences in Susceptibility, Biology, and Therapeutic Response. Clinical Lung Cancer, 2006, 8, 22-29.	2.6	26

#	Article	IF	CITATIONS
473	Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Carcinoma. Clinical Lung Cancer, 2006, 8, S31-S35.	2.6	24
474	A review of erlotinib and its clinical use. Expert Opinion on Pharmacotherapy, 2006, 7, 177-193.	1.8	74
475	Multifunctional Polymeric Nanoparticles from Diverse Bioactive Agents. Journal of the American Chemical Society, 2006, 128, 4168-4169.	13.7	97
476	Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. Journal of Medicinal Chemistry, 2006, 49, 441-444.	6.4	45
477	Signal Integration During Development: Mechanisms of EGFR and Notch Pathway Function and Cross-Talk. Critical Reviews in Biochemistry and Molecular Biology, 2006, 41, 339-385.	5.2	118
478	Role of Receptor Tyrosine Kinase Transmembrane Domains in Cell Signaling and Human Pathologies. Biochemistry, 2006, 45, 6241-6251.	2.5	212
479	Tumor Endothelial Cells Express Epidermal Growth Factor Receptor (EGFR) but not ErbB3 and Are Responsive to EGF and to EGFR Kinase Inhibitors. Cancer Research, 2006, 66, 2173-2180.	0.9	200
480	ErbB receptors and epithelial-cadherin–catenin complex in human carcinomas. Future Oncology, 2006, 2, 765-781.	2.4	34
481	The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. British Journal of Cancer, 2006, 94, 1703-1709.	6.4	74
482	Sequestering ErbB2 in endoplasmic reticulum by its autoinhibitor from translocation to cell surface: An autoinhibition mechanism of ErbB2 expression. Biochemical and Biophysical Research Communications, 2006, 342, 19-27.	2.1	13
483	Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006, 366, 2-16.	2.2	1,744
484	Breast cancer markers. Cancer Letters, 2006, 243, 145-159.	7.2	29
485	Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. European Journal of Cancer, 2006, 42, 186-192.	2.8	25
486	Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors, 2006, 24, 121-136.	1.7	127
487	The Transmembrane Domain of the Oncogenic Mutant ErbB-2 Receptor: A Structure Obtained from Site-specific Infrared Dichroism and Molecular Dynamics. Journal of Molecular Biology, 2006, 361, 945-953.	4.2	23
488	Mitogenic and Apoptotic Actions of Epidermal Growth Factor on Neuroblastoma Cells Are Concentration-Dependent. Journal of Surgical Research, 2006, 135, 209-212.	1.6	15
489	Compensatory Increases in Her-2/neu Activation in Response to EGFR Tyrosine Kinase Inhibition in Colon Cancer Cell Lines. Journal of Surgical Research, 2006, 136, 227-231.	1.6	12
490	Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics, 2006, 1, 299-310.	0.4	6

#	Article	IF	CITATIONS
491	ErbB and HB-ECF Signaling in Heart Development and Function. Cell Structure and Function, 2006, 31, 1-14.	1.1	115
492	Src-Family Tyrosine Kinases in Wound- and Ligand-Induced Epidermal Growth Factor Receptor Activation in Human Corneal Epithelial Cells. , 2006, 47, 2832.		46
493	Cytostatic gene therapy for occlusive vascular disease. Expert Opinion on Therapeutic Patents, 2006, 16, 507-522.	5.0	0
494	Steric Hindrance of the HER-2/neu Dimerization Loop by Peptide Mimic Antibodies. , 2006, , 635-636.		0
495	A Phosphoproteomic Analysis of the ErbB2 Receptor Tyrosine Kinase Signaling Pathwaysâ€. Biochemistry, 2006, 45, 15529-15540.	2.5	49
496	Clinicopathologic Significance of EGFR and Her-2/neu in Colorectal Adenocarcinomas. Cancer Journal (Sudbury, Mass), 2006, 12, 229-236.	2.0	47
497	Trastuzumab and Antiestrogen Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 90-95.	1.3	31
498	Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. , 2006, 6, 5.		26
499	ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatric Pulmonology, 2006, 41, 1205-1212.	2.0	34
500	Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence. Prostate, 2006, 66, 1437-1444.	2.3	74
501	Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. International Journal of Urology, 2006, 13, 587-592.	1.0	62
502	Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. International Journal of Urology, 2006, 13, 1197-1201.	1.0	26
503	Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?. International Journal of Gynecological Cancer, 2006, 16, 416-422.	2.5	23
504	?-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Proliferation, 2006, 39, 563-574.	5.3	101
505	Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer, 2006, 6, 714-727.	28.4	661
506	Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death and Differentiation, 2006, 13, 576-585.	11.2	57
507	Neuronal survival depends on EGFR signaling in cortical but not midbrain astrocytes. EMBO Journal, 2006, 25, 752-762.	7.8	113
508	p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO Journal, 2006, 25, 5683-5692.	7.8	108

#	Article	IF	CITATIONS
509	Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene, 2006, 25, 5664-5672.	5.9	19
510	5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4021-4025.	2.2	75
511	Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("lressaâ€) and trastuzumab ("Herceptinâ€) . International Journal of Radiation Oncology Biology Physics, 2006, 66, 528-536.	0.8	31
512	Systematic molecular dynamics searching in a lipid bilayer: Application to the glycophorin A and oncogenic ErbB-2 transmembrane domains. Journal of Molecular Graphics and Modelling, 2006, 25, 226-233.	2.4	22
513	HER2 Specific Tumor Targeting with Dendrimer Conjugated Anti-HER2 mAb. Bioconjugate Chemistry, 2006, 17, 1109-1115.	3.6	201
514	Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. BioFactors, 2006, 28, 159-168.	5.4	54
515	The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 13-25.	2.7	65
516	ErbB Receptor Negative Regulatory Mechanisms: Implications in Cancer. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 89-99.	2.7	17
517	Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transduction pathway in human cancer cells. Molecular and Cellular Biochemistry, 2006, 285, 165-171.	3.1	8
518	Planning for Intracavitary Anti-EGFR Radionuclide Therapy of Gliomas. Literature Review and Data on EGFR Expression. Journal of Neuro-Oncology, 2006, 77, 33-45.	2.9	19
519	Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies. Child's Nervous System, 2006, 22, 1379-1394.	1.1	14
520	Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathology and Oncology Research, 2006, 12, 87-91.	1.9	56
521	The chemotherapeutic agent VP16 increases the stability of HB-EGF mRNA by a mechanism involving the 3′-UTR. Experimental Cell Research, 2006, 312, 3651-3658.	2.6	8
522	EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecologic Oncology, 2006, 101, 28-39.	1.4	29
523	Extracellular generation of hydrogen peroxide is responsible for activation of EGF receptor by ultraviolet A radiation. Free Radical Biology and Medicine, 2006, 41, 1478-1487.	2.9	25
524	Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cellular Signalling, 2006, 18, 2089-2097.	3.6	257
525	Cellular functions of cholesterol probed with optical biosensors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 254-261.	4.1	18
526	The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 120-139.	7.4	142

		CITATION R	REPORT	
#	Article		IF	CITATIONS
527	Epidermal Growth Factor Receptor Targeting in Cancer. Seminars in Oncology, 2006, 33,	369-385.	2.2	645
528	Steroid Receptors and Their Role in the Biology and Control of Breast Cancer Growth. See Oncology, 2006, 33, 631-641.	minars in	2.2	66
529	Human Cytomegalovirus-Induced Inhibition of Cytotrophoblast Invasion in a First Trimest Extravillous Cytotrophoblast Cell Line. Placenta, 2006, 27, 137-147.	er	1.5	44
530	Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinor Cancer, 2006, 6, 46.	mas. BMC	2.6	62
531	A Fluid Membrane-Based Soluble Ligand-Display System for Live-Cell Assays. ChemBioChe 436-440.	2006, 7,	2.6	35
532	Regulation of early Xenopus development by ErbB signaling. Developmental Dynamics, 20	006, 235, 301-314.	1.8	16
533	Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shec Journal of Cellular Biochemistry, 2006, 99, 609-623.	lding.	2.6	21
534	ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study. Jou Cellular Physiology, 2006, 206, 702-708.	urnal of	4.1	37
535	Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor among hormone-treated patients. International Journal of Cancer, 2006, 118, 284-289.	prognosis	5.1	163
536	Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based patients with metastatic breast cancer. International Journal of Cancer, 2006, 118, 1126-	therapy in 1134.	5.1	48
537	Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 block a conditional mouse tumor model. Molecular Carcinogenesis, 2006, 45, 302-308.	ing therapy in	2.7	12
538	Her2-Targeted Therapies in Non–Small Cell Lung Cancer. Clinical Cancer Research, 200	6, 12, 4377s-4383s.	7.0	63
539	Insulin Growth Factor-I and Epidermal Growth Factor Receptors Recruit Distinct Upstrean Molecules to Enhance AKT Activation in Mammary Epithelial Cells. Endocrinology, 2006, 2	n Signaling 147, 6027-6035.	2.8	18
540	Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin- Ne transgene. Carcinogenesis, 2006, 27, 1054-1067.	u oncogenic	2.8	50
541	Implantation. , 2006, , 147-188.			6
542	A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-α Fusion Protein Induces HER2 and Facilitates Repair of Injured Epithelia. Journal of Pharmacology and Experimental Ther 2006, 316, 983-991.	2/neu Signaling apeutics,	2.5	32
543	EXPRESSION OF ErbB PROTEINS IN HUMAN PROSTATE. Archives of Andrology, 2006, 52,	185-190.	1.0	4
544	ERBB2-Mediated Transcriptional Up-regulation of the α5β1 Integrin Fibronectin Recepto Tumor Cell Survival Under Adverse Conditions. Cancer Research, 2006, 66, 3715-3725.	r Promotes	0.9	65

#	Article	IF	CITATIONS
545	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells. Molecular Cancer Therapeutics, 2006, 5, 1154-1165.	4.1	90
546	Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2006, 12, 7406-7413.	7.0	20
547	Essential Role for Rac in Heregulin β1 Mitogenic Signaling: a Mechanism That Involves Epidermal Growth Factor Receptor and Is Independent of ErbB4. Molecular and Cellular Biology, 2006, 26, 831-842.	2.3	82
548	Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model. Clinical Cancer Research, 2006, 12, 183-190.	7.0	96
549	ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors. Clinical Cancer Research, 2006, 12, 1008s-1012s.	7.0	43
550	Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. Genes and Development, 2006, 20, 939-953.	5.9	49
551	Heregulin-Dependent Delay in Mitotic Progression Requires HER4 and BRCA1. Molecular and Cellular Biology, 2006, 26, 6412-6424.	2.3	41
552	Chemoresistance in solid tumours. Annals of Oncology, 2006, 17, x315-x324.	1.2	150
553	Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer, 2006, 13, S89-S97.	3.1	17
554	In Utero Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin Induces Amphiregulin Gene Expression in the Developing Mouse Ureter. Toxicological Sciences, 2006, 94, 163-174.	3.1	29
555	Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4245-4253.	1.6	63
556	Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines. Cancer Research, 2006, 66, 3802-3812.	0.9	53
557	HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. Journal of Clinical Pathology, 2006, 60, 1001-1005.	2.0	42
558	A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. Rheumatology, 2006, 45, 1466-1476.	1.9	38
559	Polymorphism ofegfrIntron1 is Associated with Susceptibility and Severity of Asthma. Journal of Asthma, 2006, 43, 711-715.	1.7	16
560	The Gefitinib-Sensitizing Mutant Epidermal Growth Factor Receptor Enables Transformation of a Mouse Fibroblast Cell Line. DNA and Cell Biology, 2006, 25, 246-251.	1.9	13
561	Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Research, 2006, 66, 1630-1639.	0.9	846
562	ErbB-3 Predicts Survival in Ovarian Cancer. Journal of Clinical Oncology, 2006, 24, 4317-4323.	1.6	190

#	Article	IF	CITATIONS
563	Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 2006, 12, 2730-2737.	7.0	114
564	rab7 Activity Affects Epidermal Growth Factor:Epidermal Growth Factor Receptor Degradation by Regulating Endocytic Trafficking from the Late Endosome. Journal of Biological Chemistry, 2006, 281, 1099-1106.	3.4	128
565	The Extracellular Domain of p185c-neuInduces Density-Dependent Inhibition of Cell Growth in Malignant Mesothelioma Cells and Reduces Growth of Mesotheliomaln Vivo. DNA and Cell Biology, 2006, 25, 530-540.	1.9	1
566	Monitoring the Activation State of Insulin/Insulin-Like Growth Factor-1 Hybrid Receptors Using Bioluminescence Resonance Energy Transfer. Molecular Pharmacology, 2006, 70, 1802-1811.	2.3	34
567	Heregulin-mediated ErbB2-ERK Signaling Activates Hyaluronan Synthases Leading to CD44-dependent Ovarian Tumor Cell Growth and Migration. Journal of Biological Chemistry, 2007, 282, 19426-19441.	3.4	130
568	Epidermal Growth Factor Directs Sex-specific Steroid Signaling through Src Activation. Journal of Biological Chemistry, 2007, 282, 10697-10706.	3.4	38
569	Apical Epidermal Growth Factor Receptor Signaling: Regulation of Stretch-dependent Exocytosis in Bladder Umbrella Cells. Molecular Biology of the Cell, 2007, 18, 1312-1323.	2.1	43
570	PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. British Journal of Cancer, 2007, 96, 801-807.	6.4	75
571	GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis, 2007, 29, 473-479.	2.8	58
572	Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. Oncologist, 2007, 12, 840-849.	3.7	100
573	Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular Cancer Therapeutics, 2007, 6, 93-100.	4.1	56
574	Independent Review of Interstitial Lung Disease Associated with Death in TRIBUTE (Paclitaxel and) Tj ETQq1 1 0.7 of Thoracic Oncology, 2007, 2, 537-543.	'84314 rgl 1.1	BT /Overloc 37
575	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. Expert Opinion on Drug Discovery, 2007, 2, 335-348.	5.0	5
576	Contribution of Membrane Mucins to Tumor Progression Through Modulation of Cellular Growth Signaling Pathways. Current Topics in Developmental Biology, 2007, 78, 1-22.	2.2	73
577	Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. Expert Opinion on Therapeutic Patents, 2007, 17, 83-102.	5.0	10
578	Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis. DNA and Cell Biology, 2007, 26, 178-185.	1.9	18
579	The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines. Clinical Cancer Research, 2007, 13, 6419-6428.	7.0	131
580	Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Gene Polymorphisms in Endometrial Cancer in a Japanese Population. Reproductive Sciences, 2007, 14, 349-357.	2.5	12

#	Article	IF	CITATIONS
581	Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing <i>EGFR</i> Gene Mutation and Amplification. Cancer Research, 2007, 67, 2046-2053.	0.9	166
582	Biology of Interactions: Antiepidermal Growth Factor Receptor Agents. Journal of Clinical Oncology, 2007, 25, 4057-4065.	1.6	209
583	UBPY-mediated Epidermal Growth Factor Receptor (EGFR) De-ubiquitination Promotes EGFR Degradation. Journal of Biological Chemistry, 2007, 282, 1658-1669.	3.4	125
584	Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis. Cancer Research, 2007, 67, 827-835.	0.9	48
585	Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies. Oncologist, 2007, 12, 1404-1415.	3.7	115
586	ErbB4 Isoforms Selectively Regulate Growth Factor–induced Madin-Darby Canine Kidney Cell Tubulogenesis. Molecular Biology of the Cell, 2007, 18, 4446-4456.	2.1	39
587	Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family. Journal of Biological Chemistry, 2007, 282, 10432-10440.	3.4	208
588	Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor–Expressing Breast Carcinomas. Clinical Cancer Research, 2007, 13, 6070-6079.	7.0	80
589	Gliclazide Inhibits Proliferation but Stimulates Differentiation of White and Brown Adipocytes. Journal of Biochemistry, 2007, 142, 639-645.	1.7	14
590	Degradation of HER2 by Cbl-Based Chimeric Ubiquitin Ligases. Cancer Research, 2007, 67, 8716-8724.	0.9	33
591	Growth Stimulation of Non–Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers. Molecular Cancer Research, 2007, 5, 393-401.	3.4	11
592	Cornichon-like Protein Facilitates Secretion of HB-EGF and Regulates Proper Development of Cranial Nerves. Molecular Biology of the Cell, 2007, 18, 1143-1152.	2.1	22
593	The α6β4 Integrin Can Regulate ErbB-3 Expression: Implications for α6β4 Signaling and Function. Cancer Research, 2007, 67, 1645-1652.	0.9	54
594	Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1. Molecular and Cellular Biology, 2007, 27, 2180-2188.	2.3	107
595	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Annals of Oncology, 2007, 18, 421-430.	1.2	40
596	UV light blocks EGFR signalling in human cancer cell lines. International Journal of Oncology, 2007, 30, 181-5.	3.3	8
597	Pharmacology of Epidermal Growth Factor Inhibitors. International Journal of Biological Markers, 2007, 22, 24-39.	1.8	10
598	Epidermal Growth Factor Receptor Serum Levels and Prognostic Value in Malignant Gliomas. Tumori, 2007, 93, 275-280.	1.1	36

ARTICLE IF CITATIONS Her-2 Protein Expression, Cellular Localization, and Gene Amplification in Colorectal Carcinoma. 599 1.2 8 Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 441-445. The cutting edge: apoptosis and therapeutic opportunity., 2007, , 117-142. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: 601 Gefitinib (Iressaâ,,¢)-induced changes in the expression and nucleo-cytoplasmic trafficking of 4.0 31 HER-ligands (Review). International Journal of Molecular Medicine, 0, , . Regulation of Xenopus gastrulation by ErbB signaling. Developmental Biology, 2007, 303, 93-107. 2.0 Developmental profile of neuregulin receptor ErbB4 in postnatal rat cerebral cortex and 603 2.3 21 hippocampus. Neuroscience, 2007, 148, 126-139. Evaluation of radiolabeled MLO4, a putative irreversible inhibitor of epidermal growth factor 604 receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nuclear Medicine and Biology, 2007, 34, 55-70. 605 5-Fluorouracil., 2007,, 263-278. 7 Activation of growth factor receptors in pancreatic cancer. American Journal of Surgery, 2007, 194, 606 1.8 S76-S83. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). European Journal of Cancer, 2007, 43, 607 2.8 142 481-489. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). 608 2.8 European Journal of Cancer, 2007, 43, 725-735. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown. Cancer 609 7.2 25 Letters, 2007, 248, 137-146. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Letters, 2007, 251, 237-246. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. 611 2.0 25 Human Pathology, 2007, 38, 1526-1531. Differential ErbB1 Signaling in Squamous Cell versus Basal Cell Carcinoma of the Skin. American Journal of Pathology, 2007, 170, 2089-2099. 3.8 EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The 613 42 5.3 Modulator Role of P13K/Akt. Neoplasia, 2007, 9, 614-624. Heregulin Î²1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer 614 cells. Breast Cancer Research, 2007, 9, R50. The involvement of lipid rafts in epidermal growth factor-induced chemotaxis of breast cancer cells. 615 2.0 32 Molecular Membrane Biology, 2007, 24, 91-101. Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways. Journal of the National Cancer Institute, 2007, 99, 6.3 288 616-627.

#	Article	IF	CITATIONS
617	Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non‣mall Cell Lung Cancer—A Review of the Literature. Oncologist, 2007, 12, 201-210.	3.7	79
619	Association study between epidermal growth factor receptor and epidermal growth factor polymorphisms and endometriosis in a Japanese population. Gynecological Endocrinology, 2007, 23, 474-478.	1.7	15
620	System properties of ErbB receptor signaling for the understanding of cancer progression. Molecular BioSystems, 2007, 3, 111-116.	2.9	4
621	Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome. Lung Cancer, 2007, 57, 193-200.	2.0	21
622	PI3K and Erk MAPK mediate ErbB signaling in Xenopus gastrulation. Mechanisms of Development, 2007, 124, 657-667.	1.7	25
623	Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behavioral and Brain Functions, 2007, 3, 31.	3.3	107
624	Enumeration of Oligomerization States of Membrane Proteins in Living Cells by Homo-FRET Spectroscopy and Microscopy: Theory and Application. Biophysical Journal, 2007, 92, 3098-3104.	0.5	91
625	Basic aspects of implantation. Reproductive BioMedicine Online, 2007, 15, 728-739.	2.4	63
626	HB-EGF, Transactivation, and Cardiac Hypertrophy. International Journal of Gerontology, 2007, 1, 2-9.	0.6	5
627	Erlotinib in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2579-2592.	1.8	11
628	A Dimerization Hierarchy in the Transmembrane Domains of the HER Receptor Family. Biochemistry, 2007, 46, 2010-2019.	2.5	67
629	Análise da expressão imuno-histoquÃmica de c-erbB-2 e EGFR em carcinoma epidermóide de esà fago. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2007, 43, .	0.3	1
630	Cross Talk between c-Met and Epidermal Growth Factor Receptor during Retinal Pigment Epithelial Wound Healing. , 2007, 48, 2242.		78
631	Lysophosphatidic Acid Promoting Corneal Epithelial Wound Healing by Transactivation of Epidermal Growth Factor Receptor. , 2007, 48, 636.		60
633	Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activityin vitro andin vivo. International Journal of Cancer, 2007, 120, 329-336.	5.1	9
634	Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. International Journal of Cancer, 2007, 120, 1874-1882.	5.1	134
635	Signal peptide of eosinophil cationic protein upregulates transforming growth factorâ€ e lpha expression in human cells. Journal of Cellular Biochemistry, 2007, 100, 1266-1275.	2.6	18
636	Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer, 2007, 110, 509-517.	4.1	36
#	Article	IF	CITATIONS
-----	--	------	-----------
637	First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer, 2007, 110, 752-758.	4.1	38
638	Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 405-409.	0.8	115
639	Neuregulin3 alters cell fate in the epidermis and mammary gland. BMC Developmental Biology, 2007, 7, 105.	2.1	36
640	Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene, 2007, 26, 4951-4960.	5.9	78
641	Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene, 2007, 26, 3654-3660.	5.9	140
642	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene, 2007, 26, 6469-6487.	5.9	867
643	Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer. Nature Reviews Cancer, 2007, 7, 701-706.	28.4	72
644	Modulation of Porcine Wound Repair with a Transfected ErbB3 Gene and Relevant EGF-Like Ligands. Journal of Investigative Dermatology, 2007, 127, 1030-1041.	0.7	20
645	hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours. British Journal of Cancer, 2007, 96, 762-768.	6.4	9
646	Apoptosis commitment – translating survival signals into decisions on mitochondria. Cell Research, 2007, 17, 976-984.	12.0	70
647	Requirement for ErbB2/ErbB signaling in developing cartilage and bone. Development Growth and Differentiation, 2007, 49, 503-513.	1.5	36
648	Cimetidine inhibits epidermal growth factor-induced cell signaling. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 436-443.	2.8	15
649	Variant genotypes and haplotypes of the epidermal growth factor gene promoter are associated with a decreased risk of gastric cancer in a high-risk Chinese population. Cancer Science, 2007, 98, 864-868.	3.9	35
650	Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Science, 2007, 98, 1977-1984.	3.9	33
651	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptinâ"¢) in HER2-overexpressing breast cancer cells. BMC Cancer, 2007, 7, 80.	2.6	154
652	Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 383-390.	4.1	52
653	EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors. Cancer Genetics and Cytogenetics, 2007, 173, 63-67.	1.0	16
654	Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners. Cellular Signalling, 2007, 19, 466-471.	3.6	16

#	Article	IF	CITATIONS
655	Identification of a novel EGF-sensitive cell cycle checkpoint. Experimental Cell Research, 2007, 313, 511-526.	2.6	16
656	Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecologic Oncology, 2007, 104, 158-167.	1.4	49
657	Future Strategies for Targeted Therapies and Tailored Patient Management in Pancreatic Cancer. Seminars in Oncology, 2007, 34, 354-364.	2.2	9
658	Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?. Breast Cancer, 2007, 14, 156-162.	2.9	22
659	Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma. Strahlentherapie Und Onkologie, 2007, 183, 256-264.	2.0	64
660	Role of heregulin in human cancer. Cellular and Molecular Life Sciences, 2007, 64, 2358-2377.	5.4	80
661	Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Research and Treatment, 2007, 101, 249-257.	2.5	36
662	Breast cancer brain metastases. Cancer and Metastasis Reviews, 2007, 26, 635-643.	5.9	93
663	Gene copy numbers of HER family in breast cancer. Journal of Cancer Research and Clinical Oncology, 2007, 134, 271-279.	2.5	22
664	Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovascular Toxicology, 2007, 7, 114-121.	2.7	141
665	An update into the pathophysiological role of HER2 in cancer: therapeutic implications. Clinical and Translational Oncology, 2007, 9, 543-544.	2.4	1
666	Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma. Targeted Oncology, 2007, 2, 99-105.	3.6	6
667	Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Critical Reviews in Oncology/Hematology, 2007, 61, 52-69.	4.4	150
668	The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. Colloids and Surfaces B: Biointerfaces, 2007, 60, 1-6.	5.0	26
669	A case–control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clinical Biochemistry, 2008, 41, 121-125.	1.9	22
670	Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (†Iressa') response and resistance. Breast Cancer Research and Treatment, 2008, 111, 79-91.	2.5	71
671	EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women. Breast Cancer Research and Treatment, 2008, 111, 321-327.	2.5	21
672	Targeted therapy for oesophageal cancer: an overview. Cancer and Metastasis Reviews, 2008, 27, 273-288.	5.9	23

#	Article	IF	CITATIONS
673	The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer and Metastasis Reviews, 2008, 27, 575-587.	5.9	18
674	Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. International Urology and Nephrology, 2008, 40, 321-327.	1.4	55
675	Mechanistic Aspects of Crosstalk Between GH and PRL and ErbB Receptor Family Signaling. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 119-129.	2.7	24
676	The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 205-214.	2.7	43
677	ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 235-246.	2.7	85
678	Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search. European Biophysics Journal, 2008, 37, 851-864.	2.2	12
679	EGFR Inhibitor Enhances Cisplatin Sensitivity of Oral Squamous Cell Carcinoma Cell Lines. Pathology and Oncology Research, 2008, 14, 39-43.	1.9	41
680	Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochemistry and Cell Biology, 2008, 129, 563-578.	1.7	166
681	Analysis of transient phosphorylation-dependent protein-protein interactions in living mammalian cells using split-TEV. BMC Biotechnology, 2008, 8, 55.	3.3	38
682	The UPS: a promising target for breast cancer treatment. BMC Biochemistry, 2008, 9, S2.	4.4	20
683	Phosphoproteomics, oncogenic signaling and cancer research. Proteomics, 2008, 8, 4370-4382.	2.2	30
684	Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics, 2008, 8, 4383-4401.	2.2	93
685	Epitope mapping and structural analysis of an anti‣rbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins: Structure, Function and Bioinformatics, 2008, 70, 938-949.	2.6	31
686	Comparison of delphinidin, quercetin and (–)â€epigallocatechinâ€3â€gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. Molecular Nutrition and Food Research, 2008, 52, 815-822.	3.3	51
687	Fungiform papilla pattern: EGF regulates interâ€papilla lingual epithelium and decreases papilla number by means of PI3K/Akt, MEK/ERK, and p38 MAPK signaling. Developmental Dynamics, 2008, 237, 2378-2393.	1.8	35
688	Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables. International Journal of Cancer, 2008, 123, 1508-1515.	5.1	52
689	M-FISH and QuantiFISH. Imaging & Microscopy, 2008, 10, 46-49.	0.1	0
690	Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloproteaseâ€dependent ectodomain shedding and exosome secretion. Journal of Cellular Biochemistry, 2008, 103, 1783-1797.	2.6	104

#	Article	IF	CITATIONS
691	MMTVâ€ECF receptor transgene promotes preneoplastic conversion of multiple steroid hormoneâ€responsive tissues. Journal of Cellular Biochemistry, 2008, 103, 2010-2018.	2.6	13
692	Downâ€modulation of erbB2 activity is necessary but not enough in the differentiation of 3T3‣1 preadipocytes. Journal of Cellular Biochemistry, 2008, 104, 274-285.	2.6	15
693	Quercetinâ€induced ubiquitination and downâ€regulation of Herâ€2/ <i>neu</i> . Journal of Cellular Biochemistry, 2008, 105, 585-595.	2.6	65
694	The role of the EGFR signaling in tumor microenvironment. Journal of Cellular Physiology, 2008, 214, 559-567.	4.1	323
695	Synergistic antiâ€proliferative and proâ€apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with antiâ€epidermal growth factor receptor (EGFR) drugs in human cancer cells. Journal of Cellular Physiology, 2008, 216, 698-707.	4.1	33
696	The Development of HKIâ€⊋72 and Related Compounds for the Treatment of Cancer. Archiv Der Pharmazie, 2008, 341, 465-477.	4.1	145
697	Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3495-3499.	2.2	51
698	Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biology International, 2008, 32, 814-826.	3.0	18
699	4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4615-4619.	2.2	69
700	Differential Efficacy of Combined Therapy With Radiation and AEE788 in High and Low EGFR-Expressing Androgen-Independent Prostate Tumor Models. International Journal of Radiation Oncology Biology Physics, 2008, 71, 237-246.	0.8	15
701	HER-2, P53 and hormonal receptors protein expression as predictive factors in breast cancer prognosis. Chinese Journal of Clinical Oncology, 2008, 5, 413-417.	0.0	1
702	Computational Study of the Binding Mode of Epidermal Growth Factor Receptor Kinase Inhibitors. Chemical Biology and Drug Design, 2008, 71, 434-446.	3.2	17
703	Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow), 2008, 73, 605-618.	1.5	35
704	The reduced catalase expression in TrkA-induced cells leads to autophagic cell death via ROS accumulation. Experimental Cell Research, 2008, 314, 3094-3106.	2.6	134
705	Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Experimental Cell Research, 2008, 314, 3415-3425.	2.6	46
706	The status and role of ErbB receptors in human cancer. Experimental and Molecular Pathology, 2008, 84, 79-89.	2.1	77
707	Unraveling the Biologic and Clinical Complexities of HER2. Clinical Breast Cancer, 2008, 8, 392-401.	2.4	92
708	Can We Circumvent Resistance To ErbB2-Targeted Agents By Targeting Novel Pathways?. Clinical Breast Cancer, 2008, 8, S121-S130.	2.4	22

#	Article	IF	CITATIONS
709	Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 232-265.	7.4	134
710	Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1786, 105-113.	7.4	27
711	Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. Journal of Cellular and Molecular Medicine, 2008, 12, 1527-1534.	3.6	91
712	ErbB2 and fatty acid synthase (FAS) expression in 102 squamous cell carcinomas of the tongue: Correlation with clinical outcomes. Oral Oncology, 2008, 44, 484-490.	1.5	22
713	Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase. Structure, 2008, 16, 460-467.	3.3	159
714	Clinicopathological and prognostic significance of EGFR, VECF, and HER2 expression in cholangiocarcinoma. British Journal of Cancer, 2008, 98, 418-425.	6.4	348
715	Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients. Lung Cancer, 2008, 61, 328-339.	2.0	45
716	Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer. Clinical Breast Cancer, 2008, 8, S100-S113.	2.4	37
717	Modeling Morphogenesis and Oncogenesis in Three-Dimensional Breast Epithelial Cultures. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 313-339.	22.4	113
718	HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology, 2008, 19, 295102.	2.6	79
719	High expression of Ki-67 and cyclin D1 in invasive extramammary Paget's disease. Journal of Dermatological Science, 2008, 50, 177-184.	1.9	45
720	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. European Journal of Cancer, Supplement, 2008, 6, 86-90.	2.2	2
721	Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Research, 2008, 10, R70.	5.0	24
722	Monoclonal Antibody Therapy for Prostate Cancer. Handbook of Experimental Pharmacology, 2008, , 237-256.	1.8	10
723	ErbB3 mRNA Expression Correlated with Specific Clinicopathologic Features of Japanese Lung Cancers. Journal of Surgical Research, 2008, 146, 43-48.	1.6	18
724	De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure. Molecular Immunology, 2008, 45, 106-116.	2.2	5
725	Dimerization properties of the transmembrane domains of Arabidopsis CRINKLY4 receptor-like kinase and homologs. Archives of Biochemistry and Biophysics, 2008, 477, 219-226.	3.0	14
726	Clinical utility of type 1 growth factor receptor expression in colon cancer. American Journal of Surgery, 2008, 195, 604-610.	1.8	17

#	Article	IF	CITATIONS
727	Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nuclear Medicine and Biology, 2008, 35, 579-588.	0.6	69
728	ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. Journal of Molecular and Cellular Cardiology, 2008, 44, 831-854.	1.9	155
729	Expression profile of ErbB receptor's family in human alveolar type 2-like cell line A549 exposed to hexavalent chromium. Toxicology in Vitro, 2008, 22, 541-547.	2.4	11
731	Quantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking. Biochemical and Biophysical Research Communications, 2008, 371, 220-224.	2.1	20
732	Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clinical Therapeutics, 2008, 30, 14-30.	2.5	61
733	Targeted therapies in breast cancer. Seminars in Diagnostic Pathology, 2008, 25, 245-261.	1.5	39
734	Molecular Genetics of Pancreatic Cancer. , 2008, , 27-39.		4
735	System theoretical investigation of human epidermal growth factor receptor-mediated signalling. IET Systems Biology, 2008, 2, 273-284.	1.5	60
736	Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State. Journal of Biological Chemistry, 2008, 283, 6950-6956.	3.4	189
737	Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. Cancer Investigation, 2008, 26, 757-768.	1.3	9
738	First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 847-853.	5.6	66
739	The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor Activation. Journal of Biological Chemistry, 2008, 283, 18393-18401.	3.4	163
740	t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways. Carcinogenesis, 2008, 29, 1013-1021.	2.8	21
741	Gefitinib: a consideration of cost. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 223-232.	1.4	0
742	Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity <i>in vitro</i> and in human tumor xenografts. Molecular Cancer Therapeutics, 2008, 7, 3223-3236.	4.1	27
743	High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer. Clinical Cancer Research, 2008, 14, 7843-7849.	7.0	123
744	Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3-K, Akt and both p38 and p42/44 mitogen-activated protein kinases. Human Reproduction, 2008, 23, 1733-1741.	0.9	58
745	Killing cancer cells by targeting the EGF receptor. Cancer Biology and Therapy, 2008, 7, 243-244.	3.4	1

#	Article	IF	CITATIONS
746	Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. Breast Care, 2008, 3, 7-12.	1.4	1
747	Neuregulin-mediated ErbB3 signaling is required for formation of zebrafish dorsal root ganglion neurons. Development (Cambridge), 2008, 135, 2615-2625.	2.5	74
748	Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics, 2008, 7, 1846-1850.	4.1	70
749	Mutational Activation of ErbB2 Reveals a New Protein Kinase Autoinhibition Mechanism. Journal of Biological Chemistry, 2008, 283, 1588-1596.	3.4	35
750	Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. Clinical Cancer Research, 2008, 14, 4943-4950.	7.0	63
751	Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis. Cancer Research, 2008, 68, 2122-2131.	0.9	45
752	Synergistic Growth Inhibition by 9- <i>cis</i> -Retinoic Acid Plus Trastuzumab in Human Hepatocellular Carcinoma Cells. Clinical Cancer Research, 2008, 14, 2806-2812.	7.0	32
753	Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques. Journal of Histochemistry and Cytochemistry, 2008, 56, 667-675.	2.5	14
754	A Central Role for HER3 in <i>HER2</i> -Amplified Breast Cancer: Implications for Targeted Therapy. Cancer Research, 2008, 68, 5878-5887.	0.9	559
755	Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis, 2008, 29, 704-712.	2.8	99
756	Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. Molecular and Cellular Proteomics, 2008, 7, 1902-1924.	3.8	103
757	HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Molecular Cancer Therapeutics, 2008, 7, 3499-3508.	4.1	121
758	Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clinical Cancer Research, 2008, 14, 4877-4882.	7.0	294
759	Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model. Clinical Cancer Research, 2008, 14, 2253-2262.	7.0	49
760	Chemical and Pathway Proteomics. Molecular and Cellular Proteomics, 2008, 7, 1887-1901.	3.8	43
761	A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. Oncologist, 2008, 13, 467-473.	3.7	53
762	Autoantibody Biomarkers in Prostate Cancer. Laboratory Medicine, 2008, 39, 165-171.	1.2	3
763	Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL. Cancer Research, 2008, 68, 8312-8321.	0.9	33

#	Article	IF	CITATIONS
764	Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2008, 14, 6730-6734.	7.0	102
765	ErbB Antagonists Patenting: "Playing Chess with Cancer". Recent Patents on Biotechnology, 2008, 2, 181-187.	0.8	8
766	Memo Is Homologous to Nonheme Iron Dioxygenases and Binds an ErbB2-derived Phosphopeptide in Its Vestigial Active Site. Journal of Biological Chemistry, 2008, 283, 2734-2740.	3.4	25
767	Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation. Molecular Pharmacology, 2008, 74, 807-822.	2.3	54
768	All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. Journal of Cell Science, 2008, 121, 3207-3217.	2.0	180
769	New small-molecule inhibitors of mitogen-activated protein kinase kinase. Expert Opinion on Drug Discovery, 2008, 3, 801-817.	5.0	1
770	TypeÂl receptor tyrosine kinases as predictive or prognostic markers in early breast cancer. Biomarkers in Medicine, 2008, 2, 397-407.	1.4	7
771	SDF-1/54-DCN: A Novel Recombinant Chimera with Dual Inhibitory Effects on Proliferation and Chemotaxis of Tumor Cells. Biological and Pharmaceutical Bulletin, 2008, 31, 1086-1091.	1.4	7
772	ErbB receptors modulation in different types of peripheral nerve regeneration. NeuroReport, 2008, 19, 1605-1609.	1.2	15
773	The EGFR family of receptors sensitizes cancer cells towards UV light. Proceedings of SPIE, 2008, , .	0.8	2
774	Mass Spectrometry Based Proteomics as aÂTool for the Analysis of Protein–Protein Interactions in Signaling Processes. , 2008, , 315-329.		1
775	Targeting Receptor Tyrosine Kinases for Chemoprevention by Green Tea Catechin, EGCG. International Journal of Molecular Sciences, 2008, 9, 1034-1049.	4.1	91
776	Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 707.	3.2	17
777	Topological Analysis of MAPK Cascade for Kinetic ErbB Signaling. PLoS ONE, 2008, 3, e1782.	2.5	22
778	Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens. Current Pharmacogenomics and Personalized Medicine, 2009, 7, 263-274.	0.2	56
779	Multiple roles and therapeutic implications of Akt signaling in cancer. OncoTargets and Therapy, 2009, 2, 135.	2.0	14
780	Effects of \hat{I} ±-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells. Nutrition Research and Practice, 2009, 3, 265.	1.9	42
781	Rational Optimization of a Bispecific Ligand Trap Targeting EGF Receptor Family Ligands. Molecular Medicine, 2009, 15, 11-20.	4.4	8

#	Article	IF	CITATIONS
782	Expression of the Epidermal Growth Factor Receptor Family in Correlation to the Estrogen Receptor α Expression in Peritoneal and Ovarian Endometriosis. Journal of Endometriosis, 2009, 1, 122-130.	1.0	0
783	Pathogenic and opportunistic respiratory bacteria-induced apoptosis. Brazilian Journal of Infectious Diseases, 2009, 13, 226-231.	0.6	18
784	Biomolecular Markers in Cancer of the Tongue. Journal of Oncology, 2009, 2009, 1-11.	1.3	18
785	Epidermal Growth Factor-like Repeats of Thrombospondins Activate Phospholipase CÎ ³ and Increase Epithelial Cell Migration through Indirect Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry, 2009, 284, 6389-6402.	3.4	48
786	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research, 2009, 15, 6639-6648.	7.0	113
787	Silencing of ErbB3/ErbB2 Signaling by Immunoglobulin-like Necl-2. Journal of Biological Chemistry, 2009, 284, 23793-23805.	3.4	52
788	Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. Oncologist, 2009, 14, 378-390.	3.7	176
789	Genetic Polymorphisms in the EGFR (R521K) and Estrogen Receptor (T594T) Genes, EGFR and ErbB-2 Protein Expression, and Breast Cancer Risk in Tunisia. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-6.	3.0	22
790	Role of ADAMs in Cancer Formation and Progression. Clinical Cancer Research, 2009, 15, 1140-1144.	7.0	196
791	PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis. Journal of Biological Chemistry, 2009, 284, 19018-19026.	3.4	66
792	Nedd4 mediates ErbB4 JMâ€a/CYT–1 ICD ubiquitination and degradation in MDCK II cells. FASEB Journal, 2009, 23, 1935-1945.	0.5	43
793	Luciferase Fragment Complementation Imaging of Conformational Changes in the Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 2009, 284, 7474-7482.	3.4	36
794	Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17. International Journal of Surgical Pathology, 2009, 17, 198-205.	0.8	40
795	PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer. Clinical Cancer Research, 2009, 15, 3184-3188.	7.0	296
796	Expression of Epidermal Growth Factor Receptor or ErbB3 Facilitates Geldanamycin-Induced Down-Regulation of ErbB2. Molecular Cancer Research, 2009, 7, 275-284.	3.4	16
797	Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro-Oncology, 2009, 11, 250-259.	1.2	23
798	Resistance to Trastuzumab in Breast Cancer. Clinical Cancer Research, 2009, 15, 7479-7491.	7.0	397
799	Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines, Journal of Thoracic Oncology, 2009, 4, 161-166,	1.1	59

#	Αρτιςι ε	IF	CITATIONS
" 800	Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity. Cancer Research, 2009, 69, 2461-2470.	0.9	28
801	Muscle-Specific Overexpression of Heparin-Binding Epidermal Growth Factor-Like Growth Factor Increases Peripheral Glucose Disposal and Insulin Sensitivity. Endocrinology, 2009, 150, 2683-2691.	2.8	23
802	The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data. PLoS Computational Biology, 2009, 5, e1000438.	3.2	164
803	Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity. Molecular Cancer Research, 2009, 7, 1563-1571.	3.4	38
804	Hyaluronan Fragments/CD44 Mediate Oxidative Stress–Induced MUC5B Up-Regulation in Airway Epithelium. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 277-285.	2.9	71
805	The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Oncologist, 2009, 14, 1116-1130.	3.7	57
806	Obestatin stimulates Akt signalling in gastric cancer cells through β-arrestin-mediated epidermal growth factor receptor transactivation. Endocrine-Related Cancer, 2009, 16, 599-611.	3.1	45
807	Memo is a cofilin-interacting protein that influences PLCÎ ³ 1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration. Journal of Cell Science, 2009, 122, 787-797.	2.0	32
808	Double <i>EGFR</i> mutants containing rare <i>EGFR</i> mutant types show reduced <i>in vitro</i> response to gefitinib compared with common activating missense mutations. Molecular Cancer Therapeutics, 2009, 8, 2142-2151.	4.1	67
809	Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling. Molecular Cancer Research, 2009, 7, 1882-1892.	3.4	23
810	Target-based therapies in breast cancer: current status and future perspectives. Endocrine-Related Cancer, 2009, 16, 675-702.	3.1	62
811	Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer, 2009, 9, 1.	2.6	220
812	Overcoming Drug Resistance in Patients with Metastatic Breast Cancer. Pharmacotherapy, 2009, 29, 954-965.	2.6	53
813	Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression. Clinical Breast Cancer, 2009, 9, S50-S57.	2.4	21
814	Endocytosis and intracellular trafficking of ErbBs. Experimental Cell Research, 2009, 315, 683-696.	2.6	581
815	ErbB receptors and cell polarity: New pathways and paradigms for understanding cell migration and invasion. Experimental Cell Research, 2009, 315, 707-716.	2.6	48
816	Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy. Experimental Cell Research, 2009, 315, 2847-2855.	2.6	47
817	Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer. Clinical Therapeutics, 2009, 31, 2332-2348.	2.5	97

#	Article	IF	CITATIONS
818	Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochemical Pharmacology, 2009, 77, 508-520.	4.4	145
819	A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms. Biochemical Pharmacology, 2009, 77, 1787-1794.	4.4	33
820	Drug targets for tumorigenesis: Insights from structural analysis of EGFR signaling network. Journal of Biomedical Informatics, 2009, 42, 228-236.	4.3	16
821	ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology, 2009, 21, 177-184.	5.4	832
822	Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: Agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cellular Signalling, 2009, 21, 428-439.	3.6	46
823	ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site. Cellular Signalling, 2009, 21, 810-818.	3.6	8
824	Differential erbB signaling in astrocytes from the cerebral cortex and the hypothalamus of the human brain. Glia, 2009, 57, 362-379.	4.9	50
825	Increased expression of ErbBâ€2 in liver is associated with hepatitis B × antigen and shorter survival in patients with liver cancer. International Journal of Cancer, 2009, 125, 1894-1901.	5.1	36
826	Protein expression profiling of primary mammary epithelial cells derived from MMTVâ€ <i>neu</i> mice revealed that HER2/NEUâ€driven changes in protein expression are functionally clustered. IUBMB Life, 2010, 62, 41-50.	3.4	4
827	Delphinidin inhibits a broad spectrum of receptor tyrosine kinases of the ErbB and VEGFR family. Molecular Nutrition and Food Research, 2009, 53, 1075-1083.	3.3	30
828	The role and regulation of the nuclear receptor co-activator AlB1 in breast cancer. Breast Cancer Research and Treatment, 2009, 116, 225-237.	2.5	80
829	ER Re-expression and Re-sensitization to Endocrine Therapies in ER-negative Breast Cancers. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 67-78.	2.7	56
830	An Analysis of Potential Surrogate Markers of Target-Specific Therapy in Archival Materials of Adrenocortical Carcinoma. Endocrine Pathology, 2009, 20, 17-23.	9.0	18
831	The Egf Receptor-Sox2-Egf Receptor Feedback Loop Positively Regulates the Self-Renewal of Neural Precursor Cells. Stem Cells, 2010, 28, 279-286.	3.2	75
832	Heregulin upregulates the expression of nitric oxide synthase (NOS)-1 in rat cerebellar granule neurons via the ErbB4 receptor. Journal of Neurochemistry, 2009, 76, 312-315.	3.9	16
833	Epidermal growth factor receptor lacking Câ€ŧerminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Science, 2009, 100, 552-557.	3.9	14
834	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 2009, 9, 463-475.	28.4	993
835	Vaccinia-induced epidermal growth factor receptor-MEK signalling and the anti-apoptotic protein F1L synergize to suppress cell death during infection. Cellular Microbiology, 2009, 11, 1208-1218	2.1	36

#	Article	IF	CITATIONS
836	A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: A proof of concept on HER2 receptor. Bioorganic and Medicinal Chemistry, 2009, 17, 7015-7020.	3.0	20
837	Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1332-1336.	2.2	39
838	In Vitro Enzymatic Characterization of Near Full Length EGFR in Activated and Inhibited States. Biochemistry, 2009, 48, 6624-6632.	2.5	47
839	Suppression of the Kinase Activity of Receptor Tyrosine Kinases by Anthocyanin-Rich Mixtures Extracted from Bilberries and Grapes. Journal of Agricultural and Food Chemistry, 2009, 57, 3094-3101.	5.2	31
840	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews, 2009, 35, 685-691.	7.7	52
841	Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Letters, 2009, 275, 227-233.	7.2	41
842	Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Cancer Letters, 2009, 281, 134-143.	7.2	16
843	Cellular signals involved in cyclooxygenase-2 expression induced by human cytomegalovirus. Virus Research, 2009, 146, 89-96.	2.2	13
844	The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience, 2009, 16, 748-754.	1.5	325
845	Two GxxxG-Like Motifs Facilitate Promiscuous Interactions of the Human ErbB Transmembrane Domains. Journal of Molecular Biology, 2009, 389, 10-16.	4.2	55
846	Molecular Targets for Tumor Radiosensitization. Chemical Reviews, 2009, 109, 2974-2988.	47.7	49
847	Tissue remodeling induced by hypersecreted epidermal growth factor and amphiregulin in the airway after an acute asthma attack. Journal of Allergy and Clinical Immunology, 2009, 124, 913-920.e7.	2.9	116
848	Correlation between morphology and EGFR mutations in lung adenocarcinomas. Lung Cancer, 2009, 63, 235-240.	2.0	89
849	Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. Lung Cancer, 2009, 64, 251-256.	2.0	34
850	Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2009, 18, 293-301.	4.1	15
851	The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Journal of Experimental and Clinical Cancer Research, 2009, 28, 97.	8.6	21
852	ErbB receptors protect the perfused heart against injury induced by epinephrine combined with low-flow ischemia. Growth Factors, 2009, 27, 203-213.	1.7	9
853	Human Epidermal Growth Factor Receptor Dimerization Analysis in Breast Cancer Diagnosis. Molecular Diagnosis and Therapy, 2009, 13, 359-365.	3.8	3

#	Article	IF	CITATIONS
854	Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. Journal of Receptor and Signal Transduction Research, 2009, 29, 182-194.	2.5	17
855	ErbB4 REGULATES SURFACTANT SYNTHESIS AND PROLIFERATION IN ADULT RAT PULMONARY EPITHELIAL CELLS. Experimental Lung Research, 2009, 35, 29-47.	1.2	16
856	MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Review of Molecular Diagnostics, 2009, 9, 423-440.	3.1	64
857	Place du cetuximab dans le traitement des stades III non chirurgicaux : des résultats encourageants des essais de phase II avec la radiothérapie. Revue De Pneumologie Clinique, 2009, 65, H2-H5.	0.0	0
858	Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth. Molecular and Cellular Biology, 2009, 29, 1249-1265.	2.3	57
859	Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy. Current Cancer Drug Targets, 2009, 9, 748-760.	1.6	165
860	Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. European Journal of Gastroenterology and Hepatology, 2009, 21, 289-293.	1.6	11
861	CETUXIMAB: From Bench to Bedside. Current Cancer Drug Targets, 2010, 10, 80-95.	1.6	107
862	EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?. Current Drug Targets, 2010, 11, 682-698.	2.1	12
863	High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World Journal of Gastroenterology, 2010, 16, 4047.	3.3	32
865	Analysis of ERBB4 Mutations and Expression in Japanese Patients with Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1859-1861.	1.1	9
866	Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients. Journal of Thoracic Oncology, 2010, 5, 1536-1543.	1.1	20
867	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biology, 2010, 31, 171-180.	1.8	61
868	Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Targeted Oncology, 2010, 5, 231-235.	3.6	14
869	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Medical Oncology, 2010, 27, 91-97.	2.5	15
870	Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma. Medical Oncology, 2010, 27, 708-714.	2.5	19
871	HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies. Breast Cancer Research and Treatment, 2010, 124, 771-778.	2.5	24
872	ErbB4 signals Neuregulin1-stimulated cell proliferation and c-fos gene expression through phosphorylation of serum response factor by mitogen-activated protein kinase cascade. Molecular and Cellular Biochemistry, 2010, 339, 119-125.	3.1	17

ARTICLE IF CITATIONS Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: 873 2.9 5 the concept of divergent targeting. Journal of Neuro-Oncology, 2010, 100, 345-361. Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Nonâ€"Small-Cell Lung Cancer. 874 2.6 Clinical Lung Cancer, 2010, 11, 257-263. Enhanced antiproliferative and apoptotic response to combined treatment of Î³-tocotrienol with 875 2.6 52 erlotinib or gefitinib in mammary tumor cells. BMC Cancer, 2010, 10, 84. Secondâ€line treatments after firstâ€line gefitinib therapy in advanced nonsmall cell lung cancer. 5.1 International Journal of Cancer, 2010, 126, 247-255. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. Clinical 877 1.9 15 Biochemistry, 2010, 43, 545-548. Synthesis and biological evaluation of novel 2,4 $\hat{\epsilon}^2$ -bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors. European Journal of 5.5 Medicinal Chemistry, 2010, 45, 4113-4121 Interaction of integrin α₆β₄ with ErbB3 and implication in heregulinâ€induced 879 1.2 12 ErbB3/ErbB2â€mediated DNA synthesis. Genes To Cells, 2010, 15, 995-1001. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. 880 2.9 Histopathology, 2010, 56, 560-572. Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. British 881 6.4 21 Journal of Cancer, 2010, 103, 889-898. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO Journal, 2010, 29, 1091-1104. Human epidermal growth factor receptor 2 expression status provides independent prognostic 883 information in patients with urothelial carcinoma of the urinary bladder. BJU International, 2010, 106, 77 2.5 1216-1222. Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism?. Oncotarget, 2010, 1, 734-740. 884 1.8 139 Downregulation of Epidermal Growth Factor Receptor Expression Contributes to < mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>î±</mml:mi></mml:math>-TEA's 885 1.3 16 Proapoptotic Effects in Human Ovarian Cancer Cell Lines. Journal of Oncology, 2010, 2010, 1-11. Growth factors in tumor microenvironment. Frontiers in Bioscience - Landmark, 2010, 15, 151. 64 Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics: 888 3.2 9 Targets and Therapy, 2010, 4, 237. HER2-positive male breast cancer: an update. Breast Cancer: Targets and Therapy, 2010, 2, 45. 1.8 A Bispecific Enediyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based 890 Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor 7.0 44 Receptor 2 Shows Potent Antitumor Activity. Clinical Cancer Research, 2010, 16, 2085-2094. Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal 891 89 Cancer. Clinical Cancer Research, 2010, 16, 3378-3389.

#	Article	IF	CITATIONS
892	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research, 2010, 16, 2688-2695.	7.0	137
893	Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2010, 28, 4221-4227.	1.6	71
894	Signal Transduction Networks in Cancer: Quantitative Parameters Influence Network Topology. Cancer Research, 2010, 70, 1773-1782.	0.9	32
895	AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer. Clinical Cancer Research, 2010, 16, 1159-1169.	7.0	105
896	Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15039-15044.	7.1	171
897	Power to detect selective allelic amplification in genome-wide scans of tumor data. Bioinformatics, 2010, 26, 518-528.	4.1	9
898	HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opinion on Biological Therapy, 2010, 10, 1343-1355.	3.1	15
899	Lapatinib, a Dual ECFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <i>In vitro</i> and <i>In vivo</i> . Clinical Cancer Research, 2010, 16, 1509-1519.	7.0	190
900	Therapeutic targeting of EGFR in malignant gliomas. Expert Opinion on Therapeutic Targets, 2010, 14, 303-316.	3.4	23
901	Genetics of medulloblastoma: clues for novel therapies. Expert Review of Neurotherapeutics, 2010, 10, 811-823.	2.8	15
902	Emerging drugs for ovarian cancer. Expert Opinion on Emerging Drugs, 2010, 15, 635-652.	2.4	4
903	Characterization of HKI-272 Covalent Binding to Human Serum Albumin. Drug Metabolism and Disposition, 2010, 38, 1083-1093.	3.3	56
904	The Vulnerability of the Heart As a Pluricellular Paracrine Organ. Circulation Research, 2010, 106, 35-46.	4.5	177
905	P2Y2 Nucleotide Receptors Mediate Metalloprotease-dependent Phosphorylation of Epidermal Growth Factor Receptor and ErbB3 in Human Salivary Gland Cells. Journal of Biological Chemistry, 2010, 285, 7545-7555.	3.4	45
906	Attenuation of PI3K/Akt-Mediated Tumorigenic Signals through PTEN Activation by DNA Vaccine-Induced Anti-ErbB2 Antibodies. Journal of Immunology, 2010, 184, 4170-4177.	0.8	19
907	Optical molecular imaging and its emerging role in colorectal cancer. American Journal of Physiology - Renal Physiology, 2010, 299, G807-G820.	3.4	18
908	HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. PLoS Biology, 2010, 8, e1000563.	5.6	116
909	ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biology and Therapy, 2010, 10, 555-563.	3.4	56

#	Article	IF	CITATIONS
910	Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells. Cancer Research, 2010, 70, 5994-6003.	0.9	49
911	Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer. Molecular Cancer Therapeutics, 2010, 9, 3090-3099.	4.1	21
912	Differential Contribution to Neuroendocrine Tumorigenesis of Parallel Egfr Signaling in Cancer Cells and Pericytes. Genes and Cancer, 2010, 1, 125-141.	1.9	21
913	FOXO1A Is a Target for HER2-Overexpressing Breast Tumors. Cancer Research, 2010, 70, 5475-5485.	0.9	43
914	Amphiregulin Carboxy-Terminal Domain Is Required for Autocrine Keratinocyte Growth. Journal of Investigative Dermatology, 2010, 130, 2031-2040.	0.7	30
915	Epidermal Growth Factor Stimulates Human Trophoblast Cell Migration through Rho A and Rho C Activation. Endocrinology, 2010, 151, 1732-1742.	2.8	52
916	The ECFR Polymorphism rs884419 is Associated With Freedom From Recurrence in Patients With Resected Prostate Cancer. Journal of Urology, 2010, 183, 2062-2069.	0.4	20
917	Stem Cells in Normal Development and Cancer. Progress in Molecular Biology and Translational Science, 2010, 95, 113-158.	1.7	57
918	Cell-based assays for kinase drug discovery. Drug Discovery Today: Technologies, 2010, 7, e13-e19.	4.0	13
919	HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. Pharmacological Research, 2010, 62, 150-165.	7.1	63
920	Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer, 2010, 70, 43-50.	2.0	27
921	Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. Lung Cancer, 2010, 69, 259-264.	2.0	19
922	Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. Journal of Translational Medicine, 2010, 8, 135.	4.4	86
923	CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer, 2010, 10, 489-491.	2.4	128
924	Identification of the Amyloid β-Protein Precursor and Cystatin C as Novel Epidermal Growth Factor Receptor Regulated Secretory Proteins in Nasopharyngeal Carcinoma by Proteomics. Journal of Proteome Research, 2010, 9, 6101-6111.	3.7	28
925	ErbB receptor signaling in astrocytes: A mediator of neuron-glia communication in the mature central nervous system. Neurochemistry International, 2010, 57, 344-358.	3.8	25
926	Support for the involvement of the ERBB4 gene in schizophrenia: A genetic association analysis. Neuroscience Letters, 2010, 481, 120-125.	2.1	19
927	Spatial Structure of the Transmembrane Domain Heterodimer of ErbB1 and ErbB2 Receptor Tyrosine Kinases. Journal of Molecular Biology, 2010, 400, 231-243.	4.2	130

	Сг	tation Report	
#	Article	IF	Citations
929	Growth factors and corneal epithelial wound healing. Brain Research Bulletin, 2010, 81, 229-235.	3.0	169
930	Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level. Cancer Letters, 2010, 290, 192-203.	7.2	54
931	Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. Cancer Letters, 2010, 293, 23-30.	7.2	23
932	Prognostic significance and clinical relevance of the expression of the HER family of type I receptor tyrosine kinases in human laryngeal squamous cell carcinoma. European Journal of Cancer, 2010, 46, 1144-1152.	2.8	9
933	Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). European Journal of Cancer, 2010, 46, 1703-1711.	/ 2.8	58
934	Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development. Cell, 2010, 140, 268-279.	28.9	311
935	Sequence-Dependent Oligomerization of the Neu Transmembrane Domain Suggests Inhibition of "Conformational Switching―by an Oncogenic Mutant. Biochemistry, 2010, 49, 2811-2820.	2.5	19
936	Spatio-temporal modeling of signaling protein recruitment to EGFR. BMC Systems Biology, 2010, 4, 5	7. 3.0	53
937	Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Experier From an Area in Which Betel Nut Chewing Is Popular. Journal of the Chinese Medical Association, 201 73, 292-299.	nce 0, 1.4	7
938	Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion. American Journal of Pathology 2010, 177, 3145-3158.	' 3.8	34
939	A functional epidermal growth factor (EGF) polymorphism, EGF serum levels and renal cell carcinoma risk in a Chinese population. Journal of Human Genetics, 2010, 55, 236-240.	2.3	13
940	Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling. Antioxidants and Redox Signaling, 2010, 13, 691-719.	5.4	174
941	EGFR Signals Downregulate Tumor Suppressors miR-143 and miR-145 in Western Diet–Promoted N Colon Cancer: Role of G1 Regulators. Molecular Cancer Research, 2011, 9, 960-975.	Aurine 3.4	114
942	DARPP-32 Increases Interactions Between Epidermal Growth Factor Receptor and ERBB3 to Promote Tumor Resistance to Gefitinib. Gastroenterology, 2011, 141, 1738-1748.e2.	1.3	42
943	A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics in Chest Medicine, 2011, 32, 839-851.	2.1	58
944	Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers, 2011, 3, 2444-2461.	3.7	65
945	Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2- <i>d</i>]pyrimidine Scaffold. Journal of Medicinal Chemistry, 2011, 54, 8030-8050.	6.4	159
946	Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor–targeted therapy with cetuximab and gefitinib. Cancer Letters, 2011, 306, 85-91.	7.2	10

		CITATION F	Report	
#	Article		IF	CITATIONS
947	Expression of activated HER2 in human testes. Fertility and Sterility, 2011, 95, 2725-27	28.	1.0	7
948	Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardion Biochemical and Biophysical Research Communications, 2011, 411, 421-426.	1yocyte death.	2.1	16
949	Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) ty inhibitors. SAR and QSAR in Environmental Research, 2011, 22, 239-263.	rosine kinase	2.2	41
950	MiR-148a inhibits angiogenesis by targeting ERBB3. Journal of Biomedical Research, 201	11, 25, 170-177.	1.6	65
951	Interference of Silver, Gold, and Iron Oxide Nanoparticles on Epidermal Growth Factor S Transduction in Epithelial Cells. ACS Nano, 2011, 5, 10000-10008.	ignal	14.6	113
952	In tumor cells regulation of DNA double strand break repair through EGF receptor involvand HR and is independent of p53 and K-Ras status. Radiotherapy and Oncology, 2011,	ves both NHEJ 101, 147-151.	0.6	50
953	Molecular imaging metrics to evaluate response to preclinical therapeutic regimens. Fro Bioscience - Landmark, 2011, 16, 393.	ntiers in	3.0	2
954	ErbB2/HER2: Its Contribution to Basic Cancer Biology and the Development of Molecula Therapy. , 2011, , .	ar Targeted		2
955	HER2 splice variants and their relevance in breast cancer. Journal of Nucleic Acids Invest 2, 9.	igation, 2011,	0.8	3
956	Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer Reviews in Therapeutic Drug Carrier Systems, 2011, 28, 293-356.	r. Critical	2.2	5
957	Epidermal Growth Factor Receptor (EGFR) Phosphorylation, Signaling and Trafficking in Cancer. , O, , .	Prostate		4
958	Chemopreventive Activity of Vitamin E in Breast Cancer: A Focus on \hat{I}^3 - and \hat{I} -Tocophero 3, 962-986.	l. Nutrients, 2011,	4.1	71
959	AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2 Antitumor Activity Both In Vitro and In Vivo. PLoS ONE, 2011, 6, e21487.	2, Exhibits	2.5	40
960	Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian can Current Opinion in Obstetrics and Gynecology, 2011, 23, 24-30.	cer therapy.	2.0	30
961	Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Witho Epidermal Growth Factor Receptor (EGFR) Mutations. Medicine (United States), 2011, 9	out Testing for 90, 159-167.	1.0	30
962	Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies. Current Pharmaceu 2011, 17, 293-319.	tical Design,	1.9	31
963	Therapeutic potential of histone deacetylase inhibitors for breast cancer. Clinical Investi 1, 519-532.	gation, 2011,	0.0	0
964	Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue He Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Po Journal of Carcinogenesis & Mutagenesis, 2011, 02, .	aling Agents: rogression.	0.3	16

#	Article	IF	CITATIONS
965	Unique <i>p53</i> and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepitheliomaâ€like carcinomas. Cancer Science, 2011, 102, 282-287.	3.9	63
966	Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). Veterinary and Comparative Oncology, 2011, 9, 106-117.	1.8	32
967	Somatosensory mechanisms in zebrafish lacking dorsal root ganglia. Journal of Anatomy, 2011, 218, 271-276.	1.5	10
968	Regulation of Cigarette Smoke-Induced Mucin Expression by Neuregulin1î²/ErbB3 Signalling in Human Airway Epithelial Cells. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 63-72.	2.5	16
969	Bacterial synthesis, purification, and solubilization of transmembrane segments of ErbB family receptors. Molecular Biology, 2011, 45, 823-832.	1.3	5
970	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 2011, 30, 2547-2557.	5.9	471
971	Tocotrienols: inflammation and cancer. Annals of the New York Academy of Sciences, 2011, 1229, 18-22.	3.8	49
972	Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand. Journal of Cellular and Molecular Medicine, 2011, 15, 2525-2538.	3.6	18
973	Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: Histopathological and immunohistochemical study. Veterinary Journal, 2011, 189, 318-322.	1.7	33
974	Analysis of the Prognostic Value of Soluble Epidermal Growth Factor Receptor Plasma Concentration in Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2011, 12, 320-327.	2.6	15
975	The challenge of developing robust drugs to overcome resistance. Drug Discovery Today, 2011, 16, 755-61.	6.4	21
976	The multiple roles of amphiregulin in human cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 119-131.	7.4	148
977	A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies. Cancer Cell, 2011, 20, 472-486.	16.8	319
978	NKT ligand-loaded, antigen-expressing B cells function as long-lasting antigen presenting cells in vivo. Cellular Immunology, 2011, 270, 135-144.	3.0	11
979	Identification of in Vitro Autophosphorylation Sites and Effects of Phosphorylation on the <i>Arabidopsis</i> CRINKLY4 (ACR4) Receptor-like Kinase Intracellular Domain: Insights into Conformation, Oligomerization, and Activity. Biochemistry, 2011, 50, 2170-2186.	2.5	23
980	Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2011, 18, 1122-1129.	1.5	24
981	EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy. Annals of Surgical Oncology, 2011, 18, 2952-2960.	1.5	51
982	Receptor tyrosine kinases: from biology to pathology. Journal of Receptor and Signal Transduction Research, 2011, 31, 387-394.	2.5	36

#	Article	IF	CITATIONS
983	Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts. Investigational New Drugs, 2011, 29, 22-32.	2.6	52
984	Role of hyaluronan and CD44 in reactive oxygen species-induced mucus hypersecretion. Molecular and Cellular Biochemistry, 2011, 352, 65-75.	3.1	17
985	Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. Journal of Neuro-Oncology, 2011, 104, 679-687.	2.9	52
986	Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process. European Journal of Nutrition, 2011, 50, 465-478.	3.9	67
987	Polysaccharides from Capsosiphon fulvescens Stimulate the Growth of IEC-6 Cells by Activating the MAPK Signaling Pathway. Marine Biotechnology, 2011, 13, 433-440.	2.4	30
988	Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells. Cancer Chemotherapy and Pharmacology, 2011, 68, 1315-1323.	2.3	21
989	Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine, 2011, 40, 168-180.	2.3	20
990	Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunologic Research, 2011, 50, 261-268.	2.9	42
991	Significance of epidermal growth factor receptor expression in breast cancer. Medical Oncology, 2011, 28, 121-128.	2.5	51
992	Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Science, 2011, 9, 35.	1.7	30
993	Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. Journal of Translational Medicine, 2011, 9, 126.	4.4	59
994	Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity. BMC Systems Biology, 2011, 5, 29.	3.0	8
995	Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Molecular Carcinogenesis, 2011, 50, 901-912.	2.7	22
996	Knockâ€down of amphiregulin inhibits cellular invasion in inflammatory breast cancer. Journal of Cellular Physiology, 2011, 226, 2691-2701.	4.1	38
997	Calpainâ€1 expression is associated with relapseâ€free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. International Journal of Cancer, 2011, 129, 1773-1780.	5.1	34
998	Novel Luciferase-Based Reporter System to Monitor Activation of ErbB2/Her2/neu Pathway Noninvasively During Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 233-238.	0.8	15
999	Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1601-1606.	2.2	23
1000	Monte Carlo simulations of plasma membrane corral-induced EGFR clustering. Journal of Biotechnology, 2011, 151, 261-270.	3.8	19

#	Article	IF	CITATIONS
1001	ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Modern Pathology, 2011, 24, 1055-1059.	5.5	9
1002	Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution. American Journal of Physiology - Renal Physiology, 2011, 301, G368-G376.	3.4	31
1003	The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer. Clinical Cancer Research, 2011, 17, 3619-3630.	7.0	46
1004	Polysaccharides from Capsosiphon fulvescens Stimulate the Growth of Gastrointestinal Cells. Advances in Food and Nutrition Research, 2011, 64, 179-190.	3.0	4
1005	Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics, 2011, 12, 27-39.	1.3	20
1006	Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion. Mini-Reviews in Medicinal Chemistry, 2011, 11, 1019-1030.	2.4	37
1007	Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 131-149.	0.5	63
1008	The Tethering Arm of the EGF Receptor Is Required for Negative Cooperativity and Signal Transduction. Journal of Biological Chemistry, 2011, 286, 1545-1555.	3.4	17
1009	Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors. Molecular Cancer Therapeutics, 2011, 10, 1367-1374.	4.1	45
1010	Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3. Clinical Cancer Research, 2011, 17, 6218-6228.	7.0	53
1011	Neuregulins are essential for spermatogonial proliferation and meiotic initiation in neonatal mouse testis. Development (Cambridge), 2011, 138, 3159-3168.	2.5	49
1012	Dominant Inhibition of Akt/Protein Kinase B Signaling by the Matrix Protein of a Negative-Strand RNA Virus. Journal of Virology, 2011, 85, 422-431.	3.4	37
1013	Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer. Molecular Cancer Research, 2011, 9, 1767-1779.	3.4	62
1014	Gefitinib in Non Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-14.	3.0	19
1015	Involvement of Epidermal Growth Factor Receptor-Linked Signaling Responses in Pseudomonas fluorescens-Infected Alveolar Epithelial Cells. Infection and Immunity, 2011, 79, 1998-2005.	2.2	13
1016	Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. International Journal of Breast Cancer, 2011, 2011, 1-11.	1.2	82
1017	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	7.1	291
1018	Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns. Journal of Thoracic Oncology, 2011, 6, 1066-1072.	1.1	45

#	Article	IF	CITATIONS
1019	Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes. Journal of Biological Chemistry, 2011, 286, 27729-27740.	3.4	23
1020	Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo. Journal of Biological Chemistry, 2011, 286, 13626-13637.	3.4	45
1021	Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome. Journal of Clinical Oncology, 2011, 29, 3030-3036.	1.6	217
1022	<i>In Vitro</i> Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells. Nucleic Acid Therapeutics, 2011, 21, 173-178.	3.6	83
1023	Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. British Journal of Cancer, 2011, 105, 807-813.	6.4	108
1024	Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer, 2011, 105, 1554-1562.	6.4	62
1025	Diverse injurious stimuli reduce protein tyrosine phosphatase-μ expression and enhance epidermal growth factor receptor signaling in human airway epithelia. Experimental Lung Research, 2011, 37, 327-343.	1.2	15
1026	Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. Clinical Cancer Research, 2011, 17, 5060-5070.	7.0	158
1027	Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. American Journal of Physiology - Renal Physiology, 2011, 300, G264-G272.	3.4	26
1028	EGFR and IL-1 Signaling Synergistically Promote Keratinocyte Antimicrobial Defenses in a Differentiation-Dependent Manner. Journal of Investigative Dermatology, 2011, 131, 329-337.	0.7	81
1029	Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L79-L90.	2.9	18
1030	The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1498-1507.	3.7	44
1031	Epidermal Growth Factor Receptor in Pancreatic Cancer. Cancers, 2011, 3, 1513-1526.	3.7	114
1032	EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis, 2012, 33, 1169-1177.	2.8	20
1033	Dramatic Response to Trastuzumab and Paclitaxel in a Patient With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Cholangiocarcinoma. Journal of Clinical Oncology, 2012, 30, e271-e273.	1.6	49
1034	Cross-talk between TGFβ1 and EGFR signalling pathways induces TM4SF5 expression and epithelial–mesenchymal transition. Biochemical Journal, 2012, 443, 691-700.	3.7	56
1035	Signaling Pathways in Inflammatory Breast Cancer. , 2012, , 151-160.		0
1036	Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle, 2012, 11, 1455-1467.	2.6	29

#	Article	IF	CITATIONS
1037	Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis. Advances in Urology, 2012, 2012, 1-11.	1.3	15
1038	NEU1 Sialidase Expressed in Human Airway Epithelia Regulates Epidermal Growth Factor Receptor (EGFR) and MUC1 Protein Signaling. Journal of Biological Chemistry, 2012, 287, 8214-8231.	3.4	69
1039	The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner. Carcinogenesis, 2012, 33, 1031-1039.	2.8	27
1040	SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>In Vitro</i> and <i>In Vivo</i> . Molecular Cancer Therapeutics, 2012, 11, 952-962.	4.1	21
1041	ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6584-6589.	7.1	97
1042	Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. Journal of Human Genetics, 2012, 57, 26-32.	2.3	24
1043	Mechanisms Mediating the Synergistic Anticancer Effects of Combined Î ³ -Tocotrienol and Sesamin Treatment. Planta Medica, 2012, 78, 1731-1739.	1.3	29
1044	Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3417-3420.	1.6	61
1045	Expression of the erbB/HER receptor family in the bovine uterus during the sexual cycle and the relation of this family to serum sex steroids. Biotechnic and Histochemistry, 2012, 87, 105-116.	1.3	12
1046	Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis, 2012, 1, e16-e16.	4.9	69
1047	Endosomal Accumulation of the Activated Epidermal Growth Factor Receptor (EGFR) Induces Apoptosis. Journal of Biological Chemistry, 2012, 287, 712-722.	3.4	70
1048	Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21058-21063.	7.1	34
1049	P2Y2 receptor inhibits EGF-induced MAPK pathway to stabilise keratinocyte hemidesmosomes Journal of Cell Science, 2012, 125, 4264-77.	2.0	11
1050	The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries. Journal of Signal Transduction, 2012, 2012, 1-17.	2.0	4
1051	Receptor Tyrosine Kinases: Molecular Switches Regulating CNS Axon Regeneration. Journal of Signal Transduction, 2012, 2012, 1-14.	2.0	15
1052	Advances in Targeting HER3 as an Anticancer Therapy. Chemotherapy Research and Practice, 2012, 2012, 1-9.	1.6	36
1053	Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder. Libyan Journal of Medicine, 2012, 7, 14694.	1.6	11
1054	Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13984-13989.	7.1	42

#	Article	IF	CITATIONS
1055	Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA. Molecular Pharmacology, 2012, 81, 527-540.	2.3	53
1056	Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms?. Cardiology, 2012, 122, 253-259.	1.4	36
1057	Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis. Cardiovascular Research, 2012, 93, 516-524.	3.8	54
1058	Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab. Journal of Immunotherapy, 2012, 35, 367-373.	2.4	28
1059	Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?. Current Hypertension Reviews, 2012, 8, 159-180.	0.9	6
1060	Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. International Journal of Oncology, 2012, 41, 639-651.	3.3	7
1061	Epidermal growth factor upregulates endometrial CYR61 expression via activation of the JAK2/STAT3 pathway. Reproduction, Fertility and Development, 2012, 24, 482.	0.4	14
1062	Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Oncology Reports, 2012, 27, 1639-45.	2.6	16
1063	Discovering Drug Targets for Cancer Therapy. , 2012, , 299-322.		0
1064	Towards Control of Magnetic Fluids in Patients: Directing Therapeutic Nanoparticles to Disease Locations. IEEE Control Systems, 2012, 32, 32-74.	0.8	81
1065	Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5870-5875.	2.2	35
1066	Stretch-induced Fetal Type II Cell Differentiation Is Mediated via ErbB1-ErbB4 Interactions. Journal of Biological Chemistry, 2012, 287, 18091-18102.	3.4	35
1067	Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncology, 2012, 8, 273-292.	2.4	36
1068	Winning the Arms Race by Improving Drug Discovery against Mutating Targets. ACS Chemical Biology, 2012, 7, 278-288.	3.4	14
1069	An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer. Breast Cancer Research and Treatment, 2012, 135, 759-769.	2.5	33
1070	Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer. Molecular and Cellular Biochemistry, 2012, 369, 217-225.	3.1	9
1071	Ciblage des récepteurs ErbB2Âpar immuno-histochimie et FISH pour cas équivoque, chez 160Âpatientes atteintes d'un cancer du sein de l'ouest Algérien. Immuno-Analyse Et Biologie Specialisee, 2012, 27, 310-314.	0.0	0
1072	Integrated experimental and model-based analysis reveals the spatial aspects of EGFR activation dynamics. Molecular BioSystems, 2012, 8, 2868.	2.9	15

#	Article	IF	CITATIONS
1073	Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions. Journal of Medicinal Chemistry, 2012, 55, 4594-4604.	6.4	32
1074	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Molecular BioSystems, 2012, 8, 2645.	2.9	11
1075	Epidermal growth factor receptor (EGFR) and neuregulin (Neu) activation in human airway epithelial cells exposed to nickel acetate. Toxicology in Vitro, 2012, 26, 280-287.	2.4	8
1076	Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway. Toxicon, 2012, 60, 734-743.	1.6	22
1077	Conformational Transition and Energy Landscape of ErbB4 Activated by Neuregulin1β: One Microsecond Molecular Dynamics Simulations. Journal of the American Chemical Society, 2012, 134, 6720-6731.	13.7	21
1078	Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine ⁷⁹⁰ → Methionine ⁷⁹⁰ Mutant. Journal of Medicinal Chemistry, 2012, 55, 2711-2723.	6.4	74
1079	Physical–chemical principles underlying RTK activation, and their implications for human disease. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 995-1005.	2.6	49
1080	Structural and thermodynamic insight into the process of "weak―dimerization of the ErbB4 transmembrane domain by solution NMR. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2158-2170.	2.6	66
1081	Role of ErbB2 in the prostaglandin E2-induced enhancement of the mitogenic response to epidermal growth factor in cultured hepatocytes. Biochemical and Biophysical Research Communications, 2012, 421, 255-260.	2.1	4
1082	PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacologica Sinica, 2012, 33, 1441-1458.	6.1	141
1083	Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Critical Reviews in Oncology/Hematology, 2012, 84, e49-e57.	4.4	39
1084	Prognostic gene signatures for patient stratification in breast cancer - accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions. BMC Bioinformatics, 2012, 13, 69.	2.6	45
1085	Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer, 2012, 12, 247.	2.6	12
1086	Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. BMC Research Notes, 2012, 5, 216.	1.4	17
1087	Epidermal growth factor receptor signaling pathway involved in progestinâ€resistance of human endometrial carcinoma: In a mouse model. Journal of Obstetrics and Gynaecology Research, 2012, 38, 1358-1366.	1.3	18
1088	Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 15-31.	3.4	688
1089	Local Expression of Epidermal Growth Factor-Like Growth Factors in Human Testis and Its Role in Spermatogenesis. Journal of Andrology, 2012, 33, 66-73.	2.0	17
1090	Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncology, 2012, 8, 961-987.	2.4	44

#	Article	IF	CITATIONS
1091	Ei24-deficiency attenuates protein kinase Cα signaling and skin carcinogenesis in mice. International Journal of Biochemistry and Cell Biology, 2012, 44, 1887-1896.	2.8	18
1092	Immunomodulatory roles and functional analysis of pre-B lymphocyte DT40 cells with the bursal-derived BSP-II treatment. Peptides, 2012, 36, 292-298.	2.4	6
1093	HER family receptor and ligand status in thymic carcinoma. Lung Cancer, 2012, 77, 515-521.	2.0	30
1094	Caffeine Inhibits EGF-Stimulated Trophoblast Cell Motility through the Inhibition of mTORC2 and Akt. Endocrinology, 2012, 153, 4502-4510.	2.8	11
1095	Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer. Drugs, 2012, 72, 11-19.	10.9	22
1096	The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor. Biochemical Society Transactions, 2012, 40, 195-199.	3.4	2
1097	EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry, 2012, 4, 447-469.	2.3	46
1098	Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene, 2012, 31, 3516-3524.	5.9	30
1099	EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation. Amino Acids, 2012, 43, 2027-2035.	2.7	33
1100	Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant. MedChemComm, 2012, 3, 1155.	3.4	16
1101	Animal Models for Breast Cancer Prevention Research. , 2012, , 497-526.		1
1102	Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death and Disease, 2012, 3, e295-e295.	6.3	54
1103	Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. Journal of Medicinal Chemistry, 2012, 55, 2251-2264.	6.4	53
1104	Cross-Phosphorylation, Signaling and Proliferative Functions of the Tyro3 and Axl Receptors in Rat2 Cells. PLoS ONE, 2012, 7, e36800.	2.5	41
1105	Neuregulin Promotes Incomplete Autophagy of Prostate Cancer Cells That Is Independent of mTOR Pathway Inhibition. PLoS ONE, 2012, 7, e36828.	2.5	18
1106	Alteration of EGFR Spatiotemporal Dynamics Suppresses Signal Transduction. PLoS ONE, 2012, 7, e39682.	2.5	55
1107	Genetic polymorphisms of EGF 5'-UTR and NAT2 857G/A associated with glioma in a case control study of Malaysian patients. Genetics and Molecular Research, 2012, 11, 2939-2945.	0.2	4
1108	Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Frontiers in Bioscience - Landmark, 2012, 17, 2698.	3.0	17

#	Article	IF	CITATIONS
1109	Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies. Current Radiopharmaceuticals, 2012, 5, 59-64.	0.8	2
1110	Liver Regeneration 2012 20-35		0
1110			0
1111	Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells. Molecular Medicine, 2012, 18, 565-576.	4.4	96
1112	Investigating the Conformation of HER Membrane Proteins in Cells via Single Molecule and FLIM Microscopy. , 2012, , .		0
1113	Mechanisms of HBx Mediated Liver Cancer: Multiple Pathways and Opportunities. , 2012, , .		1
1114	HER2 as a Therapeutic Target in Ovarian Cancer. , 0, , .		1
1115	Assessing the clinical significance of tumor markers in common neoplasms. Frontiers in Bioscience - Elite, 2012, E4, 2558-2578.	1.8	8
1116	UV Light Effects on Proteins: From Photochemistry to Nanomedicine. , 0, , .		15
1117	The ErbB4 extracellular region retains a tetheredâ€ l ike conformation in the absence of the tether. Protein Science, 2012, 21, 152-155.	7.6	13
1118	The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H2139-H2147.	3.2	110
1119	Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: Antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma. Laryngoscope, 2012, 122, 1724-1733.	2.0	14
1120	The pathologic characteristics of breast cancer in China and its shift during 1999–2008: A nationalâ€wide multicenter crossâ€sectional image over 10 years. International Journal of Cancer, 2012, 131, 2622-2631.	5.1	65
1121	Neuregulin induces CTGF expression in hypertrophic scarring fibroblasts. Molecular and Cellular Biochemistry, 2012, 365, 181-189.	3.1	27
1122	Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 319-325.	2.6	1
1123	EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cellular Signalling, 2012, 24, 532-538.	3.6	43
1124	Dual specificity phosphatases 10 and 16 are positive regulators of EGF-stimulated ERK activity: Indirect regulation of ERK signals by JNK/p38 selective MAPK phosphatases. Cellular Signalling, 2012, 24, 1002-1011.	3.6	28
1125	Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2012, 13, 267-279.	2.6	21
1126	Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling. Biochemical Pharmacology, 2012, 83, 286-295.	4.4	33

#	Article	IF	CITATIONS
1127	Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 456-460.	2.2	14
1128	Cetuximab ± chemotherapy enhances dendritic cellâ€mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigenâ€specific cytotoxic Tâ€cell response <i>in vitro</i> . International Journal of Cancer, 2012, 130, 1577-1589.	5.1	67
1129	ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviews, 2012, 32, 166-215.	10.5	72
1130	Synergistic anticancer effects of combined \hat{I}^3 -tocotrienol with statin or receptor tyrosine kinase inhibitor treatment. Genes and Nutrition, 2012, 7, 63-74.	2.5	18
1131	Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Research and Treatment, 2012, 131, 371-383.	2.5	57
1132	Modeling approaches for qualitative and semi-quantitative analysis of cellular signaling networks. Cell Communication and Signaling, 2013, 11, 43.	6.5	106
1133	High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. Journal of Translational Medicine, 2013, 11, 90.	4.4	31
1134	Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR. ACS Medicinal Chemistry Letters, 2013, 4, 974-978.	2.8	22
1135	Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors. European Journal of Medicinal Chemistry, 2013, 66, 82-90.	5.5	19
1136	Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5385-5388.	2.2	25
1137	Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 3090-3104.	3.0	25
1138	Microarray and deep sequencing cross-platform analysis of the mirRNome and isomiR variation in response to epidermal growth factor. BMC Genomics, 2013, 14, 371.	2.8	33
1139	Two-in-One antibodies with dual action Fabs. Current Opinion in Chemical Biology, 2013, 17, 400-405.	6.1	36
1140	Preparation of pro-oncogenic mutant forms V659E and V659Q of the transmembrane domain of receptor protein kinase ErbB2 for structural studies. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2013, 7, 91-99.	0.6	1
1141	Signaling mechanisms regulating myelination in the central nervous system. Neuroscience Bulletin, 2013, 29, 199-215.	2.9	29
1142	Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer. Breast Cancer, 2013, 20, 103-110.	2.9	11
1143	HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Research and Treatment, 2013, 139, 741-750.	2.5	52
1144	Combined gene expression and proteomic analysis of EGF induced apoptosis in A431 cells suggests multiple pathways trigger apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1291-1305.	4.9	23

#	Article	IF	CITATIONS
1145	Characterization of the EGFR interactome reveals associated protein complex networks and intracellular receptor dynamics. Proteomics, 2013, 13, 3131-3144.	2.2	54
1146	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. International Journal of Cancer, 2013, 133, 235-246.	5.1	16
1147	Effect of Microformulation on the Bioactivity of an Anthocyanin-rich Bilberry Pomace Extract (Vaccinium myrtillus L.) in Vitro. Journal of Agricultural and Food Chemistry, 2013, 61, 4873-4881.	5.2	19
1148	Molecular pathways and potential therapeutic targets in glioblastoma multiforme. Expert Review of Anticancer Therapy, 2013, 13, 1307-1318.	2.4	5
1149	SMURF1 Plays a Role in EGF-Induced Breast Cancer Cell Migration and Invasion. Molecules and Cells, 2013, 36, 548-555.	2.6	38
1150	Impedimetric biosensor for cancer cell detection. Electrochemistry Communications, 2013, 37, 36-39.	4.7	33
1151	Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Bioorganic and Medicinal Chemistry, 2013, 21, 7988-7998.	3.0	23
1152	Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features. Asian Pacific Journal of Tropical Medicine, 2013, 6, 260-264.	0.8	21
1153	Molecular profiling of <scp>EGFR</scp> family in chronic obstructive pulmonary disease: correlation with airway obstruction. European Journal of Clinical Investigation, 2013, 43, 1299-1306.	3.4	10
1154	Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo. Arthritis Research and Therapy, 2013, 15, R60.	3.5	39
1155	Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanotechnology, 2013, 4, 145-157.	3.7	39
1156	Discovery of Pteridin-7(8 <i>H</i>)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant. Journal of Medicinal Chemistry, 2013, 56, 7821-7837.	6.4	58
1157	NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Toxicology and Applied Pharmacology, 2013, 272, 736-745.	2.8	54
1158	Design and evaluation of radiolabeled tracers for tumor imaging. Biotechnology and Applied Biochemistry, 2013, 60, 365-383.	3.1	15
1159	Apple procyanidins affect several members of the ErbB receptor tyrosine kinase family in vitro. Food and Function, 2013, 4, 689.	4.6	9
1160	Atomic force microscopy study of the effect of HER 2 antibody on EGF mediated ErbB ligand–receptor interaction. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 627-635.	3.3	44
1161	Oligopeptides derived from autophosphorylation sites of EGF receptor suppress EGF-stimulated responses in human lung carcinoma A549 cells. European Journal of Pharmacology, 2013, 698, 87-94.	3.5	7
1162	Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer. Neoplasia, 2013, 15, 61-IN18.	5.3	13

#	Article	IF	CITATIONS
1163	Necl-2/CADM1 interacts with ErbB4 and regulates its activity in GABAergic neurons. Molecular and Cellular Neurosciences, 2013, 56, 234-243.	2.2	23
1164	HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells. Biochemical and Biophysical Research Communications, 2013, 434, 81-86.	2.1	21
1165	IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model. Biochemical and Biophysical Research Communications, 2013, 436, 740-745.	2.1	30
1166	<i>EGFR</i> and <i>KRAS</i> mutations, and <i>ALK</i> fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics, 2013, 14, 1765-1777.	1.3	38
1167	Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer. European Journal of Medicinal Chemistry, 2013, 69, 833-841.	5.5	21
1168	p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway. Oncogene, 2013, 32, 1050-1058.	5.9	13
1169	Design, synthesis and inÂvitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors. European Journal of Medicinal Chemistry, 2013, 61, 132-145.	5.5	41
1170	Cross-talk between GPER and growth factor signaling. Journal of Steroid Biochemistry and Molecular Biology, 2013, 137, 50-56.	2.5	73
1171	Epidermal Growth Factor Receptor-Containing Exosomes Induce Tumor-Specific Regulatory T Cells. Cancer Investigation, 2013, 31, 330-335.	1.3	126
1172	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Medicinal Chemistry Letters, 2013, 4, 742-746.	2.8	34
1173	ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Frontiers in Cellular Neuroscience, 2013, 7, 4.	3.7	101
1174	Shedding of Soluble Epidermal Growth Factor Receptor (sEGFR) Is Mediated by a Metalloprotease/Fibronectin/Integrin Axis and Inhibited by Cetuximab. Biochemistry, 2013, 52, 4531-4540.	2.5	24
1175	Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 3889-3903.	6.4	92
1176	Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2013, 56, 4738-4748.	6.4	67
1177	The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treatment Reviews, 2013, 39, 68-76.	7.7	20
1178	Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells. Toxicology in Vitro, 2013, 27, 1-10.	2.4	32
1179	DNA-Mediated Assembly of Protein Heterodimers on Membrane Surfaces. Journal of the American Chemical Society, 2013, 135, 5012-5016.	13.7	27
1180	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene, 2013, 32, 3846-3856.	5.9	104

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1181	Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene, 2013, 32, 3443-3451.		5.9	63
1182	Simultaneous Profiling of 194 Distinct Receptor Transcripts in Human Cells. Science Signaling, 2 rs13.	2013, 6,	3.6	30
1183	Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuate Antitumor Effects in <i>BRAF</i> -Mutant Thyroid Carcinomas. Cancer Discovery, 2013, 3, 520-5	s Their 533.	9.4	328
1184	Inactivation of Epidermal Growth Factor by Porphyromonas gingivalis as a Potential Mechanism Periodontal Tissue Damage. Infection and Immunity, 2013, 81, 55-64.	for	2.2	46
1185	Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation. Science Translat Medicine, 2013, 5, 199ra111.	ional	12.4	197
1186	Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Maligna Progression and Drug Resistance in Breast Cancer. Cancer Research, 2013, 73, 6424-6434.	nt	0.9	68
1187	Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Frontiers in One 2013, 3, 86.	cology,	2.8	64
1188	EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis fro genome-wide association study in never-smoking women. Carcinogenesis, 2013, 34, 612-619.	m a	2.8	15
1189	Major Signaling Pathways Involved in Breast Cancer. , 2013, , 47-64.			3
1190	Expression Levels and Significance of Nuclear Factor-κB and Epidermal Growth Facto Receptor in Hepatolithiasis Associated with Intrahepatic Cholangiocarcinoma. Digestive Surgery 30, 309-316.	r , 2013,	1.2	14
1191	Tosylate salts of the anticancer drug lapatinib. Acta Crystallographica Section C: Crystal Structu Communications, 2013, 69, 1516-1523.	ire	0.4	4
1192	Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals of Oncology, 2013 273-282.	8, 24,	1.2	128
1195	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. Journal of the National Cane Institute, 2013, 105, 266-273.	cer	6.3	168
1196	Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma. British Journal of Cancer, 2013, 109, 482-492.		6.4	12
1197	An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoc Erxian Decoction, on Human Ovarian Cancer Models. Integrative Cancer Therapies, 2013, 12, 33	tion, 36-346.	2.0	13
1198	Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Ir Cancer Research, 2013, 73, 1190-1200.	hibitors.	0.9	98
1200	Therapeutic Effects of Autologous Lymphocytes Activated with Trastuzumab for Xenograft Mou Models of Human Breast Cancer. Biological and Pharmaceutical Bulletin, 2013, 36, 861-865.	ISE	1.4	1
1201	Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic pote SKOV-3 human ovarian carcinoma cells. Oncology Reports, 2013, 29, 1133-1139.	ential of	2.6	7

#	Article	IF	CITATIONS
1202	Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. Oncology Reports, 2013, 30, 1087-1093.	2.6	41
1203	erbB expression changes in ethanol and 7,12- dimethylbenz (a)anthracene-induced oral carcinogenesis. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2013, 18, e325-e331.	1.7	4
1205	Deregulation of HER2 Downstream Signaling in Breast Cancer Cells by a Cocktail of Anti-HER2 scFvs. Oncology Research, 2013, 20, 333-340.	1.5	13
1206	The function of human epidermal growth factor receptor-3 and its role in tumors (Review). Oncology Reports, 2013, 30, 2563-2570.	2.6	14
1207	Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas. OncoTargets and Therapy, 2013, 6, 1065.	2.0	1
1208	HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3). Archivio Italiano Di Urologia Andrologia, 2013, 85, 73.	0.8	10
1209	HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment. , 0, , .		2
1210	Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Management and Research, 2013, 9, 1.	1.9	28
1211	Targeting the EGFR family of receptor tyrosine kinases. , 0, , 843-853.		0
1212	ErbB2-Dependent Chemotaxis Requires Microtubule Capture and Stabilization Coordinated by Distinct Signaling Pathways. PLoS ONE, 2013, 8, e55211.	2.5	22
1213	Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3. PLoS ONE, 2013, 8, e71518.	2.5	28
1214	CyTargetLinker: A Cytoscape App to Integrate Regulatory Interactions in Network Analysis. PLoS ONE, 2013, 8, e82160.	2.5	117
1215	Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. PLoS ONE, 2013, 8, e66302.	2.5	26
1216	Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer. , 0, , 58-75.		0
1218	Phenotypic Diversity of Breast Cancer-Related Mutations in Metalloproteinase-Disintegrin ADAM12. PLoS ONE, 2014, 9, e92536.	2.5	11
1219	Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e93102.	2.5	87
1220	BMP Signaling in Astrocytes Downregulates EGFR to Modulate Survival and Maturation. PLoS ONE, 2014, 9, e110668.	2.5	55
1221	Novel [99mTcN]2+ Labeled EGFR Inhibitors as Potential Radiotracers for Single Photon Emission Computed Tomography (SPECT) Tumor Imaging. Molecules, 2014, 19, 5508-5521.	3.8	8

#	Article	IF	CITATIONS
1222	Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. OncoTargets and Therapy, 2015, 8, 7.	2.0	22
1223	Regulation of ERBB3/HER3 signaling in cancer. Oncotarget, 2014, 5, 10222-10236.	1.8	90
1224	New Strategies to Enhance the Efficacy of Surgical Treatment for Colorectal Liver Metastasis. , 2014, , .		1
1225	The Cellular Mastermind(?)—Mechanotransduction and the Nucleus. Progress in Molecular Biology and Translational Science, 2014, 126, 157-203.	1.7	30
1226	Panitumumab: leading to better overall survival in metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 535-548.	3.1	1
1227	Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochimica Et Biophysica Sinica, 2014, 46, 190-198.	2.0	37
1228	Deletion of ErbB4 accelerates polycystic kidney disease progression in cpk mice. Kidney International, 2014, 86, 538-547.	5.2	22
1229	Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. Cell Research, 2014, 24, 1354-1366.	12.0	29
1230	HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Archives of Pathology and Laboratory Medicine, 2014, 138, 343-350.	2.5	120
1231	Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway. Oncology Letters, 2014, 8, 2110-2116.	1.8	11
1232	Live cell off-target identification of lapatinib using ligand-directed tosyl chemistry. Chemical Communications, 2014, 50, 14097-14100.	4.1	15
1233	α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling. Molecular Medicine Reports, 2014, 9, 993-998.	2.4	15
1234	Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment. Seminars in Oncology, 2014, 41, 653-660.	2.2	70
1235	Positron Emission Tomography Imaging with 18F-Labeled Z <i>HER2:2891</i> Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies. Clinical Cancer Research, 2014, 20, 1632-1643.	7.0	32
1236	FIH-1 Disrupts an LRRK1/EGFR Complex to Positively Regulate Keratinocyte Migration. American Journal of Pathology, 2014, 184, 3262-3271.	3.8	9
1237	Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. Archives of Gynecology and Obstetrics, 2014, 290, 1221-1229.	1.7	12
1238	Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines. BMC Systems Biology, 2014, 8, 75.	3.0	36
1239	Emerging drugs for biliary cancer. Expert Opinion on Emerging Drugs, 2014, 19, 11-24.	2.4	6

	Сіта	tion Report	
#	Article	IF	CITATIONS
1240	Lapatinib. Recent Results in Cancer Research, 2014, 201, 125-143.	1.8	16
1241	An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma Chemoresistance. Genetics Research International, 2014, 2014, 1-13.	2.0	7
1242	When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Cells, 2014, 3, 53-78.	4.1	30
1243	Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers. Cells, 2014, 3, 304-330.	4.1	153
1244	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. Pharmaceuticals, 2014, 7, 311-338.	3.8	62
1245	Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). Molecular and Clinical Oncology, 2014, 2, 175-181.	1.0	48
1246	Targeting HER2 amplifications in gastric cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 11.	5.5	1
1247	Her2/neu expression in urothelial dysplasia, carcinoma in situ, and superficial urothelial carcinoma and its value in assessing the response to BCG therapy. Egyptian Journal of Pathology, 2014, 34, 25-31.	0.0	1
1248	Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases. Oncogene, 2014, 33, 986-995.	5.9	13
1249	Developmental defects in zebrafish for classification of EGF pathway inhibitors. Toxicology and Applied Pharmacology, 2014, 274, 339-349.	2.8	17
1250	Interdependent epidermal growth factor receptor signalling and trafficking. International Journal of Biochemistry and Cell Biology, 2014, 51, 23-28.	2.8	67
1251	Solubleâ€Eâ€eadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers Molecular Carcinogenesis, 2014, 53, 893-906.	. 2.7	28
1252	Grb2 interacts with SGEF and antagonizes the ability of SGEF to enhance EGF-induced ERK1/2 activation Molecular and Cellular Biochemistry, 2014, 389, 239-247.	l. 3.1	6
1253	Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3 in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 511-516.	, 2.3	37
1254	Molecular Pathogenesis of Uterine Serous Carcinoma. Current Obstetrics and Gynecology Reports, 2014, 3, 33-39.	0.8	0
1255	Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread. Clinical and Experimental Metastasis, 2014, 31, 307-316.	3.3	17
1256	Metabolism and Pharmacokinetics of Allitinib in Cancer Patients: The Roles of Cytochrome P450s and Epoxide Hydrolase in its Biotransformation. Drug Metabolism and Disposition, 2014, 42, 872-884.	3.3	10
1257	Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor. Journal of Oral Pathology and Medicine, 2014, 43, 250-257.	2.7	30

#	Article	IF	CITATIONS
1258	ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation. Journal of Cellular Biochemistry, 2014, 115, 498-509.	2.6	75
1259	Biomarkers of drugs targeting <scp>HER</scp> â€family signalling in cancer. Journal of Pathology, 2014, 232, 219-229.	4.5	49
1260	Bioengineered Bacterial Outer Membrane Vesicles as Cell-Specific Drug-Delivery Vehicles for Cancer Therapy. ACS Nano, 2014, 8, 1525-1537.	14.6	373
1261	ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Oncogene, 2014, 33, 589-598.	5.9	38
1262	Clinicopathologic characteristics and prognostic significance of <i>EGFR</i> and <i>p53</i> mutations in surgically resected lung adenocarcinomas â‰⊉ cm in maximal dimension. Journal of Surgical Oncology, 2014, 110, 99-106.	1.7	32
1263	Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opinion on Emerging Drugs, 2014, 19, 459-470.	2.4	24
1264	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. Cancer Treatment Reviews, 2014, 40, 1048-1055.	7.7	34
1265	Mapping the resting and stimulated ECFR in cell membranes with topography and recognition imaging. Analytical Methods, 2014, 6, 7689-7694.	2.7	6
1266	The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines. Molecular Biology Reports, 2014, 41, 8031-8036.	2.3	12
1267	Optimization of gefitinib analogues with potent anticancer activity. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5247-5250.	2.2	20
1268	Mutual regulation of TGF-β1, TβRII and ErbB receptors expression in human thyroid carcinomas. Experimental Cell Research, 2014, 327, 24-36.	2.6	12
1269	Molecular Imaging Reveals Trastuzumab-Induced Epidermal Growth Factor Receptor Downregulation In Vivo. Journal of Nuclear Medicine, 2014, 55, 1002-1007.	5.0	16
1270	Characterization of Membrane Protein Interactions by Isothermal Titration Calorimetry. Journal of Molecular Biology, 2014, 426, 3670-3680.	4.2	26
1271	Genetically Encoding an Electrophilic Amino Acid for Protein Stapling and Covalent Binding to Native Receptors. ACS Chemical Biology, 2014, 9, 1956-1961.	3.4	84
1272	Inhibiting Epidermal Growth Factor Receptor at a Distance. Journal of the American Chemical Society, 2014, 136, 11232-11235.	13.7	27
1273	S100A14, a Member of the EF-hand Calcium-binding Proteins, Is Overexpressed in Breast Cancer and Acts as a Modulator of HER2 Signaling. Journal of Biological Chemistry, 2014, 289, 827-837.	3.4	49
1275	Predicting dynamic signaling network response under unseen perturbations. Bioinformatics, 2014, 30, 2772-2778.	4.1	13
1276	The role of HER3 in gastric cancer. Biomedicine and Pharmacotherapy, 2014, 68, 809-812.	5.6	16

#	Article	IF	CITATIONS
1277	A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. Journal of Molecular Medicine, 2014, 92, 969-981.	3.9	16
1278	Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. Journal of Molecular Medicine, 2014, 92, 681-695.	3.9	15
1279	Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1889-1897.	6.4	54
1280	Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer Chemotherapy and Pharmacology, 2014, 73, 685-693.	2.3	32
1281	Analysis of Protein–Protein Interactions by Coimmunoprecipitation. Methods in Enzymology, 2014, 541, 35-47.	1.0	9
1282	Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 2366-2378.	3.0	35
1283	Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway. Medical Oncology, 2014, 31, 903.	2.5	39
1284	Neuregulin-ErbB4 signaling in the developing lung alveolus: a brief review. Journal of Cell Communication and Signaling, 2014, 8, 105-111.	3.4	9
1285	Targeting of erbB3 receptor to overcome resistance in cancer treatment. Molecular Cancer, 2014, 13, 105.	19.2	142
1286	n-3 polyunsaturated fatty acids and HER2-positive breast cancer: Interest of the fat-1 transgenic mouse model over conventional dietary supplementation. Biochimie, 2014, 96, 22-27.	2.6	10
1287	A bispecific transmembrane antibody simultaneously targeting intra―and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth. International Journal of Cancer, 2014, 134, 2547-2559.	5.1	3
1288	Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA–microRNA regulatory network in nasopharyngeal carcinoma model systems. FEBS Open Bio, 2014, 4, 128-140.	2.3	38
1289	AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. Cellular Signalling, 2014, 26, 1021-1029.	3.6	37
1290	Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. European Journal of Medicinal Chemistry, 2014, 77, 75-83.	5.5	20
1291	AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Letters, 2014, 350, 61-68.	7.2	35
1292	Personalized medicine for breast cancer: it is a new day!. American Journal of Surgery, 2014, 207, 321-325.	1.8	7
1293	In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells. Immunotherapy, 2014, 6, 43-49.	2.0	15
1295	Short Linear Motifs: Ubiquitous and Functionally Diverse Protein Interaction Modules Directing Cell Regulation. Chemical Reviews, 2014, 114, 6733-6778.	47.7	389
# 1296	ARTICLE Molecular modeling of polynucleotide complexes. Biomaterials, 2014, 35, 7068-7076.	IF 11.4	Citations 36
-----------	--	----------------------------------	-----------------
1297	Resistance to Cetuximab in EGFR-Overexpressing Esophageal Squamous Cell Carcinoma Xenografts Due to FGFR2 Amplification and Overexpression. Journal of Pharmacological Sciences, 2014, 126, 77-83.	2.5	10
1298	Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines. Oncology Reports, 2014, 32, 1218-1224.	2.6	41
1299	Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncology Reports, 2014, 32, 1681-1688.	2.6	24
1300	Tailoring Chimeric Ligands for Studying and Biasing ErbB Receptor Family Interactions. Angewandte Chemie - International Edition, 2014, 53, 2662-2666.	13.8	23
1302	Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors. Scientific Reports, 2015, 5, 13934.	3.3	14
1304	Circulating human epidermal growth factor receptor 2 (<scp>HER2</scp>) is associated with hyperglycaemia and insulin resistance循玨ä,çš"ä≌ç±»èj¨çš®ç"Ÿé•¿å>åå⊷体2ï¼ `HER2)ä,Žé«~èj€ç³−以å	å Š ef ⁸ å²›ç´	抵抗æœ
1305	Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind―side effect in a case report. BMC Cancer, 2015, 15, 973.	2.6	28
1306	Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck. Oncologist, 2015, 20, 1393-1403.	3.7	7
1307	The Significance of Neuregulin-1/ErbB Expression in Autogenous Vein Grafts in a Diabetic Rat Model. Journal of Cardiovascular Pharmacology, 2015, 66, 300-306.	1.9	4
1308	Increase EGFR Mutations Detection Rate in Lung Adenocarcinoma by Real-Time PCR Screening Followed by Direct Sequencing. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 343-348.	1.2	7
1309	Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Drug Design, Development and Therapy, 2015, 9, 3837.	4.3	7
1310	Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders. International Review of Neurobiology, 2015, 124, 113-131.	2.0	10
1311	Recent advances in the HER2 targeted therapy of gastric cancer. World Journal of Clinical Cases, 2015, 3, 42.	0.8	39
1312	Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy. Theranostics, 2015, 5, 378-398.	10.0	59
1313	mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer. PLoS ONE, 2015, 10, e0117818.	2.5	39
1314	MicroRNAs Are Part of the Regulatory Network that Controls EGF Induced Apoptosis, Including Elements of the JAK/STAT Pathway, in A431 Cells. PLoS ONE, 2015, 10, e0120337.	2.5	25
1315	Inhibiting EGFR Dimerization Using Triazolyl-Bridged Dimerization Arm Mimics. PLoS ONE, 2015, 10, e0118796.	2.5	31

#	Article	IF	CITATIONS
1316	The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation. PLoS ONE, 2015, 10, e0129661.	2.5	34
1317	Protein-Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a Neuregulin 2a-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis. PLoS ONE, 2015, 10, e0130688.	2.5	18
1318	Phosphorylation of Threonine 794 on Tie1 by Rac1/PAK1 Reveals a Novel Angiogenesis Regulatory Pathway. PLoS ONE, 2015, 10, e0139614.	2.5	8
1319	Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role. PLoS ONE, 2015, 10, e0143076.	2.5	20
1320	Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease. Analytical Cellular Pathology, 2015, 2015, 1-10.	1.4	34
1321	EGFR and NF-κB: partners in cancer. Trends in Molecular Medicine, 2015, 21, 385-393.	6.7	180
1322	Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells. Nutrition and Cancer, 2015, 67, 771-782.	2.0	9
1323	Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future Oncology, 2015, 11, 1109-1122.	2.4	18
1324	Epidermal Growth Factor Signaling in Transformed Cells. International Review of Cell and Molecular Biology, 2015, 314, 1-41.	3.2	86
1325	Highly expressed EGFR in pearl sac may facilitate the pearl formation in the pearl oyster, Pinctada fucata. Gene, 2015, 566, 201-211.	2.2	12
1326	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clinical Cancer Research, 2015, 21, 2462-2470.	7.0	51
1327	Cohesin modulates transcription of estrogen-responsive genes. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 257-269.	1.9	18
1328	Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors. Bioorganic Chemistry, 2015, 59, 124-129.	4.1	15
1329	PTEN Loss Is Associated with Worse Outcome in <i>HER2</i> Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clinical Cancer Research, 2015, 21, 2065-2074.	7.0	59
1330	Overview of high-risk HPV's 16 and 18 infected cervical cancer: Pathogenesis to prevention. Biomedicine and Pharmacotherapy, 2015, 70, 103-110.	5.6	55
1331	Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer. Molecular Carcinogenesis, 2015, 54, 1700-1709.	2.7	12
1332	Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia, 2015, 17, 101-113.	5.3	40
1333	Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFR–Cysteine 797 and <i>N</i> -(4-Anilinoquinazolin-6-yl) Acrylamide. Journal of Chemical Information and Modeling, 2015, 55, 589-599.	5.4	42

~		~	
	ON	REDC	DT
\sim		IVEL V	

#	Article	IF	CITATIONS
1334	Molecular Pathways: Targeting <i>NRG1</i> Fusions in Lung Cancer. Clinical Cancer Research, 2015, 21, 1989-1994.	7.0	61
1335	Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine, 2015, 2, 264-271.	6.1	40
1336	A global microRNA screen identifies regulators of the ErbB receptor signaling network. Cell Communication and Signaling, 2015, 13, 5.	6.5	35
1337	Growth Factors and Tyrosine Kinase Receptors. , 2015, , 1-26.		1
1338	Kinase Activator-Receiver Preference in ErbB Heterodimers Is Determined by Intracellular Regions and Is Not Coupled to Extracellular Asymmetry. Journal of Biological Chemistry, 2015, 290, 1570-1579.	3.4	21
1339	The Potential of panHER Inhibition in Cancer. Frontiers in Oncology, 2015, 5, 2.	2.8	33
1340	Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer. Journal of Clinical Pathology, 2015, 68, 795-801.	2.0	22
1341	Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers. Molecular Cancer Therapeutics, 2015, 14, 2049-2059.	4.1	28
1342	A novel multivalent 99m Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts. Nuclear Medicine and Biology, 2015, 42, 547-554.	0.6	11
1343	Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling. Journal of Molecular Graphics and Modelling, 2015, 61, 61-84.	2.4	4
1344	The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. Scientific Reports, 2015, 5, 12054.	3.3	22
1345	EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. Archives of Biochemistry and Biophysics, 2015, 575, 69-76.	3.0	7
1346	Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity. European Journal of Medicinal Chemistry, 2015, 102, 115-131.	5.5	26
1347	Trans-regulation of Syndecan Functions by Hetero-oligomerization. Journal of Biological Chemistry, 2015, 290, 16943-16953.	3.4	24
1348	Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Experimental and Therapeutic Medicine, 2015, 9, 17-24.	1.8	20
1349	Transforming growth factor-α induces human ovarian cancer cell invasion by down-regulating E-cadherin in a Snail-independent manner. Biochemical and Biophysical Research Communications, 2015, 461, 128-135.	2.1	18
1350	Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. Bioorganic and Medicinal Chemistry, 2015, 23, 2767-2780.	3.0	37
1351	EGFR Inhibition by Curcumin in Cancer Cells: A Dual Mode of Action. Biomacromolecules, 2015, 16, 1634-1642.	5.4	64

#	Article	IF	CITATIONS
1352	Chemoradiation in oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 193-209.	2.4	16
1353	Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World Journal of Urology, 2015, 33, 1951-1957.	2.2	20
1354	The epidermal growth factor receptor (EGRF) in lung cancer. Translational Respiratory Medicine, 2015, 3, 1.	3.8	34
1355	Heterotrimeric G Proteins Directly Regulate MMP14/Membrane Type-1 Matrix Metalloprotease. Journal of Biological Chemistry, 2015, 290, 9941-9947.	3.4	33
1356	Embryo Implantation. , 2015, , 1697-1739.		8
1357	Design, synthesis, molecular modeling and anti-breast cancer activity of novel quinazolin-4-one derivatives linked to thiazolidinone, oxadiazole or pyrazole moieties. Medicinal Chemistry Research, 2015, 24, 2993-3007.	2.4	17
1358	Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells. Experimental Cell Research, 2015, 333, 116-126.	2.6	36
1359	A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells. Stem Cells and Development, 2015, 24, 1691-1702.	2.1	11
1360	1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents. European Journal of Medicinal Chemistry, 2015, 97, 124-141.	5.5	142
1361	Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Anti-Cancer Drugs, 2015, 26, 371-378.	1.4	10
1362	Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. Journal of Clinical Pathology, 2015, 68, 374-380.	2.0	26
1363	Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles. Human Reproduction, 2015, 30, 789-799.	0.9	32
1364	Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Biomarkers in Medicine, 2015, 9, 363-375.	1.4	11
1365	HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochimica Et Biophysica Sinica, 2016, 48, 39-48.	2.0	65
1366	Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1. American Journal of Clinical Pathology, 2015, 144, 686-703.	0.7	55
1367	Clinical significance of the integrin $\hat{l}\pm 6\hat{l}^24$ in human malignancies. Laboratory Investigation, 2015, 95, 976-986.	3.7	166
1368	Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression. Apmis, 2015, 123, 383-393.	2.0	2
1369	Epidermal growth factor–stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. Molecular Biology of the Cell, 2015, 26, 3504-3519.	2.1	75

#	Article	IF	CITATIONS
1370	ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1271-H1280.	3.2	85
1371	Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents. Future Journal of Pharmaceutical Sciences, 2015, 1, 33-41.	2.8	44
1372	Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacological Research, 2015, 102, 123-131.	7.1	51
1373	A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1599-1612.	4.9	9
1374	Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. European Journal of Medicinal Chemistry, 2015, 104, 115-126.	5.5	16
1375	ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. Cellular Signalling, 2015, 27, 2261-2271.	3.6	29
1376	Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model. Molecular Cancer Therapeutics, 2015, 14, 2642-2652.	4.1	23
1377	Quantification of Epidermal Growth Factor Receptor Expression Level and Binding Kinetics on Cell Surfaces by Surface Plasmon Resonance Imaging. Analytical Chemistry, 2015, 87, 9960-9965.	6.5	161
1378	4â€Substitutedâ€1â€phenylâ€1 <i>H</i> â€pyrazolo[3,4â€ <i>d</i>]pyrimidine Derivatives: Design, Synthesis, Ant and <scp>EGFR</scp> Tyrosine Kinase Inhibitory Activity. Chemical Biology and Drug Design, 2015, 85, 608-622.	itumor 3.2	16
1379	The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence. Journal of Urology, 2015, 193, 19-29.	0.4	64
1380	Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals. Targeted Oncology, 2015, 10, 337-353.	3.6	19
1381	Combination of novel HER2â€ŧargeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2â€positive gastric cancer. Molecular Oncology, 2015, 9, 398-408.	4.6	31
1382	Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget, 2016, 7, 69450-69465.	1.8	60
1383	Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. International Journal of Molecular Sciences, 2016, 17, 1605.	4.1	39
1384	The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond. Journal of Gastrointestinal Oncology, 2016, 7, 750-762.	1.4	45
1385	HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. Disease Markers, 2016, 2016, 1-6.	1.3	20
1386	HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery. Theranostics, 2016, 6, 1261-1273.	10.0	45
1387	The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family. Frontiers in Cell and Developmental Biology, 2016, 4, 88.	3.7	52

#	Article	IF	CITATIONS
1388	Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells. International Journal of Molecular Sciences, 2016, 17, 563.	4.1	5
1389	Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance. International Journal of Molecular Sciences, 2016, 17, 593.	4.1	39
1390	The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. International Journal of Molecular Sciences, 2016, 17, 1618.	4.1	4
1391	Complement Membrane Attack and Tumorigenesis. Journal of Biological Chemistry, 2016, 291, 14927-14938.	3.4	24
1392	Effects of the Transforming Growth Factor Beta Signaling Pathway on the Differentiation of Chicken Embryonic Stem Cells into Male Germ Cells. Cellular Reprogramming, 2016, 18, 401-410.	0.9	28
1393	Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cells. Molecular Medicine Reports, 2016, 13, 1909-1913.	2.4	2
1394	Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway. Oncology Reports, 2016, 36, 3058-3064.	2.6	13
1395	The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer. BMC Cancer, 2016, 16, 910.	2.6	13
1397	Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 11±. Molecular and Cellular Biology, 2016, 36, 2011-2026.	2.3	46
1398	Synthesis and evaluation of novel non-covalent binding quinazoline glycoside derivatives targeting the L858R and T790M variants of EGFR. RSC Advances, 2016, 6, 36857-36862.	3.6	7
1399	Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out?. Journal of Clinical Oncology, 2016, 34, 2072-2073.	1.6	2
1400	Synergistic inhibitory effect of cetuximab and tectochrysin on human colon cancer cell growth via inhibition of EGFR signal. Archives of Pharmacal Research, 2016, 39, 721-729.	6.3	10
1401	ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells. Oncogene, 2016, 35, 5759-5769.	5.9	19
1402	Two-Photon Tracer for Human Epidermal Growth Factor Receptor-2: Detection of Breast Cancer in a Live Tissue. Analytical Chemistry, 2016, 88, 9412-9418.	6.5	9
1403	Activation of Epidermal Growth Factor Receptor in Macrophages Mediates Feedback Inhibition of M2 Polarization and Gastrointestinal Tumor Cell Growth. Journal of Biological Chemistry, 2016, 291, 20462-20472.	3.4	26
1404	Bloodâ€based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance). Cancer Medicine, 2016, 5, 2249-2260.	2.8	19
1405	High affinity nanobodies against human epidermal growth factor receptor selected on cells by <i>E. coli</i> display. MAbs, 2016, 8, 1286-1301.	5.2	28
1406	Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy. Molecular Pharmaceutics, 2016, 13, 3370-3380.	4.6	15

#	Article	IF	CITATIONS
1407	The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 1549-1555.	3.1	5
1408	EGFR transactivation contributes to neuroinflammation in Streptococcus suis meningitis. Journal of Neuroinflammation, 2016, 13, 274.	7.2	31
1409	The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency. Scientific Reports, 2016, 6, 35850.	3.3	21
1410	A monoclonal antibody targeting the dimer interface of epidermal growth factor receptor (EGFR). Immunology Letters, 2016, 180, 39-45.	2.5	8
1411	Switching of the positive feedback for RAS activation by a concerted function of SOS membrane association domains. Biophysics and Physicobiology, 2016, 13, 1-11.	1.0	12
1413	MicroRNA-148a Suppresses the Proliferation and Migration of Pancreatic Cancer Cells by Down-regulating ErbB3. Pancreas, 2016, 45, 1263-1271.	1.1	26
1414	A study of the prognostic and predictive role of HER-2 expression in bladder urothelial carcinoma. Egyptian Journal of Pathology, 2016, 36, 241-250.	0.0	0
1415	Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation. Molecular Nutrition and Food Research, 2016, 60, 519-529.	3.3	56
1416	A phasor approach analysis of multiphoton FLIM measurements of three-dimensional cell culture models. Proceedings of SPIE, 2016, , .	0.8	1
1417	Interaction with epsin 1 regulates the constitutive clathrin-dependent internalization of ErbB3. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1179-1188.	4.1	17
1418	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics, 2016, 15, 1900-1909.	4.1	55
1419	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
1420	HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies. Cancer Drug Discovery and Development, 2016, , 231-261.	0.4	0
1421	ErbB2 blockade with Herceptin (trastuzumab) enhances peripheral nerve regeneration after repair of acute or chronic peripheral nerve injury. Annals of Neurology, 2016, 80, 112-126.	5.3	19
1422	Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1597-1608.	2.8	51
1423	Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2016, 24, 2871-2881.	3.0	25
1424	The Conserved Phenylalanine in the Transmembrane Domain Enhances Heteromeric Interactions of Syndecans. Journal of Biological Chemistry, 2016, 291, 872-881.	3.4	13
1425	Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. Bioorganic and Medicinal Chemistry, 2016, 24, 179-190.	3.0	19

#	Article	IF	CITATIONS
1426	Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1571-1575.	2.2	29
1427	Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. MAbs, 2016, 8, 551-561.	5.2	35
1428	Synthesis, crystal structure, superoxide scavenging activity, anticancer and docking studies of novel adamantyl nitroxide derivatives. Journal of Molecular Structure, 2016, 1108, 611-617.	3.6	11
1429	Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival. Oncogene, 2016, 35, 3986-3994.	5.9	26
1430	Antiproliferative effects of Î ³ -tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells. Journal of Nutritional Biochemistry, 2016, 27, 266-277.	4.2	46
1431	The genetic and regulatory architecture of ERBB3-type 1 diabetes susceptibility locus. Molecular and Cellular Endocrinology, 2016, 419, 83-91.	3.2	31
1432	Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients. Tumor Biology, 2016, 37, 857-863.	1.8	7
1433	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 228-235.	2.5	6
1434	Critical effects on binding of epidermal growth factor produced by amino acid substitutions. Journal of Biomolecular Structure and Dynamics, 2017, 35, 1085-1101.	3.5	6
1435	Deciphering the molecular signaling pathways in breast cancer pathogenesis and their role in diagnostic and treatment modalities. Gene Reports, 2017, 7, 1-17.	0.8	4
1436	Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway. Oncology Letters, 2017, 13, 347-355.	1.8	14
1437	The Development of a Dimroth Rearrangement Route to AZD8931. Organic Process Research and Development, 2017, 21, 336-345.	2.7	5
1438	Lung Cancer Metastasis. , 2017, , 61-76.		3
1439	Influence of node abundance on signaling network state and dynamics analyzed by mass cytometry. Nature Biotechnology, 2017, 35, 164-172.	17.5	39
1440	Applying phasor approach analysis of multiphoton FLIM measurements to probe the metabolic activity of three-dimensional in vitro cell culture models. Scientific Reports, 2017, 7, 42730.	3.3	52
1441	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. , 2017, 175, 91-106.		167
1442	SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors. SAR and QSAR in Environmental Research, 2017, 28, 111-132.	2.2	5
1443	ErbB1 and ErbB4 generate opposing signals regulating mesenchymal cell proliferation during valvulogenesis. Journal of Cell Science, 2017, 130, 1321-1332.	2.0	10

#	Article	IF	CITATIONS
1444	Myocardial ischemia/reperfusion upregulates the transcription of the Neuregulin1 receptor ErbB3, but only postconditioning preserves protein translation: Role in oxidative stress. International Journal of Cardiology, 2017, 233, 73-79.	1.7	15
1445	Design, synthesis, SAR discussion, inÂvitro and inÂvivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants. European Journal of Medicinal Chemistry, 2017, 135, 12-23.	5.5	27
1446	<i>HER2</i> somatic mutations are associated with poor survival in HER2â€negative breast cancers. Cancer Science, 2017, 108, 671-677.	3.9	53
1447	Ensemble clustering of phosphoproteomic data identifies differences in protein interactions and cell–cell junction integrity of HER2-overexpressing cells. Integrative Biology (United Kingdom), 2017, 9, 539-547.	1.3	1
1448	Development of a human epidermal growth factor derivative with EGFR-blocking and depleted biological activities: A comparative in vitro study using EGFR-positive breast cancer cells. International Journal of Biological Macromolecules, 2017, 103, 275-285.	7.5	12
1449	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 143-151.	2.8	2
1450	Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells. ACS Applied Materials & Interfaces, 2017, 9, 18423-18428.	8.0	47
1451	Protein lysine methyltransferase <scp>SMYD</scp> 3 is involved in tumorigenesis through regulation of <scp>HER</scp> 2 homodimerization. Cancer Medicine, 2017, 6, 1665-1672.	2.8	25
1452	HER3., 2017, , 719-737.		0
1453	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78.	17.0	232
1453 1455	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78.	17.0 2.5	232 31
1453 1455 1456	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Medical Oncology, 2017, 34, 3. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Journal of Biological Chemistry, 2017, 292, 1288-1301.	17.0 2.5 3.4	232 31 30
1453 1455 1456 1457	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Medical Oncology, 2017, 34, 3. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Journal of Biological Chemistry, 2017, 292, 1288-1301. Antiangiogenic and Toxic Effects of Genistein, Usnic Acid, and Their Copper Complexes in Zebrafish Embryos at Different Developmental Stages. Chemistry and Biodiversity, 2017, 14, e1600302.	17.0 2.5 3.4 2.1	232 31 30 23
1453 1455 1456 1457 1458	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Medical Oncology, 2017, 34, 3. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Journal of Biological Chemistry, 2017, 292, 1288-1301. Antiangiogenic and Toxic Effects of Genistein, Usnic Acid, and Their Copper Complexes in Zebrafish Embryos at Different Developmental Stages. Chemistry and Biodiversity, 2017, 14, e1600302. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1219-1227.	17.0 2.5 3.4 2.1 3.3	232 31 30 23 32
1453 1455 1456 1457 1458	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78.Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Medical Oncology, 2017, 34, 3.A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Journal of Biological Chemistry, 2017, 292, 1288-1301.Antiangiogenic and Toxic Effects of Genistein, Usnic Acid, and Their Copper Complexes in Zebrafish Embryos at Different Developmental Stages. Chemistry and Biodiversity, 2017, 14, e1600302.Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1219-1227.Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. Journal of Controlled Release, 2017, 268, 259-268.	17.0 2.5 3.4 2.1 3.3 9.9	232 31 30 23 32 61
1453 1455 1456 1457 1458 1459	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Medical Oncology, 2017, 34, 3. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Journal of Biological Chemistry, 2017, 292, 1288-1301. Antiangiogenic and Toxic Effects of Genistein, Usnic Acid, and Their Copper Complexes in Zebrafish Embryos at Different Developmental Stages. Chemistry and Biodiversity, 2017, 14, e1600302. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1219-1227. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. Journal of Controlled Release, 2017, 268, 259-268. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion. Journal of Pathology, 2017, 243, 481-495.	17.0 2.5 3.4 2.1 3.3 9.9 4.5	232 31 30 23 32 61 9
1453 1455 1456 1457 1458 1459 1460	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Medical Oncology, 2017, 34, 3. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Journal of Biological Chemistry, 2017, 292, 1288-1301. Antiangiogenic and Toxic Effects of Genistein, Usnic Acid, and Their Copper Complexes in Zebrafish Embryos at Different Developmental Stages. Chemistry and Biodiversity, 2017, 14, e1600302. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1219-1227. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. Journal of Controlled Release, 2017, 268, 259-268. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion. Journal of Fathology, 2017, 243, 481-495. Synthesis, characterization and biological evaluation of formononetin derivatives as novel EGFR inhibitors (sivia r/i) inhibiting growth, migration and inducing apoptosis in breast cancer cell line. RSC Advances, 2017, 7, 48404-48419.	17.0 2.5 3.4 2.1 3.3 9.9 4.5 3.6	232 31 30 23 32 61 9 12

#	Article	IF	CITATIONS
1463	Quantifying the Interaction between EGFR Dimers and Grb2 in Live Cells. Biophysical Journal, 2017, 113, 1353-1364.	0.5	23
1464	Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. Radiotherapy and Oncology, 2017, 124, 190-199.	0.6	35
1465	Oncogenic signalling pathways in benign odontogenic cysts and tumours. Oral Oncology, 2017, 72, 165-173.	1.5	52
1466	Association between ErbB4 single nucleotide polymorphisms and susceptibility to schizophrenia. Medicine (United States), 2017, 96, e5920.	1.0	5
1467	Analysis of Epithelial–Mesenchymal Transition Induced by Overexpression of Twist. Methods in Molecular Biology, 2017, 1652, 259-274.	0.9	7
1468	A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Research and Treatment, 2017, 165, 375-382.	2.5	17
1469	Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer cells. Archives of Biochemistry and Biophysics, 2017, 636, 110-122.	3.0	30
1470	An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds. European Journal of Medicinal Chemistry, 2017, 142, 328-375.	5.5	88
1471	A role for ErbB signaling in the induction of reactive astrogliosis. Cell Discovery, 2017, 3, 17044.	6.7	22
1472	Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib. Phytomedicine, 2017, 37, 58-61.	5.3	34
1473	EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Scientific Reports, 2017, 7, 15654.	3.3	38
1474	Bioinformatics analysis of transcription profiling of solid pseudopapillary neoplasm of the pancreas. Molecular Medicine Reports, 2017, 16, 1635-1642.	2.4	9
1475	Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents. MedChemComm, 2017, 8, 1810-1816.	3.4	44
1476	Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2283-2290.	2.5	13
1477	Evolution of anti-HER2 therapies for cancer treatment. Cancer Treatment Reviews, 2017, 59, 1-21.	7.7	73
1478	Ridle for sparse regression with mandatory covariates with application to the genetic assessment of histologic grades of breast cancer. BMC Medical Research Methodology, 2017, 17, 12.	3.1	2
1479	Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC Clinical Pathology, 2017, 17, 3.	1.8	10
1480	Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4). Tumor Biology, 2017, 39, 101042831770743.	1.8	5

#	Article	IF	CITATIONS
1481	Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration. Molecular Neurobiology, 2017, 54, 5085-5106.	4.0	8
1482	Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 135-144.	4.9	17
1483	Inhibition of MHCâ€I by Brucella abortus is an early event during infection and involves EGFR pathway. Immunology and Cell Biology, 2017, 95, 388-398.	2.3	23
1484	Differential effects of epidermal growth factor (EGF) receptor ligands on receptor binding, downstream signalling pathways and DNA synthesis in hepatocytes. Growth Factors, 2017, 35, 239-248.	1.7	6
1485	Structural basis of a novel heterodimeric Fc for bispecific antibody production. Oncotarget, 2017, 8, 51037-51049.	1.8	41
1486	Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. BMB Reports, 2017, 50, 132-137.	2.4	110
1487	Kaempferia parviflora Extract Exhibits Anti-cancer Activity against HeLa Cervical Cancer Cells. Frontiers in Pharmacology, 2017, 8, 630.	3.5	32
1488	Clinical targeting recombinant immunotoxins for cancer therapy. OncoTargets and Therapy, 2017, Volume 10, 3645-3665.	2.0	33
1489	Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. International Journal of Molecular Sciences, 2017, 18, 2420.	4.1	102
1490	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 2017, 9, 52.	3.7	1,153
1491	Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model― Cells, 2017, 6, 13.	4.1	118
1492	Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Frontiers in Immunology, 2017, 8, 1850.	4.8	161
1493	Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies. Frontiers in Oncology, 2017, 7, 100.	2.8	25
1494	Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 1527-1533.	2.0	13
1495	The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive. OncoTargets and Therapy, 2017, Volume 10, 4507-4515.	2.0	13
1496	HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss. PLoS ONE, 2017, 12, e0176778.	2.5	36
1497	Adoptive T-Cell Therapy for Solid Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 193-204.	3.8	44
1498	Rational Design of Threo as Well Erythro Noscapines, an Anticancer Drug: A Molecular Docking and Molecular Dynamic Approach. Biochemistry & Pharmacology: Open Access, 2017, 06, .	0.2	13

#	Article	IF	CITATIONS
1499	The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking. Oncotarget, 2017, 8, 33316-33328.	1.8	22
1500	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. Oncotarget, 2017, 8, 100863-100898.	1.8	16
1501	Adoptive T-Cell Therapy for Solid Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 193-204.	3.8	61
1502	HER3 expression is enhanced during progression of lung adenocarcinoma without <i>EGFR</i> mutation from stage 0 to IA1. Thoracic Cancer, 2018, 9, 466-471.	1.9	8
1503	Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. Molecular Neurobiology, 2018, 55, 8236-8242.	4.0	5
1504	Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging, 2018, 17, 153601211774538.	1.4	57
1505	Lipid-Protein Interplay in Dimerization of Juxtamembrane Domains of Epidermal Growth Factor Receptor. Biophysical Journal, 2018, 114, 893-903.	0.5	33
1506	Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. Journal of Biological Chemistry, 2018, 293, 8439-8448.	3.4	50
1507	Identification of EGFR in pearl oyster (<i>Pinctada fucata martensii</i>) and correlation analysis of its expression and growth traits. Bioscience, Biotechnology and Biochemistry, 2018, 82, 1073-1080.	1.3	12
1508	Discovery of new erbB4 inhibitors: Repositioning an orphan chemical library by inverse virtual screening. European Journal of Medicinal Chemistry, 2018, 152, 253-263.	5.5	18
1509	Comparative experimental/theoretical studies on the EGFR dimerization under the effect of EGF/EGF analogues binding: Highlighting the importance of EGF/EGFR interactions at site III interface. International Journal of Biological Macromolecules, 2018, 115, 401-417.	7.5	11
1510	Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold. Bioorganic and Medicinal Chemistry, 2018, 26, 1810-1822.	3.0	9
1511	6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. European Journal of Medicinal Chemistry, 2018, 147, 77-89.	5.5	39
1512	Design of cyclic and <scp>d</scp> â€amino acids containing peptidomimetics for inhibition of proteinâ€protein interactions of HER2â€HER3. Journal of Peptide Science, 2018, 24, e3066.	1.4	10
1513	Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer. Cell Death and Disease, 2018, 9, 47.	6.3	26
1514	Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. Journal of Controlled Release, 2018, 271, 127-138.	9.9	9
1515	BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene, 2018, 37, 1576-1593.	5.9	37
1516	Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2. International Journal of Biological Macromolecules, 2018, 111, 569-586.	7.5	19

#	Article	IF	CITATIONS
1517	Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer. Molecular Therapy - Nucleic Acids, 2018, 10, 317-330.	5.1	66
1518	Construction, Expression, and Characterization of rSEA-EGF and <i>In Vitro</i> Evaluation of its Antitumor Activity Against Nasopharyngeal Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381876291.	1.9	8
1519	Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2173-2185.	3.0	26
1520	ErbB4 deletion accelerates renal fibrosis following renal injury. American Journal of Physiology - Renal Physiology, 2018, 314, F773-F787.	2.7	22
1521	Erbin and ErbB2 play roles in the sexual differentiation of the song system nucleus HVC in bengalese finches (<i>Lonchura Striata</i> var. <i>domestica</i>). Developmental Neurobiology, 2018, 78, 15-38.	3.0	5
1522	Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treatment Reviews, 2018, 62, 1-8.	7.7	69
1523	Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discovery Today, 2018, 23, 745-753.	6.4	99
1524	Design and synthesis of some new piritrexim analogs as potential anticancer agents. Research on Chemical Intermediates, 2018, 44, 749-767.	2.7	3
1525	Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 337-348.	2.5	6
1526	Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. Cancer Letters, 2018, 412, 118-130.	7.2	42
1527	Algorithmically probable mutations reproduce aspects of evolution, such as convergence rate, genetic memory and modularity. Royal Society Open Science, 2018, 5, 180399.	2.4	19
1528	Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage. Mediators of Inflammation, 2018, 2018, 1-22.	3.0	93
1529	The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC. Bioorganic and Medicinal Chemistry, 2018, 26, 6087-6095.	3.0	9
1530	Inhibition of EGFR Activation by Bivalent Ligands Based on a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR. Chemical and Pharmaceutical Bulletin, 2018, 66, 1083-1089.	1.3	10
1531	Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophysics Reports, 2018, 4, 243-253.	0.8	17
1532	An Improved Method for Prediction of Cancer Prognosis by Network Learning. Genes, 2018, 9, 478.	2.4	33
1533	Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. Oncology, 2018, 95, 353-359.	1.9	6
1534	Peptideâ€Based Multifunctional Nanomaterials for Tumor Imaging and Therapy. Advanced Functional Materials, 2018, 28, 1804492.	14.9	94

#	Article	IF	CITATIONS
1535	Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer. Medicine (United States), 2018, 97, e12317.	1.0	9
1536	Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381880690.	1.9	11
1537	The Auricular VX2 Carcinoma Is a Suitable Animal Model for Identifying Biomarkers for HNSCC Therapy Response. Anticancer Research, 2018, 38, 5067-5078.	1.1	0
1538	Agonist-Biased Signaling via Matrix Metalloproteinase-9 Promotes Extracellular Matrix Remodeling. Cells, 2018, 7, 117.	4.1	23
1539	Current therapeutic landscape for advanced gastroesophageal cancers. Annals of Translational Medicine, 2018, 6, 78-78.	1.7	7
1540	The promise of stem cell markers in the diagnosis and therapy of epithelial dysplasia and oral squamous cell carcinoma. Journal of Cellular Physiology, 2018, 233, 8499-8507.	4.1	13
1541	Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. Bioorganic and Medicinal Chemistry, 2018, 26, 3619-3633.	3.0	14
1542	Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells. Journal of Biological Chemistry, 2018, 293, 11076-11087.	3.4	21
1543	A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics. Biochemistry and Cell Biology, 2018, 96, 295-305.	2.0	16
1544	Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Breast Cancer Research and Treatment, 2018, 171, 675-683.	2.5	9
1545	Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. Journal of Neurochemistry, 2018, 147, 99-109.	3.9	20
1546	Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics. Oncology Letters, 2018, 16, 1087-1094.	1.8	5
1547	Lapatinib. Recent Results in Cancer Research, 2018, 211, 19-44.	1.8	75
1548	Circulating HER‑2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer. Oncology Letters, 2018, 16, 3726-3734.	1.8	8
1549	ErbB4 deletion predisposes to development of metabolic syndrome in mice. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E583-E593.	3.5	39
1550	Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometriod Endometrial Cancer. Frontiers in Pharmacology, 2018, 9, 750.	3.5	3
1551	The role of ErbB3 binding protein 1 in cancer: Friend or foe?. Journal of Cellular Physiology, 2018, 233, 9110-9120.	4.1	20
1552	A phase II trial of the panâ€HER inhibitor poziotinib, in patients with HER2â€positive metastatic breast cancer who had received at least two prior HER2â€directed regimens: results of the NOV120101â€203 trial. International Journal of Cancer, 2018, 143, 3240-3247.	5.1	46

#	Article	IF	CITATIONS
1553	Rho A Regulates Epidermal Growth Factor-Induced Human Osteosarcoma MG63 Cell Migration. International Journal of Molecular Sciences, 2018, 19, 1437.	4.1	14
1554	EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?. Respiratory Disease Series, 2018, , 275-293.	0.0	0
1555	Novel Systemic Therapies for Advanced Gastric Cancer. Journal of Gastric Cancer, 2018, 18, 1.	2.5	33
1556	Neuregulin-1 attenuates experimental cerebral malaria (ECM) pathogenesis by regulating ErbB4/AKT/STAT3 signaling. Journal of Neuroinflammation, 2018, 15, 104.	7.2	32
1557	Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Medical Oncology, 2018, 35, 87.	2.5	24
1558	HER3 signaling and targeted therapy in cancer. Oncology Reviews, 2018, 12, 355.	1.8	109
1559	Combined Quantum Mechanics and Molecular Mechanics Studies of Enzymatic Reaction Mechanisms. Advances in Protein Chemistry and Structural Biology, 2018, 113, 1-32.	2.3	10
1560	Functional miRNAs in breast cancer drug resistance. OncoTargets and Therapy, 2018, Volume 11, 1529-1541.	2.0	89
1561	Role of Tocotrienols in Chemosensitization of Cancer. , 2018, , 77-97.		2
1562	Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorganic Chemistry, 2018, 80, 375-395.	4.1	98
1563	Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharmaceutica Sinica B, 2018, 8, 503-510.	12.0	80
1564	The first draft genome of Lophophorus: A step forward for Phasianidae genomic diversity and conservation. Genomics, 2019, 111, 1209-1215.	2.9	9
1565	The role of the EGFR signaling pathway in stem cell differentiation during planarian regeneration and homeostasis. Seminars in Cell and Developmental Biology, 2019, 87, 45-57.	5.0	14
1566	Tongxinluo Attenuates Myocardiac Fibrosis after Acute Myocardial Infarction in Rats via Inhibition of Endothelial-to-Mesenchymal Transition. BioMed Research International, 2019, 2019, 1-13.	1.9	16
1567	Biomaterials and controlled release strategy for epithelial wound healing. Biomaterials Science, 2019, 7, 4444-4471.	5.4	47
1568	Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. American Journal of Pathology, 2019, 189, 1898-1912.	3.8	42
1569	Inhibition of HER2â€Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2â€Glycanâ€Imprinted Nanoparticles. Angewandte Chemie, 2019, 131, 10731-10735.	2.0	22
1570	Auger electrons for cancer therapy – a review. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 27	3.9	196

#	Article	IF	CITATIONS
1571	HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo. Nucleic Acids Research, 2019, 47, 11020-11043.	14.5	7
1572	Receptor Heterodimerization Modulates Endocytosis through Collaborative and Competitive Mechanisms. Biophysical Journal, 2019, 117, 646-658.	0.5	4
1573	Dynamical Rearrangement of Human Epidermal Growth Factor Receptor 2 upon Antibody Binding: Effects on the Dimerization. Biomolecules, 2019, 9, 706.	4.0	6
1574	The calciumâ€sensing receptor: A novel target for treatment and prophylaxis of neratinibâ€induced diarrhea. Pharmacology Research and Perspectives, 2019, 7, e00521.	2.4	5
1575	Novel Pituitary Actions of Epidermal Growth Factor: Receptor Specificity and Signal Transduction for UTS1, EGR1, and MMP13 Regulation by EGF. International Journal of Molecular Sciences, 2019, 20, 5172.	4.1	6
1576	Targeting of early endosomes by autophagy facilitates <scp>EGFR</scp> recycling and signalling. EMBO Reports, 2019, 20, e47734.	4.5	65
1577	Epidermal Growth Factor Potentiates Migration of MDA-MB 231 Breast Cancer Cells by Increasing Na _V 1.5 Channel Expression. Oncology, 2019, 97, 373-382.	1.9	9
1578	A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clinical Cancer Research, 2019, 25, 7151-7161.	7.0	88
1579	1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. European Journal of Medicinal Chemistry, 2019, 182, 111607.	5.5	26
1580	Therapeutic efficacy of neuregulin 1-expressing human adipose-derived mesenchymal stem cells for ischemic stroke. PLoS ONE, 2019, 14, e0222587.	2.5	17
1581	Effective targeted therapy based on dynamic monitoring of gene mutations in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 532-538.	2.8	6
1582	Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?. Hormones and Cancer, 2019, 10, 64-70.	4.9	9
1583	CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. Cancer Letters, 2019, 447, 130-140.	7.2	32
1584	Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. DNA and Cell Biology, 2019, 38, 184-192.	1.9	26
1585	The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Research and Treatment, 2019, 175, 5-15.	2.5	48
1586	Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with <i>EGFR</i> Wild-Type Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2019, 82, 62.	1.8	9
1587	Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- <i>d</i>]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 1274-1290.	6.4	33
1588	Investigation of Neuregulin-1 and Glial Cell-Derived Neurotrophic Factor in Rodent Astrocytes and Microglia. Journal of Molecular Neuroscience, 2019, 67, 484-493.	2.3	11

#	Article	IF	CITATIONS
1589	Dysregulated microRNAs in colorectal carcinogenesis: New insight to cell survival and apoptosis regulation. Journal of Cellular Physiology, 2019, 234, 21683-21693.	4.1	26
1590	Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. British Journal of Cancer, 2019, 121, 237-248.	6.4	15
1591	Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair. Progress in Neurobiology, 2019, 180, 101643.	5.7	74
1592	Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. Journal of Translational Medicine, 2019, 17, 201.	4.4	14
1593	Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma. Pathology Research and Practice, 2019, 215, 152438.	2.3	21
1594	Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein and Cell, 2019, 10, 787-807.	11.0	163
1595	Inhibition of HER2â€Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2â€Glycanâ€Imprinted Nanoparticles. Angewandte Chemie - International Edition, 2019, 58, 10621-10625.	13.8	138
1596	Novel sulfonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1030-1040.	5.2	47
1597	Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways. Anticancer Research, 2019, 39, 2377-2383.	1.1	11
1598	Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2019, 20, 1121-1126.	3.4	16
1599	Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biological Procedures Online, 2019, 21, 5.	2.9	48
1600	Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual ECFR/HER2 inhibitors and apoptosis inducers. Bioorganic Chemistry, 2019, 88, 102944.	4.1	119
1601	EGFR Signaling: Friend or Foe for Cartilage?. JBMR Plus, 2019, 3, e10177.	2.7	36
1602	Clinical significance of HER2 and ECFR expression in colorectal cancer patients with ovarian metastasis. BMC Clinical Pathology, 2019, 19, 3.	1.8	16
1603	The Role of Lipid Rafts in Mediating the Anticancer Effects of \hat{I}^3 -Tocotrienol. , 2019, , 125-140.		0
1604	HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer. Pathology Research and Practice, 2019, 215, 910-917.	2.3	4
1605	Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence. Cancer Medicine, 2019, 8, 1269-1278.	2.8	37
1606	The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial. Radiotherapy and Oncology, 2019, 134, 74-80.	0.6	14

~			~	
(ПТ.	ΔΤΙ	ON.	REDO	NRT.
			ILLI U	TO D

#	Article	IF	CITATIONS
1607	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. Molecular Cancer Therapeutics, 2019, 18, 1909-1915.	4.1	21
1608	Current Approaches in NSCLC Targeting K-RAS and EGFR. International Journal of Molecular Sciences, 2019, 20, 5701.	4.1	47
1609	Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Frontiers in Oncology, 2019, 9, 1308.	2.8	82
1610	Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers, 2019, 11, 1826.	3.7	132
1611	Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Communication and Signaling, 2019, 17, 154.	6.5	192
1612	The RTK Interactome: Overview and Perspective on RTK Heterointeractions. Chemical Reviews, 2019, 119, 5881-5921.	47.7	59
1613	Crosstalk between receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCR) in the brain: Focus on heteroreceptor complexes and related functional neurotrophic effects. Neuropharmacology, 2019, 152, 67-77.	4.1	50
1614	Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in AssessmentÂMethods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review. Urologia Internationalis, 2019, 102, 249-261.	1.3	15
1615	Transactivated Epidermal Growth Factor Receptor Recruitment of α-actinin-4 From F-actin Contributes to Invasion of Brain Microvascular Endothelial Cells by Meningitic Escherichia coli. Frontiers in Cellular and Infection Microbiology, 2018, 8, 448.	3.9	20
1616	Molecular and Transcriptional Signatures for ErbB2-Induced Invasion. Current Pharmacology Reports, 2019, 5, 43-55.	3.0	0
1617	The Molecular Biology of HER2 and HER2-Targeted Therapies. , 2019, , 1-11.		3
1618	Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells. Translational Research, 2019, 207, 44-55.	5.0	10
1619	Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder. Veterinary Pathology, 2019, 56, 369-376.	1.7	25
1620	Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy. Targeted Oncology, 2019, 14, 93-105.	3.6	28
1621	An ExÂVivo Human Tumor Assay Shows DistinctÂPatterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. Journal of Investigative Dermatology, 2019, 139, 213-223.	0.7	19
1622	Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. European Journal of Medicinal Chemistry, 2019, 163, 367-380.	5.5	28
1623	MicroRNA-218–5p inhibit the migration and proliferation of pterygium epithelial cells by targeting EGFR via PI3K/Akt/mTOR signaling pathway. Experimental Eye Research, 2019, 178, 37-45.	2.6	23
1624	Context-dependent regulation of receptor tyrosine kinases: Insights from systems biology approaches. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2019, 11, e1437.	6.6	4

#	Article	IF	CITATIONS
1625	Stimuliâ€responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1527.	6.1	231
1626	Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2. International Journal of Biological Macromolecules, 2020, 142, 94-113.	7.5	18
1627	Revisiting a controversy: The effect of EGF on EGFR dimer stability. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183015.	2.6	14
1628	Current Development of Monoclonal Antibodies in Cancer Therapy. Recent Results in Cancer Research, 2020, 214, 1-70.	1.8	16
1629	Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3. Phytomedicine, 2020, 66, 153109.	5.3	14
1630	Liposomes as Anticancer Therapeutic Drug Carrier's Systems: More than a Tour de Force. Current Nanomedicine, 2020, 10, 178-185.	0.6	8
1631	Cyclosporin A activates human hepatocellular carcinoma (HepG2 cells) proliferation: implication of EGFR-mediated ERK1/2 signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 897-908.	3.0	7
1632	10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models. Molecular Cancer Therapeutics, 2020, 19, 490-501.	4.1	9
1633	Characterization of Streptococcus iniae-induced microRNA profiles in Paralichthys olivaceus and identification of pol-3p-10740_175 as a regulator of antibacterial immune response. Fish and Shellfish Immunology, 2020, 98, 860-867.	3.6	9
1634	Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2. Journal of Computer-Aided Molecular Design, 2020, 34, 293-303.	2.9	7
1635	Gastric Cancer: Role of Phytochemicals and Tyrosine Kinase Inhibitors. , 2020, , 189-208.		0
1636	PEG-SOD attenuates the mitogenic ERK1/2 signaling cascade induced by cyclosporin A in the liver and kidney of albino mice. Chemico-Biological Interactions, 2020, 330, 109245.	4.0	4
1637	ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia, 2020, 34, 2798-2804.	7.2	16
1638	Gas6 Induces Myelination through Anti-Inflammatory IL-10 and TGF-Î ² Upregulation in White Matter and Glia. Cells, 2020, 9, 1779.	4.1	23
1639	Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation. Scientific Reports, 2020, 10, 16906.	3.3	3
1640	Theoretical evaluation of EGFR kinase inhibition and toxicity of di-indol-3-yl disulphides with anti-cancer potency. Journal of Biomolecular Structure and Dynamics, 2022, 40, 622-634.	3.5	4
1641	Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR ^{WT} and EGFR ^{T790M} . Organic and Biomolecular Chemistry, 2020, 18, 7608-7634.	2.8	83
1642	Subepithelial Corneal Deposits Associated with Exemestane. Case Reports in Ophthalmological Medicine, 2020, 2020, 1-4.	0.5	1

#	Article	IF	CITATIONS
1643	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers, 2020, 12, 2392.	3.7	171
1644	Role of tyrosine kinases in bladder cancer progression: an overview. Cell Communication and Signaling, 2020, 18, 127.	6.5	19
1645	Mechanistic Model of Signaling Dynamics Across an Epithelial Mesenchymal Transition. Frontiers in Physiology, 2020, 11, 579117.	2.8	6
1646	Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2 ⁺ Breast Cancer Cells to 5-Fluorouracil. Oncology Research, 2020, 28, 519-531.	1.5	13
1647	HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability. Journal of Medicinal Chemistry, 2020, 63, 15906-15945.	6.4	15
1648	Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3. Molecular Cancer Therapeutics, 2020, 19, 1474-1485.	4.1	27
1649	Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer. Molecular Biology Reports, 2020, 47, 4553-4568.	2.3	15
1650	An <scp>EGFR</scp> signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. International Journal of Cancer, 2020, 147, 2621-2633.	5.1	13
1651	ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain. Neurobiology of Disease, 2020, 142, 104961.	4.4	13
1652	PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer. Expert Opinion on Biological Therapy, 2020, 20, 965-970.	3.1	17
1653	Synthesis, biological evaluation and kinase profiling of novel S-benzo[4,5]thiazolo[2,3-c][1,2,4]triazole derivatives as cytotoxic agents with apoptosis-inducing activity. Journal of Molecular Structure, 2020, 1219, 128567.	3.6	23
1654	Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Oncology, 2020, 2020, 1-13.	1.3	16
1655	Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs. Frontiers in Oncology, 2020, 10, 62.	2.8	14
1656	Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy. Gynecologic Oncology, 2020, 158, 785-793.	1.4	9
1657	Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90). Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127374.	2.2	10
1658	Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with ¹⁷⁷ Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines. Molecular Pharmaceutics, 2020, 17, 1226-1236.	4.6	14
1659	EGF-Containing Membrane-Bound Mucins: A Hidden ErbB2 Targeting Pathway?. Journal of Medicinal Chemistry, 2020, 63, 5074-5088.	6.4	8
1660	ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020, 129, 377-387.	0.4	2

		Citation R	EPORT	
#	Article		IF	CITATIONS
1661	Modulation of polycystic kidney disease by non-coding RNAs. Cellular Signalling, 2020,	71, 109548.	3.6	22
1662	Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death Nature Nanotechnology, 2020, 15, 145-153.	n in vivo.	31.5	159
1663	Identification of herbal categories active in pain disorder subtypes by machine learning novel molecular mechanisms of algesia. Pharmacological Research, 2020, 156, 104797	help reveal '.	7.1	9
1664	The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets an American Society of Clinical Oncology Educational Book / ASCO American Society of C Oncology Meeting, 2020, 40, e58-e74.	id Payloads. linical	3.8	36
1665	Pseudokinases: Prospects for expanding the therapeutic targets armamentarium. Adva Chemistry and Structural Biology, 2021, 124, 121-185.	nces in Protein	2.3	1
1666	Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cance Angewandte Chemie - International Edition, 2021, 60, 3858-3869.	er Therapy.	13.8	113
1667	CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data. Jou Gastrointestinal Cancer, 2021, 52, 1-10.	ırnal of	1.3	15
1668	The Biased Ligands NGF and NT-3 Differentially Stabilize Trk-A Dimers. Biophysical Jourr 55-63.	nal, 2021, 120,	0.5	16
1669	Neuregulin Signaling in the Tumor Microenvironment. Advances in Experimental Medic 2021, 1270, 1-29.	ine and Biology,	1.6	1
1670	Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cance Angewandte Chemie, 2021, 133, 3902-3913.	er Therapy.	2.0	9
1671	Targeted Drug Delivery: Advancements, Applications, and Challenges. , 2021, , 195-212	2.		2
1672	Liposomal nanotherapeutics in cancer treatment. , 2021, , 121-129.			1
1673	Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mut Breast Cancer. JCO Precision Oncology, 2021, 5, 27-32.	ated Metastatic	3.0	2
1674	Defining Breast Cancer. , 2021, , 1-31.			0
1675	Methods Ligand Binding to Receptor Tyrosine Kinases: Thermodynamic Cycles and Ex Approaches. , 2021, , 766-779.	cperimental		0
1676	Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersint combination with trastuzumab in xenograft models. Investigational New Drugs, 2021,	uzumab in 39, 697-704.	2.6	5
1677	RNA binding protein CUGBP1 mediates the liver metastasis of colorectal cancer by regusing signal pathway. Translational Cancer Research, 2021, 10, 3373-3388.	ulating the ErbB	1.0	3
1678	Proliferation of MDA-MB-231 can be suppressed by dimeric-epigallocatechin gallate thr competitive inhibition of amphiregulin-epidermal growth factor receptor signaling. Anti Drugs, 2021, 32, 647-656.	ough -Cancer	1.4	4

#	Article	IF	CITATIONS
1679	Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. OncoTargets and Therapy, 2021, Volume 14, 1341-1366.	2.0	12
1681	History and emerging trends in chemotherapy for gastric cancer. Annals of Gastroenterological Surgery, 2021, 5, 446-456.	2.4	25
1682	SMYD3: a regulator of epigenetic and signaling pathways in cancer. Clinical Epigenetics, 2021, 13, 45.	4.1	31
1683	Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. Clinical Cancer Research, 2021, 27, 3528-3539.	7.0	66
1684	HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer. PLoS ONE, 2021, 16, e0245832.	2.5	5
1685	Shape Transformable Strategies for Drug Delivery. Advanced Functional Materials, 2021, 31, 2009765.	14.9	57
1686	Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma. Clinical Case Reports (discontinued), 2021, 9, 2264-2268.	0.5	0
1687	A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization. Molecular Cancer Therapeutics, 2021, 20, 1142-1152.	4.1	5
1688	Structural Insight of the Anticancer Properties of Doxazosin on Overexpressing EGFR/HER2 Cell Lines. , 0, , .		1
1689	Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth. Heliyon, 2021, 7, e06394.	3.2	9
1690	Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. Oncogene, 2021, 40, 2651-2666.	5.9	13
1691	Estudos In silico sobre as atividades anticancerÃgenas do Eugenol presente no Cravo Da Ãndia (Syzygium aromaticum). Research, Society and Development, 2021, 10, e27910414165.	0.1	1
1692	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Frontiers in Oncology, 2021, 11, 638482.	2.8	16
1693	Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncology Letters, 2021, 21, 448.	1.8	5
1694	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. Critical Reviews in Oncology/Hematology, 2021, 160, 103300.	4.4	6
1695	A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2. Current Research in Translational Medicine, 2021, 69, 103277.	1.8	4
1697	miR-155 and miR-146a collectively regulate meningitic Escherichia coli infection-mediated neuroinflammatory responses. Journal of Neuroinflammation, 2021, 18, 114.	7.2	13
1698	Composites of Nucleic Acids and Boron Clusters (C2B10H12) as Functional Nanoparticles for Downregulation of EGFR Oncogene in Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 4863.	4.1	8

#	Article	IF	CITATIONS
1699	Complementarity principle in terms of electron density for the study of EGFR complexes. Future Medicinal Chemistry, 2021, 13, 863-875.	2.3	17
1701	Growth factor–dependent ErbB vesicular dynamics couple receptor signaling to spatially and functionally distinct Erk pools. Science Signaling, 2021, 14, .	3.6	18
1702	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opinion on Drug Discovery, 2021, 16, 1091-1103.	5.0	6
1703	Interactions between Ligand-Bound EGFR and VEGFR2. Journal of Molecular Biology, 2021, 433, 167006.	4.2	3
1704	Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduction and Targeted Therapy, 2021, 6, 218.	17.1	242
1705	Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. Cancers, 2021, 13, 2922.	3.7	29
1706	Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion. International Journal of Molecular Sciences, 2021, 22, 6483.	4.1	11
1707	Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer. Expert Review of Anticancer Therapy, 2021, 21, 1097-1104.	2.4	2
1708	Long Non-Coding RNA LINC01410 Promoted Tumor Progression via the ErbB Signaling Pathway by Targeting STAT5 in Gallbladder Cancer. Frontiers in Oncology, 2021, 11, 659123.	2.8	1
1709	Demethoxycurcumin induces apoptosis in <scp>HER2</scp> overexpressing bladder cancer cells through degradation of <scp>HER2</scp> and inhibiting the <scp>PI3K</scp> /Akt pathway. Environmental Toxicology, 2021, 36, 2186-2195.	4.0	20
1710	Amphiregulin stimulates human chorionic gonadotropin expression by inducing ERK1/2-mediated ID3 expression in trophoblast cells. Placenta, 2021, 112, 73-80.	1.5	5
1711	A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. Oncologist, 2021, 26, e1844-e1853.	3.7	18
1712	Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2. Pharmaceuticals, 2021, 14, 791.	3.8	7
1713	Amphiregulin promotes hair regeneration of skinâ€derived precursors via the PI3K and MAPK pathways. Cell Proliferation, 2021, 54, e13106.	5.3	18
1714	Identification of steroidal saponins from Tribulus terrestris and their in silico docking studies. Journal of Cellular Biochemistry, 2021, 122, 1665-1685.	2.6	4
1715	Epitope Mapping of an Antihuman EGFR Monoclonal Antibody (EMab-134) Using the REMAP Method. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 191-195.	1.6	19
1716	An Anti-HER2 Monoclonal Antibody H ₂ Mab-41 Exerts Antitumor Activities in Mouse Xenograft Model Using Dog HER2-Overexpressed Cells. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 184-190.	1.6	10
1718	Recombinant immunotoxins development for HER2-based targeted cancer therapies. Cancer Cell International, 2021, 21, 470.	4.1	16

#	Article	IF	CITATIONS
1719	Labelâ€free quantitative proteomic and phosphoproteomic analyses of renal biopsy tissues in membranous nephropathy. Proteomics - Clinical Applications, 2022, 16, e2000069.	1.6	0
1720	The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis. Frontiers in Oncology, 2021, 11, 653491.	2.8	19
1721	Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
1722	Allosteric Inhibition of HER2 by Moesin-Mimicking Compounds Targets HER2-Positive Cancers and Brain Metastases. Cancer Research, 2021, 81, 5464-5476.	0.9	7
1723	Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma. Journal of Translational Medicine, 2021, 19, 408.	4.4	4
1724	Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression. Cancers, 2021, 13, 4790.	3.7	11
1725	Epidermal growth factor receptor and integrins meet redox signaling through P66shc and Rac1. Cytokine, 2021, 146, 155625.	3.2	9
1726	Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors. European Journal of Medicinal Chemistry, 2021, 226, 113845.	5.5	9
1727	Omeprazole activates the mitogenic cell response in rat kidney: Implication of ERK1/2 signaling cascade. Azhar International Journal of Pharmaceutical and Medical Sciences, 2021, 1, 70-76.	0.3	0
1728	Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. Signal Transduction and Targeted Therapy, 2021, 6, 12.	17.1	68
1730	Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 307-315.	1.0	1
1731	Mitochondrial metabolism and carcinogenesis. , 2021, , 119-163.		0
1732	Ovarian cancer: Targeted therapies and mechanisms of resistance. , 2021, , 283-301.		1
1733	Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. , 2005, 63, 93-115.		10
1734	Targeting Small Molecules in Cancer. Cancer Treatment and Research, 2007, 135, 239-255.	0.5	2
1735	Dual/Pan-Her Tyrosine Kinase Inhibitors: Focus in Breast Cancer. Advances in Experimental Medicine and Biology, 2006, 587, 329-340.	1.6	1
1736	Tumor Antigens as Modulators of the Tumor Microenvironment. , 2008, , 91-119.		1
1737	Chicken Models of Retroviral Insertional Mutagenesis. , 2011, , 77-112.		1

#	Article	IF	CITATIONS
1738	Antibodies as Cancer Immunotherapy. , 2013, , 335-376.		2
1739	The Role of Akt Pathway Signaling in Glucose Metabolism and Metabolic Oxidative Stress. , 2012, , 21-46.		15
1740	Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancer. , 2011, , 91-107.		3
1741	HER-2 Involvement in Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, 804, 161-177.	1.6	12
1742	Safety Aspects of Biologics: Lessons Learnt from Monoclonal Antibodies. , 2007, , 169-174.		1
1743	Identifying Critical Signaling Molecules for the Treatment of Cancer. , 2007, 172, 5-24.		3
1744	Targeting ERBB Receptors in Cancer. , 2007, 172, 45-57.		8
1745	Lapatinib. Recent Results in Cancer Research, 2010, 184, 45-59.	1.8	7
1746	Molecular Aspects of AT2 Receptor. Handbook of Experimental Pharmacology, 2004, , 375-397.	1.8	2
1747	Possible Mechanisms of ω-3 PUFA Anti-tumour Action. , 2010, , 3-38.		7
1748	ErbB-4. , 2003, , 69-80.		2
1749	Liver Regeneration. , 2006, , 23-36.		2
1750	Pediatric Radiation Oncology. , 2009, , 241-255.		4
1751	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
1752	HER-2/neu vaccines. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 275-285.	0.5	4
1753	Epidermal growth factor receptor pathway inhibitors. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 205-223.	0.5	14
1754	HB-EGF. The AFCS-nature Molecule Pages, 0, , .	0.2	8
1755	Recombinant Protein Hydrogels for Cell Injection and Transplantation. RSC Soft Matter, 2014, , 48-72.	0.4	2

#	Article	IF	CITATIONS
1756	Comprehensive analysis of the value of RAB family genes in prognosis of breast invasive carcinoma. Bioscience Reports, 2020, 40, .	2.4	8
1758	ErbB2: From an EGFR Relative to a Central Target for Cancer Therapy. Cancer Research, 2016, 76, 3659-3662.	0.9	12
1759	Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. Journal of Clinical Investigation, 2013, 123, 3459-3471.	8.2	62
1760	Antiproliferative and Apoptotic Effects of Tocotrienols on Normal and Neoplastic Mammary Epithelial Cells. , 2008, , 119-139.		3
1761	Tumours. , 2008, , 1821-2000.		6
1762	Heterogeneity of signal transduction at the subcellular level: microsphere-based focal EGF receptor activation and stimulation of Shc translocation. Journal of Cell Science, 2001, 114, 2437-2447.	2.0	23
1763	The peroxisome proliferator-activated receptor \hat{I}^3 is an inhibitor of ErbBs activity in human breast cancer cells. Journal of Cell Science, 2001, 114, 4117-4126.	2.0	44
1764	Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 72-75.	1.6	11
1765	Absence of Epidermal Growth Factor Receptor Gene Mutations in Lung and Liver Tumors in Rats. Journal of Toxicologic Pathology, 2007, 20, 65-69.	0.7	1
1768	HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells. PLoS ONE, 2008, 3, e2881.	2.5	65
1769	Serum HER2 Level Measured by Dot Blot: A Valid and Inexpensive Assay for Monitoring Breast Cancer Progression. PLoS ONE, 2011, 6, e18764.	2.5	24
1770	A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death. PLoS ONE, 2011, 6, e24071.	2.5	141
1771	Subchronic Peripheral Neuregulin-1 Increases Ventral Hippocampal Neurogenesis and Induces Antidepressant-Like Effects. PLoS ONE, 2011, 6, e26610.	2.5	50
1772	LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling. PLoS ONE, 2011, 6, e27720.	2.5	94
1773	Cardiac-Specific Over-Expression of Epidermal Growth Factor Receptor 2 (ErbB2) Induces Pro-Survival Pathways and Hypertrophic Cardiomyopathy in Mice. PLoS ONE, 2012, 7, e42805.	2.5	50
1774	Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells. PLoS ONE, 2013, 8, e55657.	2.5	14
1775	Berberine Inhibits Proliferation and Down-Regulates Epidermal Growth Factor Receptor through Activation of Cbl in Colon Tumor Cells. PLoS ONE, 2013, 8, e56666.	2.5	57
1776	PKG II Inhibits EGF/EGFR-Induced Migration of Gastric Cancer Cells. PLoS ONE, 2013, 8, e61674.	2.5	30

		CITATION REPORT	
#	ARTICLE Profiling Epidermal Crowth Factor Receptor and Heregulin Receptor 3 Heteromerization Using	IF	CITATIONS
1777	Receptor Tyrosine Kinase Heteromer Investigation Technology. PLoS ONE, 2013, 8, e64672.	2.5	14
1778	Assembly of Bio-Nanoparticles for Double Controlled Drug Release. PLoS ONE, 2013, 8, e74679.	2.5	21
1779	Theranostic Protein Targeting ErbB2 for Bioluminescence Imaging and Therapy for Cancer. PLoS 0 2013, 8, e75288.	DNE, 2.5	10
1780	Evidence for Intermolecular Interactions between the Intracellular Domains of the Arabidopsis Receptor-Like Kinase ACR4, Its Homologs and the Wox5 Transcription Factor. PLoS ONE, 2015, 1 e0118861.	0, 2.5	20
1781	Sphingosine-1-Phosphate Induces the Migration of Thyroid Follicular Carcinoma Cells through the MicroRNA-17/PTK6/ERK1/2 Pathway. PLoS ONE, 2015, 10, e0119148.	2.5	7
1782	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. PLoS ONE, 2015, 10, e01283	d 2.5 60.	23
1783	Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs. PLoS ONE, 2015, 10, e0131241.	2.5	48
1784	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS ONE, 2015, 10, e01	43333. ^{2.5}	21
1785	HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Car Meta-Analysis. PLoS ONE, 2016, 11, e0161219.	ncer: A 2.5	24
1786	Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer ce models. PLoS ONE, 2017, 12, e0174230.	2.5	9
1787	ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tun 1 (DFT1). PLoS ONE, 2017, 12, e0177919.	10ur 2.5	8
1788	Sphingosine 1-Phosphate Activation of EGFR As a Novel Target for Meningitic Escherichia coli Penetration of the Blood-Brain Barrier. PLoS Pathogens, 2016, 12, e1005926.	4.7	41
1789	The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histology and Histopathology, 2005, 20, 1005-15.	0.7	99
1790	Deciphering the role of ErbB2/HER2 in cancer cell lines: a proto-oncogene with antiapoptotic acti Cancer Cell & Microenvironment, 0, , .	vity. 0.8	1
1791	ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocrine-Related Cancer, 2016, 23, T243-T257.	3.1	42
1792	Improved PCR-RFLP Method For Her-2 lle655val Breast Cancer Patients Detection. International Jon Advanced Science, Engineering and Information Technology, 2016, 6, 205.	purnal 0.4	1
1793	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent AC induction. Oncotarget, 2017, 8, 50570-50581.	TA2 1.8	33
1794	Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer. Oncotarget 7, 65320-65334.	, 2016, <u>1.8</u>	29

#	ARTICLE Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget, 2013, 4,	IF	CITATIONS
1795	1592-1605.	1.8	132
1796	ls ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. Oncotarget, 2016, 7, 82741-82756.	1.8	10
1797	Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget, 2017, 8, 20961-20973.	1.8	41
1798	siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. Oncotarget, 2017, 8, 52584-52593.	1.8	8
1799	HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma. Oncotarget, 2017, 8, 69559-69576.	1.8	18
1800	DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. Oncotarget, 2017, 8, 77207-77218.	1.8	30
1801	Activating HER3 mutations in breast cancer. Oncotarget, 2018, 9, 27773-27788.	1.8	23
1802	Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers. Oncotarget, 2020, 11, 31-45.	1.8	11
1803	MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC). Oncotarget, 2015, 6, 7454-7469.	1.8	22
1804	Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget, 2015, 6, 5164-5181.	1.8	42
1805	PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2018, 9, 24914-24926.	1.8	24
1806	Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget, 2015, 6, 21085-21099.	1.8	31
1807	<i>In vitro</i> and <i>in vivo</i> inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget, 2016, 7, 9250-9270.	1.8	112
1808	JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients. Oncotarget, 2016, 7, 36865-36884.	1.8	10
1809	HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget, 2016, 7, 51012-51026.	1.8	28
1810	Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study. Annals of Translational Medicine, 2016, 4, 209-209.	1.7	1
1811	Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents. Current Drug Targets, 2016, 18, 147-159.	2.1	55
1812	Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets. Current Gene Therapy, 2020, 20, 237-258.	2.0	22

		CITATION RE	EPORT	
#	Article		IF	Citations
1813	ADAM Proteins- Therapeutic Potential in Cancer. Current Cancer Drug Targets, 2008, 8	, 720-732.	1.6	37
1814	Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer. Curr Drug Targets, 2015, 15, 544-562.	rent Cancer	1.6	6
1815	Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment Tumours. Recent Patents on Anti-Cancer Drug Discovery, 2020, 15, 200-211.	of Solid	1.6	5
1816	Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy. Anti-Cancer Agen Chemistry, 2013, 13, 1039-1047.	ts in Medicinal	1.7	31
1817	Structural Insights into the Molecular Design of HER2 Inhibitors. Open Pharmaceutical Journal, 2016, 3, 164-181.	Sciences	2.1	10
1818	Boolean Modeling of Biochemical Networks. Open Bioinformatics Journal, 2011, 5, 16-2	25.	1.0	28
1819	Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on A Signaling Pathways. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2255-2262.	\KT/ERK	1.2	4
1820	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Fronti Bioscience - Landmark, 2011, 16, 1973.	ers in	3.0	7
1821	ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Frontiers in Bioscience - 2002, 7, d1926-1940.	Landmark,	3.0	12
1822	Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Bre Cell Lines. Asian Pacific Journal of Cancer Prevention, 2020, 21, 439-447.	east Cancer	1.2	2
1823	Emerging therapies in gastrointestinal cancers. World Journal of Gastroenterology, 200	16, 12, 7440.	3.3	24
1824	Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic c cancer. World Journal of Gastroenterology, 2010, 16, 1177.	olorectal	3.3	24
1825	Targeting receptor tyrosine kinases in gastric cancer. World Journal of Gastroenterolog 4536.	y, 2014, 20,	3.3	51
1826	Changing strategies for target therapy in gastric cancer. World Journal of Gastroentero 22, 1179.	logy, 2016,	3.3	32
1827	Identification of potential hub genes associated with the pathogenesis and prognosis o duct adenocarcinoma using bioinformatics meta‑analysis of multi‑platform dataset 2019, 18, 6741-6751.	of pancreatic ts. Oncology Letters,	1.8	9
1828	Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast car Oncology Reports, 2020, 44, 2634-2644.	ncer cells.	2.6	23
1829	Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esoph adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 173-80.	lagogastric	1.4	3
1830	Interspecific variability of endocrine disruption and oxidative stress in two bivalve speci Ria Formosa Lagoon (south coast of Portugal). Scientia Marina, 2013, 77, 79-89.	es from the	0.6	2

#	Article	IF	CITATIONS
1831	Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma. Journal of Pathology and Translational Medicine, 2016, 50, 436-441.	1.1	5
1832	Mechanisms Mediating the Synergistic Anticancer Effects of Combined Î ³ -Tocotrienol and Celecoxib Treatment. Journal of Bioanalysis & Biomedicine, 2011, 03, 1-7.	0.1	24
1833	Effect of Black Tea Polyphenol on Cell-ECM Interaction and MMP. American Journal of Plant Sciences, 2017, 08, 856-866.	0.8	2
1834	Pharmacology of epidermal growth factor inhibitors. International Journal of Biological Markers, 2007, 22, 24-39.	1.8	19
1835	Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Reports, 2010, 43, 91-96.	2.4	40
1836	Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective. BMB Reports, 2020, 53, 133-141.	2.4	6
1837	Quinazoline Derivatives as Anticancer Agents: QSAR, Molecular Docking and in silico Pharmacokinetic Prediction. Indian Journal of Pharmaceutical Education and Research, 2018, 52, S309-S325.	0.6	1
1838	Immunoliposomes: A Multipurpose Strategy in Breast Cancer Targeted Therapy. , 0, , .		3
1839	Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target. Bioinformation, 2018, 14, 482-487.	0.5	7
1840	Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5343-5348.	1.2	14
1841	Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10627-10630.	1.2	8
1842	Investigating the growth performance, meat quality, immune function and proteomic profiles of plasmal exosomes in <i>Lactobacillus plantarum</i> -treated broilers with immunological stress. Food and Function, 2021, 12, 11790-11807.	4.6	11
1843	Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. Cancers, 2021, 13, 5162.	3.7	11
1844	The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Molecular Medicine, 2021, 27, 126.	4.4	9
1845	EGF stimulates human trophoblast cell invasion by downregulating ID3-mediated KISS1 expression. Cell Communication and Signaling, 2021, 19, 101.	6.5	15
1846	Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress. Bioorganic Chemistry, 2021, 116, 105393.	4.1	27
1847	Signal Transduction Pathways Modulate Androgen Receptor Transcriptional Activity. , 2002, , 57-90.		0
1848	Control of Proliferation in the Normal and Neoplastic Breast. , 2002, , 73-91.		0

#	Article	IF	CITATIONS
1849	Control of Proliferation in the Normal and Neoplastic Breast. , 2002, , 95-114.		0
1851	Tiermodelle in der biomedizinischen Forschung. , 2003, , 299-339.		0
1852	Epidermal Growth Factor Receptor Signal Trans-Activation. NATO Science Series Series II, Mathematics, Physics and Chemistry, 2003, , 93-103.	0.1	0
1853	Therapeutic strategies to improve the efficacy of oxaliplatin in gastrointestinal tumors. International Journal of Biological Markers, 2004, 19, 183-189.	1.8	1
1854	Biologic Therapy for Gynecologic Malignancies. , 2004, , 953-968.		0
1855	HER2 and Topoisomerase IIα in Breast Carcinoma. , 2004, , 261-283.		0
1856	The Potential of EGFR-Targeted Agents in Cancer Prevention. , 2004, , 317-324.		1
1858	Co-expression of ErbB family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Journal of Clinical Oncology, 2004, 22, 9522-9522.	1.6	1
1859	Three Cases of Primary Non-Small Cell Lung Carcinoma with Mutation of the Epidermal Growth Factor Receptor Gene that Responded to Gefitinib. Kitakanto Medical Journal, 2005, 55, 169-176.	0.0	0
1860	Molecular Pathogenesis of Thyroid Cancer. , 2006, , 15-32.		3
1863	Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. Translational Medicine Series, 2007, , 213-234.	0.0	0
1865	Therapeutic Targeting of Apoptosis in Cancer. , 2008, , 263-278.		1
1866	HER Family of Receptors as Treatment Targets in Pancreatic Cancer. , 2008, , 609-634.		0
1867	EGFR family heterodimers in cancer pathogenesis and treatment. , 2008, , 14-29.		4
1868	Negative regulation of signaling by the EGFR family. , 2008, , 161-178.		0
1869	Transmembrane Protein Models Based on High-Throughput Molecular Dynamics Simulations with Experimental Constraints. Methods in Molecular Biology, 2008, 443, 213-227.	0.9	1
1870	Signal Transduction Inhibitors in the Treatment of Breast Cancer. , 2009, , 177-201.		0
1871	Tumor Growth and Cell Proliferation. Medical Radiology, 2009, , 19-37.	0.1	0

#	Article	IF	CITATIONS
1872	HER2 Overexpression Attenuates the Antiproliferative Effect of Aromatase Inhibitor in MCF-7 Breast Cancer Cells Stably Expressing Aromatase. , 2009, , 3-28.		0
1873	Genetics of Osteosarcoma. , 2010, , 19-42.		0
1874	Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights. F1000 Biology Reports, 2009, 1, 72.	4.0	1
1875	A Polymorphism of the MMP-1, ECF, and IL-LB Gene Is Not Correlated with Gastric Carcinogenesis. Chonnam Medical Journal, 2010, 46, 32.	0.1	Ο
1876	Cancer Vaccines Targeting HER2/neu for Early Breast Cancer. Journal of Breast Cancer, 2010, 13, 5.	1.9	0
1877	Advances in Radiation Therapy. Pediatric Oncology, 2010, , 313-334.	0.5	2
1878	Molecular Targeted Therapy. , 2010, , 1523-1531.		0
1879	Les facteurs de croissance et les récepteurs à activité tyrosine kinase. , 2010, , 21-43.		0
1880	Role of Lipid Domains in EGF Receptor Signaling. , 2010, , 359-364.		0
1882	Neoplasms of Extrahepatic Bile Ducts. Molecular Pathology Library, 2011, , 881-890.	0.1	0
1883	Epidermal Growth Factor–Like Ligands. , 2011, , 1276-1279.		0
1884	ERBB2 (erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene) Tj ETQq1 1 0.7	784314 rg 0.1	BT_/Overloc
1885	Novel Quinazoline Derivatives Targeting on EGFR Kinase Mediated Signal Pathway in A431 Human Epidermoid Carcinoma Cells. Journal of Life Science, 2011, 21, 349-357.	0.2	0
1886	<i>In Vitro</i> Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells. Oligonucleotides, 0, , 121102072334007.	2.7	Ο
1887	Integrin-Mediated Endothelial Cell Adhesion and Activation of c-Src, EGFR and ErbB2 are Required for Endothelial-Mesenchymal Transition. , 0, , .		0
1888	ErbB Membrane Tyrosine Kinase Receptors: Analyzing Migration in a Highly Complex Signaling System. Neuromethods, 2012, , 105-131.	0.3	Ο
1889	Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody. Journal of Cancer Therapy, 2012, 03, 902-911.	0.4	0
1890	The Role of ErbB Receptors in Endometrial Cancer. , 0, , .		5

#	Article	IF	CITATIONS
1891	Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions. , 0, , .		0
1893	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
1894	Growth Factor Receptor Signaling, DNA Damage Response, and Cancer Cell Susceptibility to Chemotherapy and Relapses. , 2013, , 45-74.		1
1895	ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	0
1896	Prerequisite Genetic Traits for Metastasis. , 2013, , 403-444.		0
1897	Her-2/Neu Overexpression in Invasive Bladder Carcinoma Among a Cohort of Egyptian Patients. World Journal of Nephrology and Urology, 2013, , .	0.8	1
1901	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.		0
1904	Gender Does Not Have a Potential Predictive Value for the Presence of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma. Advances in Lung Cancer (Irvine), 2014, 03, 82-87.	0.2	0
1905	Note on Three Classes of Data Grid Operations. Journal of Computer and Communications, 2014, 02, 1-6.	0.9	1
1906	Epidermal Growth Factor-like Ligands. , 2014, , 1565-1571.		0
1907	ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer. Journal of Cancer Therapy, 2014, 05, 483-492.	0.4	2
1908	Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice. Forum of Clinical Oncology, 2014, 5, 12-15.	0.2	0
1909	MicroRNA-22E Inhibits HER-3 Protein Expression to Facilitate Metastasis of Lung Adenocarcinomas. Journal of Cancer Therapy, 2015, 06, 362-374.	0.4	0
1911	HER3., 2015, , 1-19.		0
1912	Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. Cancer Drug Discovery and Development, 2015, , 381-412.	0.4	0
1913	Critical Roles of the AKT Substrate Girdin in Disease Initiation and Progression. , 2015, , 233-250.		0
1914	Molecular Mechanisms, Expression and Clinical Role of ErbB Receptors in Endometrial Cancer. International Journal of Clinical Therapeutics and Diagnosis, 0, , 28-32.	0.0	0
1915	In silico siRNA design for SNPs in HER family receptors: A Potential cure for Cancer. Journal of Young Pharmacists, 2015, 7, 432-437.	0.2	0

#	Article	IF	CITATIONS
1916	Diversity and implication of MAPK signal transduction involved in the regulation of chemotherapy-induced DNA damage response. , 2016, , 303-328.		0
1917	How to Build Up Adequate Prognostic Markers in the Molecular Biology Context of Breast Cancer. , 2016, , 149-181.		0
1918	- Gene Body Methylation and Transcriptional Regulation: Statistical Modelling and More. , 2016, , 225-243.		0
1920	Oncogenes and the Initiation and Maintenance of Tumorigenesis. , 2017, , 143-157.		1
1921	Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. , 2017, , 1-31.		0
1922	QSAR APPROACH TO THE STUDY OF THE EGFR TYROSINE KINASE INHIBITORS: THIAZOLYL-PYRAZOLINE DERIVATIVES. Indian Drugs, 2017, 54, 5-12.	0.1	3
1924	EGFR and Cytoplasmic Kinase Src Targeting in Pancreatic Cancer. , 2018, , 97-105.		0
1925	Breast Cancer: Risk Factors, Diagnosis and Management. Medical Laboratory Journal, 2018, 12, 1-9.	0.2	1
1926	Her2neu expression in urinary bladder cancer: Histopathological, clinico-radiological and epidemiological aspects. Indian Journal of Pathology and Oncology, 2019, 6, 489-496.	0.1	0
1928	Seksual Siklus Süresince İnek Tuba Uterinasında ErbB1/HER1 ile ErbB2/HER2 Reseptörlerinin Dağılın İdealkent, 2020, 13, 87-91.	וı. 0.2	Ο
1929	Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?. Current Drug Metabolism, 2020, 21, 1009-1021.	1.2	1
1930	Cancer biology and other disorders: beneficial role of camptothecin and novel derivatives. , 2020, , 1-46.		Ο
1932	Regulation of NRG-1-ErbB4 signaling and neuroprotection by exogenous neuregulin-1 in a mouse model of epilepsy. Neurobiology of Disease, 2021, 161, 105545.	4.4	2
1935	Herceptin Resistance. , 2006, , 459-467.		0
1936	Chemo- and Radiosensitization Through Inhibition of PI3K/Akt Signaling. , 2007, , 313-334.		1
1937	The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy. , 2007, , 335-357.		0
1940	Innovative Rational-Derived, Target-Based and Cytotoxic Therapies for Breast Cancer and Other Malignancies. , 2006, , 741-780.		0
1942	Tiermodelle in der biomedizinischen Forschung. , 2008, , 207-241.		0

#	Article	IF	CITATIONS
1943	INVESTIGATION OF NEUREGULIN-1 GEN rs6994992 POLYMORPHISM IN GIFTED STUDENTS. Sakarya University Journal of Science, 0, , .	0.7	1
1944	Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827. Anti-Cancer Drugs, 2021, 32, 417-426.	1.4	0
1945	The EGF receptor family-multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Transactions of the American Clinical and Climatological Association, 2003, 114, 315-33; discussion 333-4.	0.5	48
1946	Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Therapeutics and Clinical Risk Management, 2007, 3, 871-6.	2.0	21
1947	Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics: Targets and Therapy, 2007, 1, 229-39.	3.2	5
1950	Lapatinib: the evidence for its therapeutic value in metastatic breast cancer. Core Evidence, 2005, 1, 77-87.	4.7	1
1953	Profiling serum HER-2/NEU in prostate cancer. Hippokratia, 2013, 17, 108-12.	0.3	5
1955	HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. International Journal of Clinical and Experimental Pathology, 2014, 7, 699-708.	0.5	15
1957	Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer. American Journal of Cancer Research, 2014, 4, 776-88.	1.4	4
1958	Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells. World Journal of Gastroenterology, 2005, 11, 5142-50.	3.3	33
1959	Up-regulation of cyclin E in breast cancer via estrogen receptor pathway. International Journal of Clinical and Experimental Medicine, 2015, 8, 910-5.	1.3	3
1960	The important application of thioridazine in the endometrial cancer. American Journal of Translational Research (discontinued), 2016, 8, 2767-75.	0.0	10
1962	Boeravinone B a natural rotenoid exerts anticancer activity via inducing internalization and degradation of inactivated EGFR and ErbB2 in human colon cancer cells. American Journal of Translational Research (discontinued), 2018, 10, 4183-4192.	0.0	4
1963	Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors. Bioorganic Chemistry, 2022, 118, 105471.	4.1	9
1964	Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs. Biomolecules, 2021, 11, 1690.	4.0	2
1965	Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation — molecular dynamics study. Journal of Molecular Modeling, 2021, 27, 361.	1.8	6
1966	Biomarkers in Breast Carcinomas. , 2022, , 309-333.		0
1967	Structure-Based In Silico Investigation of Agonists for Proteins Involved in Breast Cancer. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-12.	1.2	10

#	Article	IF	CITATIONS
1968	Targeted therapies in the treatment of pancreatic carcinoma. , 2003, 5, 434-442.		0
1969	ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. , 2004, 6, 12-21.		2
1970	Novel Pyridothienopyrimidine Derivatives: Design, Synthesis and Biological Evaluation as Antimicrobial and Anticancer Agents. Molecules, 2022, 27, 803.	3.8	9
1971	A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents. Current Topics in Medicinal Chemistry, 2022, 22, 493-528.	2.1	8
1972	Nrg1/ErbB signalingâ€mediated regulation of fibrosis after myocardial infarction. FASEB Journal, 2022, 36, e22150.	0.5	17
1973	The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. Pharmacological Reviews, 2022, 74, 18-47.	16.0	31
1974	Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. Journal of Medicinal Chemistry, 2022, 65, 1735-1748.	6.4	16
1975	Discovering the key genes and important DNA methylation regions in breast cancer. Hereditas, 2022, 159, 7.	1.4	5
1976	The next wave of cellular immunotherapies in pancreatic cancer. Molecular Therapy - Oncolytics, 2022, 24, 561-576.	4.4	34
1977	Origin of diverse phosphorylation patterns in the ERBB system. Biophysical Journal, 2022, 121, 470-480.	0.5	3
1978	Translocation of ErbB receptors into the nucleus. , 2003, 5, 381-389.		4
1980	More Than Meets the Kappa for Antibody Superantigen Protein L (PpL). Antibodies, 2022, 11, 14.	2.5	5
1981	Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses. Cancers, 2022, 14, 997.	3.7	2
1982	Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment. Journal of Medicinal Chemistry, 2022, , .	6.4	1
1983	Insights on ErbB glycosylation – contributions to precision oncology. Trends in Cancer, 2022, 8, 448-455.	7.4	9
1984	Combining EGFR inhibitors with SHP2 or LSD1 inhibitors to overcomeÂmultidrug resistance in cancer. Future Medicinal Chemistry, 2022, 14, 527-529.	2.3	3
1985	Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers, 2022, 14, 1795.	3.7	15
1986	The <i>Candida albicans</i> toxin candidalysin mediates distinct epithelial inflammatory responses through p38 and EGFR-ERK pathways. Science Signaling, 2022, 15, eabj6915.	3.6	17
#	Article	IF	CITATIONS
------	--	-----	-----------
1987	Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188707.	7.4	4
1988	Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H ₂ Mab-181) Using Enzyme-Linked Immunosorbent Assay. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 255-260.	1.6	9
1990	Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor. International Journal of Molecular Sciences, 2021, 22, 13308.	4.1	1
2004	Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer. Molecular Cancer Therapeutics, 2022, 21, 799-809.	4.1	7
2005	Diabetes enhances the expression of H-ras and suppresses the expression of EGFR leading to increased cell proliferation. Histology and Histopathology, 2009, 24, 531-9.	0.7	8
2007	FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells. Clinical and Experimental Metastasis, 2022, 39, 623-639.	3.3	10
2008	The Interaction of Specific Peptide Aptamers With the DNA Binding Domain and the Dimerization Domain of the Transcription Factor Stat3 Inhibits Transactivation and Induces Apoptosis in Tumor Cells. Molecular Cancer Research, 2004, 2, 170-182.	3.4	115
2009	Role of the epidermal growth factor receptor in thrombin regulated vascular smooth muscle cells proliferation. , 2013, 47, 10-20.		0
2010	Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. Molecular Cancer Therapeutics, 2004, 3, 1335-1342.	4.1	81
2011	A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach. Proteome Science, 2022, 20, 9.	1.7	7
2012	Identifying drivers of breast cancer metastasis in progressively invasive subpopulations of zebrafish-xenografted MDA-MB-231. Molecular Biomedicine, 2022, 3, .	4.4	3
2013	Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene, 2002, 21, 198-206.	5.9	0
2014	MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	12
2015	Discordance of positive immunohistochemical results among different primary HER2 antibodies used in breast cancer: A comparison between Histofine® HER2 Kit (MONO) SV2-61γ antibody and Ventana I-VIEW PATHWAYâ"¢ HER2 4B5 antibody. Revista Espanola De Patologia, 2022, , .	0.2	0
2016	Phage in cancer treatment – Biology of therapeutic phage and screening of tumor targeting peptide. Expert Opinion on Drug Delivery, 2022, 19, 873-882.	5.0	12
2017	MiR-146a-5p, targeting ErbB4, promotes 3T3-L1 preadipocyte differentiation through the ERK1/2/PPAR-Î ³ signaling pathway. Lipids in Health and Disease, 2022, 21, .	3.0	4
2018	Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. European Journal of Medicinal Chemistry, 2022, 238, 114492.	5.5	5
2019	Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease. Molecular Biology Reports, 2022, 49, 8547-8553.	2.3	1

#	Article	IF	CITATIONS
2020	Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology. Scientific Reports, 2022, 12, .	3.3	3
2022	Different proteome pattern of epidermal growth factor receptor–positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Molecular Cancer Therapeutics, 2004, 3, 1551-1558.	4.1	27
2023	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. Cancers, 2022, 14, 3674.	3.7	3
2024	The extract of Celtis choseniana Nakai alleviates testosterone-induced benign prostatic hyperplasia through inhibiting 5α reductase type 2 and the Akt/NF-κB/AR pathway. Chinese Journal of Natural Medicines, 2022, 20, 518-526.	1.3	1
2026	Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. Biomedicines, 2022, 10, 1914.	3.2	5
2027	Threonine phosphorylation regulates the molecular assembly and signaling of EGFR in cooperation with membrane lipids. Journal of Cell Science, 2022, 135, .	2.0	3
2028	Mammaglobin 1 mediates progression of trastuzumabâ€resistant breast cancer cells through regulation of cyclins and <scp>NFâ€₽B</scp> . FEBS Open Bio, 2022, 12, 1797-1813.	2.3	3
2029	Osteoclast-derived extracellular vesicles are implicated in sensory neurons sprouting through the activation of epidermal growth factor signaling. Cell and Bioscience, 2022, 12, .	4.8	5
2030	Discovery of new 1 <i>H</i> -pyrazolo[3,4- <i>d</i>]pyrimidine derivatives as anticancer agents targeting EGFR ^{WT} and EGFR ^{T790M} . Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2283-2303.	5.2	17
2031	Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells. Biochemistry and Biophysics Reports, 2022, 31, 101326.	1.3	0
2032	Control of cell metabolism by the epidermal growth factor receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119359.	4.1	13
2033	Targeted nanomedicine delivery to human epidermal growth receptor. , 2022, , 111-130.		0
2034	Neuregulin-1, a potential therapeutic target for cardiac repair. Frontiers in Pharmacology, 0, 13, .	3.5	7
2035	ErbB4 in the brain: Focus on high grade glioma. Frontiers in Oncology, 0, 12, .	2.8	4
2036	Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. Frontiers in Immunology, 0, 13, .	4.8	4
2037	Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity. Pharmaceutics, 2022, 14, 1980.	4.5	4
2038	Epidermal growth factor receptors and their ligands are expressed in the spleen of the Japanese Quail (<i>Coturnix coturnix japonica</i>) during the post-hatch period. British Poultry Science, 0, , .	1.7	0
2040	Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents. Molecular Diversity, 2023, 27, 1185-1202.	3.9	3

#	Article	IF	CITATIONS
2042	Imaging strategies for receptor tyrosine kinase dimers in living cells. Analytical and Bioanalytical Chemistry, 2023, 415, 67-82.	3.7	2
2043	Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. European Journal of Medicinal Chemistry, 2022, 244, 114775.	5.5	7
2044	Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. , 2022, , .		0
2045	HB-ECF upregulates StAR expression and stimulates progesterone production through ERK1/2 signaling in human granulosa-lutein cells. Cell Communication and Signaling, 2022, 20, .	6.5	5
2046	Biological evaluation, docking studies, and <i>in silico</i> ADME prediction of some pyrimidine and pyridine derivatives as potential EGFR ^{WT} and EGFR ^{T790M} inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, 176-191.	5.2	12
2047	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. International Journal of Molecular Sciences, 2022, 23, 13696.	4.1	0
2048	A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Molecular Therapy - Oncolytics, 2022, 27, 256-269.	4.4	4
2049	Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum. Bioanalysis, 2022, 14, 1241-1249.	1.5	2
2050	An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 13497.	4.1	0
2053	Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Lung Cancer, 2023, 175, 101-111.	2.0	1
2054	Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?. Cancers, 2022, 14, 5932.	3.7	0
2055	Cancer regulator EGFR-ErbB4 heterodimer is stabilized through glycans at the dimeric interface. Journal of Molecular Modeling, 2022, 28, .	1.8	3
2056	HER3 Alterations in Cancer and Potential Clinical Implications. Cancers, 2022, 14, 6174.	3.7	4
2057	Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma. Cancers, 2022, 14, 6210.	3.7	6
2058	Integrating Network Pharmacology Approaches to Decipher the Multi-Target Pharmacological Mechanism of Microbial Biosurfactants as Novel Green Antimicrobials against Listeriosis. Antibiotics, 2023, 12, 5.	3.7	9
2059	A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer. Case Reports in Ophthalmology, 2022, 13, 1036-1041.	0.7	2
2060	Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell lines. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5539-5545.	2.5	2
2061	Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+ breast cancers. PLoS ONE, 2022, 17, e0256788.	2.5	1

#	Article	IF	CITATIONS
2063	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology and Oncology, 2022, 15, .	17.0	46
2064	Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives. Cancer Biology and Medicine, 2022, 19, 1543-1564.	3.0	12
2066	PETrans: De Novo Drug Design with Protein-Specific Encoding Based on Transfer Learning. International Journal of Molecular Sciences, 2023, 24, 1146.	4.1	8
2067	Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages. International Journal of Molecular Sciences, 2023, 24, 1443.	4.1	3
2068	Design and synthesis of new heterocyclic compounds containing 5-[(1 <i>H</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Journal of Biomolecular Structure and Dynamics, 2023, 41, 12753-12767.	Tf 50 587 3.5	Td (-1,2,4-tri 0
2069	Nanoproteomics deciphers the prognostic value of EGFR family proteins-based liquid biopsy. Analytical Biochemistry, 2023, 671, 115133.	2.4	0
2070	Association between the Arg72Pro Genotypes in the TP53 Gene and Ile655Val in the HER2 Gene and the Risk of Developing Breast Cancer in the Population of Amapá, Northern Brazil. Asian Pacific Journal of Cancer Prevention, 2023, 24, 157-162.	1.2	0
2072	Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. Cureus, 2023, , .	0.5	1
2073	Developing SHP2-based combination therapy for KRAS-amplified cancer. JCI Insight, 2023, 8, .	5.0	2
2074	Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation. Cell Chemical Biology, 2023, 30, 175-187.e15.	5.2	4
2075	The human periconceptional maternal-embryonic space in health and disease. Physiological Reviews, 2023, 103, 1965-2038.	28.8	3
2076	HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors. , 2023, , .		0
2077	EGFR and MMP-9 are associated with neointimal hyperplasia in systemic-to-pulmonary shunts in children with complex cyanotic heart disease. Mammalian Genome, 2023, 34, 285-297.	2.2	0
2078	Surface roughness modulates EGFR signaling and stemness of triple-negative breast cancer cells. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	1
2080	Ebselen oxide and derivatives are new allosteric <scp>HER2</scp> inhibitors for <scp>HER2</scp> â€positive cancers. Molecular Oncology, 2023, 17, 1981-1999.	4.6	1
2081	Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors. Current Tissue Microenvironment Reports, 2023, 4, 1-16.	3.2	0
2082	Combined physicochemical and functional assessment of pertuzumab integrity supports extended inâ€use stability. Archiv Der Pharmazie, 2023, 356, .	4.1	0
2083	Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. Scientific Reports, 2023, 13, .	3.3	1

#	Article	IF	CITATIONS
2084	Potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma. Veterinary Research Communications, 2023, 47, 2207-2213.	1.6	0
2085	Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer. Medicinal Chemistry Research, 2023, 32, 1130-1142.	2.4	0
2086	Biased activation of the receptor tyrosine kinase HER2. Cellular and Molecular Life Sciences, 2023, 80, .	5.4	1
2087	Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma. Cancers, 2023, 15, 2634.	3.7	1
2088	An unanticipated discourse of HB-EGF with VANGL2 signaling during embryo implantation. Proceedings of the United States of America, 2023, 120, .	7.1	2
2089	ERBB Receptors and Their Ligands in the Developing Mammary Glands of Different Species: Fifteen Characters in Search of an Author. Journal of Mammary Gland Biology and Neoplasia, 2023, 28, .	2.7	0
2090	Molecular dynamic simulation reveals the molecular interactions of epidermal growth factor receptor with musk xylene are involved in the carcinogenicity. RSC Advances, 2023, 13, 16311-16320.	3.6	0
2091	Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes. International Journal of Molecular Sciences, 2023, 24, 9943.	4.1	2
2092	AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. Molecular Cancer Therapeutics, 2023, 22, 1013-1027.	4.1	3
2093	Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer. Scientific Reports, 2023, 13, .	3.3	0
2094	Colonic mucosal diffuse congestion associated with Osimertinib. Journal of Oncology Pharmacy Practice, 0, , .	0.9	0
2095	Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Pharmacological Reviews, 2023, 75, 1218-1232.	16.0	3
2096	Design, synthesis, and antitumor efficacy of novel 5-deazaflavin derivatives backed by kinase screening, docking, and ADME studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, .	5.2	1
2097	A phase Ia/Ib study of novel antiâ€ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer. International Journal of Cancer, 2023, 153, 1501-1511.	5.1	0
2098	Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3â€ <i>d</i>]pyrimidine derivatives as EGFR inhibitors. Drug Development Research, 2023, 84, 1299-1319.	2.9	2
2099	Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression. Interdisciplinary Sciences, Computational Life Sciences, 2023, 15, 452-464.	3.6	0
2100	Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. Virologica Sinica, 2023, 38, 778-786.	3.0	1
2101	Novel hydrazoneâ€isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling. Archiv Der Pharmazie, 2023, 356, .	4.1	2

ARTICLE IF CITATIONS ErbBs in Lens Cell Fibrosis and Secondary Cataract., 2023, 64, 6. 2102 2 A ligand-receptor interactome atlas of the zebrafish. IScience, 2023, 26, 107309. 2104 4.1 Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors. Assay and Drug Development Technologies, 2023, 21, 2105 1.2 1 222-233. Role of EGFR and FASN in breast cancer progression. Journal of Cell Communication and Signaling, 2106 2023, 17, 1249-1282. Anabolic phenotype in cartilage-specific Mitogen-inducible gene-6 knockout mice is independent of 2107 2.0 0 Transforming growth factor-. Osteoarthritis and Cartilage Open, 2023, , 100387. A systematic pipeline of protein structure selection for computerâ€aided drug discovery: A case study on <scp>T790M/L858R</scp> mutant <scp>EGFR</scp> structures. Protein Science, 2023, 32, . 2108 7.6 Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth 2109 4.1 2 through Reactivation of MAPK and EGFR Pathways. Cells, 2023, 12, 2022. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. Critical 2110 4.4 Reviews in Oncology/Hematology, 2023, 190, 104090. A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract 2111 1.1 0 urothelial carcinoma patients. Tumori, 2024, 110, 25-33. Epigenetic mechanisms of lncRNA in response to thermal stress during embryogenesis of allotetraploid Cyprinus carpio. Genomics, 2023, 115, 110698. HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the 2113 0 4.1 antitumor activity of gefitinib and paclitaxel. Cancer Cell International, 2023, 23, . 2114 The ErbB Signaling Network and Its Potential Role in Endometrial Cancer. Epigenomes, 2023, 7, 24. 1.8 <scp>ErbB2_{pY}</scp>_{â€1248} as a predictive biomarker for Parkinson's disease based on research with <scp>RPPA</scp> technology and in vivo verification. CNS Neuroscience and 2115 3.9 0 Therapeutics, 2024, 30, . Htr2b Promotes M1 Microglia Polarization and Neuroinflammation after Spinal Cord Injury via Inhibition of Neuregulin-1/ErbB Signaling. Molecular Neurobiology, 2024, 61, 1643-1654. 4.0 Multiâ€omic network analysis identified betacellulinÂas a novel target of omegaâ€3 fatty acidÂattenuation 2117 6.9 1 of western dietâ€induced nonalcoholic steatohepatitis. EMBO Molecular Medicine, 2023, 15, . Minor histocompatibility antigens represented in HLA-A*02:01 and their search strategies. Oncogematologiya, 2023, 18, 115-124. Entanglement of MAPK pathways with gene expression and its omnipresence in the etiology for cancer 2119 and neurodegenerative disorders. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2023, 1.9 5 1866, 194988. AXL – a new player in resistance to HER2 blockade. Cancer Treatment Reviews, 2023, 121, 102639.

#	Article	IF	CITATIONS
2121	HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies. OncoTargets and Therapy, 0, Volume 16, 849-865.	2.0	1
2122	Analysis of CD74 Occurrence in Oncogenic Fusion Proteins. International Journal of Molecular Sciences, 2023, 24, 15981.	4.1	0
2124	Amphiregulin in infectious diseases: Role, mechanism, and potential therapeutic targets. Microbial Pathogenesis, 2024, 186, 106463.	2.9	0
2125	Busting the Breast Cancer with AstraZeneca's Gefitinib. Advances in Pharmacological and Pharmaceutical Sciences, 2023, 2023, 1-26.	1.3	0
2127	A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology. Molecular Pharmacology, 0, , MOLPHARM-AR-2023-000768.	2.3	0
2128	Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFRWT and EGFRT790M with ADMET Profiling. Bioorganic Chemistry, 2024, 143, 107027.	4.1	0
2129	Genetic variants of ERBB4 gene and risk of gestational diabetes mellitus: a susceptibility and diagnostic nomogram study. Frontiers in Endocrinology, 0, 14, .	3.5	0
2130	Progress in Glioma Stem Cell Research. Cancers, 2024, 16, 102.	3.7	0
2131	Mitogenic Signal Transduction by Integrin- and Growth Factor Receptor-mediated Pathways. Molecules and Cells, 2004, 17, 188-202.	2.6	3
2132	SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with ECFR- and HER2-targeted drugs. Acta Pharmacologica Sinica, 2024, 45, 857-866.	6.1	0
2133	Tonic ErbB signaling underlies TGFÎ ² -induced activation of ERK and is required for lens cell epithelial to myofibroblast transition. Molecular Biology of the Cell, 2024, 35, .	2.1	0
2134	The progress of optional targets and approaches to enhance efficacy of CAR-T for pancreatic ductal adenocarcinoma. , 2024, , .		0
2135	Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023. Frontiers in Medicine, 0, 10, .	2.6	0
2136	Endosomal protein expression of \hat{I}^31 -adaptin is associated with tumor growth activity and relapse-free survival in breast cancer. Breast Cancer, 2024, 31, 305-316.	2.9	0
2137	Treadmill Running Regulates Adult Neurogenesis, Spatial and Non-spatial Learning, Parvalbumin Neuron Activity by ErbB4 Signaling. Cellular and Molecular Neurobiology, 2024, 44, .	3.3	0
2139	TMED2 promotes glioma tumorigenesis by being involved in EGFR recycling transport. International Journal of Biological Macromolecules, 2024, 262, 130055.	7.5	0
2140	Extracellular domain mutations of the EGF receptor differentially modulate high-affinity and low-affinity responses to EGF receptor ligands. Journal of Biological Chemistry, 2024, 300, 105763.	3.4	0
2141	<i>Artemisia argyi</i> extracts overcome lapatinib resistance via enhancing <scp>TMPRSS2</scp> activation in <scp>HER2</scp> â€positive breast cancer. Environmental Toxicology, 0, , .	4.0	0